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Abstract 
 
Headache is the most common pain problem reported by people with schizophrenia, 
with 12 month prevalence rates of around 50%. Despite this little research has been 
conducted into the characteristics, impact and management of headaches in this 
population. There is evidence to support the efficacy of physiotherapy treatment of 
cervicogenic headache and tension type headache and determining the prevalence, 
impact and current management of these types of headache was of particular interest. 
 
A pilot study was first undertaken to identify and refine an appropriate headache 
questionnaire, develop an algorithm to use for classification of headache and test the 
repeatability and reliability of using the algorithm to classify headache types. A 
previously validated questionnaire was identified and slightly modified for the mental 
health population. A two part algorithm, which utilized information from the 
questionnaire, was designed to classify headaches into cervicogenic (CGH), migraine 
(MH) or tension type (TTH) headache against the International Classification of 
Headache Disorder criteria. Participants whose headache characteristics did not enable 
them to be classified into one of these three categories were coded as Other Headache 
(OH) type.  A convenience sample of 12 chronic headache suffers not currently 
receiving care for their headache completed the questionnaire on two occasions, 
separated by 6-weeks. On each occasion two independent reviewers used the algorithm 
to characterise the headache type. The algorithm was shown to have high inter rater 
reliability (weighted-κ=.827) and moderate test re-test reliability (weighted-κ=.636). 
 
A cross-sectional observational cohort study of people with schizophrenia or 
schizoaffective disorder was then undertaken to determine the prevalence, 
characteristics, impact and management of headache in this population. Using the 
validated headache questionnaire, data was collected about headache prevalence and 
characteristics from 100 consecutive people diagnosed with schizophrenia or 
schizoaffective disorder. Headaches were classified using the algorithm by two 
independent reviewers and any disagreement settled by consensus. Clinical 
information, demographic data and information on current management of headache
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was collected and questions from the SF-36 questionnaire were included to assess 
quality of life. 
 
Males made up 66% of the sample cohort. The mean age of participants was 38.8 years 
and on average participants had been diagnosed with schizophrenia or schizoaffective 
disorder for 14.6 years. The most common comorbid physical illness was diabetes. All 
participants were taking antipsychotic medication, with 66/100 people taking some 
form of medication that listed headache as a common or very common side effect.  
 
Twelve month prevalence of headache (57%) was slightly higher than in the general 
population (46%). The two reviewers demonstrated excellent agreement on headache 
classification (weighted-κ=.85). Prevalence of CGH (5%) and MH (18%) were 
comparable to the general population and TTH had a much lower prevalence (16%) 
than that found in the general population (42%). OH was the most prevalent (19%).  
 
When considering the whole population we found no evidence of a relationship 
between mental health clinical characteristics and the presence of headache. The 
presence of any headache was not related to inpatient/outpatient status (OR=2.07, 95% 
CI [0.92-4.68]), length of time from diagnosis of mental illness (OR=0.99, 95% CI 
[0.95-1.03])) or taking medication with a side effect of headache (OR=0.94, 95% CI 
[0.40-2.19]). Similarly, there was no relationship between clinical status and the 
individual specific headache types. These data suggest that the specific headache types 
are independent of the mental health problem. We did find an association between OH 
type and medication use (OR=0.32, 95% CI [0.11-0.90]) and inpatient/outpatient 
status (OR=5.76, 95% CI [1.74-19.07]), suggesting those whose headache is not 
classifiable using International Headache Society (IHS) criteria might be suffering 
from headache which is secondary to their mental health problems. 
  
A similar analysis was undertaken utilising only data from the headache population. 
These data suggest that there is a relationship between age and CGH (OR=1.14, 95% 
CI [1.01–1.29]), medication use and MH (OR=6.14, 95% CI [1.24-30.44]) and 
inpatient/outpatient status and TTH (OR=0.28, 95% CI [0.08-0.95]) when considering 
only those people who suffer from headache.  
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The quality of life of headache sufferers in this cohort was lower than seen in healthy 
populations. Importantly, the frequency of headache was shown to be negatively 
correlated with Social Functioning (ρ=-.44, p<.001), Bodily Pain (r=-.44, p<.001) and 
Role Physical (ρ=-.32, p=.01), suggesting that headache may contribute to the reduced 
quality of life experienced by people with mental health problems. It was evident that 
very few people were receiving appropriate treatment for their  headache. No 
participant with MH had been prescribed migraine specific medication and 
physiotherapy was not included in the management of headache of any participant with 
CHG or TTH. It is recommended that better education is provided for both patients 
and mental health workers about headache and its management as well as the role of 
physiotherapy in managing the physical health and mental wellbeing of people 
accessing mental health services.  
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CHAPTER ONE 
A Pilot Study to identify and refine an appropriate questionnaire 
for data collection of headache symptoms and to develop and 
evaluate repeatability and inter-rater reliability of an algorithm 
to guide headache classification. 
 
1.1 Introduction 
Knowledge of the headache sufferer’s symptoms gathered from a comprehensive 
history, provides the clinician with essential information about the headache 
characteristics and enables classification of the headache against the International 
Headache Society’s (IHS) International Classification of Headache Disorder (ICHD) 
framework. Headache questionnaires are widely accepted tools commonly used to 
elicit this information, especially in the research environment. The purposes of this 
pilot study were threefold, firstly to identify and refine an appropriate headache 
questionnaire for data collection within the schizophrenic and schizoaffective disorder 
population, secondly to develop an algorithm to guide headache classification based 
on data collected from the questionnaire and thirdly to evaluate the repeatability and 
inter-rater reliability of the process of classifying headache using the questionnaire and 
algorithm. Headaches were to be classified into cervicogenic headache (CGH), 
migraine headache (MH), tension type headache (TTH) and a classification of other 
headache (OH) for all headaches that did not fit the other three classifications. 
 
1.2 Review of Literature  
1.2.1 Questionnaires for research 
There are many forms of headache with very different mechanisms underpinning 
symptom production. Correct classification of the headache type is essential if the 
clinician is to provide appropriate and effective treatment for the headache sufferer. 
Only with a thorough assessment will the clinician collect the evidence required to 
guide effective clinical reasoning and reach the correct classification or diagnosis 
(Liebert, Rebbeck, Elias, Hawkins, & Adams, 2013; Stovner et al., 2007; Zito, Jull, & 
Story, 2006). In clinical practice, physiotherapists initially undertake a comprehensive 
 9 
subjective assessment of all people presenting with headache, including but not limited 
to pain characteristics and distribution, associated symptoms, aggravating and easing 
factors, headache behaviour and progression, functional limitations and management 
strategies. Most of the diagnostic power in headache classification is found in 
information obtained from the subjective assessment, though in some instances 
additional information from the physical examination can aid the diagnostic process. 
However, the physical examination is generally utilised to provide clinicians with 
information about contributing factors to the clinical condition, information that is 
more important for treatment planning than diagnosis.  
 
When headaches are being investigated for research a definitive knowledge of 
contributing factors is not always essential, mitigating the necessity for a full physical 
assessment. For this reason stand-alone questionnaires have been designed to collect 
participants subjective information to provide investigators with appropriate clinical 
information that will guide classification of headache against the ICHD framework 
(Borhani Haghighi, Aflaki, & Ketabchi, 2008; Dong et al., 2012; Jull, Amiri, Bullock-
Saxton, Darnell, & Lander, 2007; Li et al., 2012; Pfaffenrath et al., 2009; Queiroz et 
al., 2009; Sjaastad, 2008; Zielman, Veenstra, Zwet, & Berg, 2012).  
 
The World Health Organisation (WHO), Lifting the Burden; The Global Campaign to 
Reduce the Burden of Headache worldwide study exposed shortcomings and 
inconsistencies between headache studies (Stovner et al., 2014). An expert consensus 
group was subsequently formed and conducted a review of headache surveys with the 
aim to provide recommendations to improve the quality of future studies exploring 
headache prevalence and burden. The expert group suggested guidelines to encourage 
uniformity in research and thus allow for comparison between studies (Stovner et al., 
2014). The review identified that most questionnaires collect data based on the ICHD 
classification system and recommended that this be the standard. This requires 
collecting data on severity, duration, location and frequency of headache, associated 
symptoms as well as aggravating and alleviating symptoms of headaches. 
Recommendations from their review include: 
 Reduce bias by ensuring the sample selection represents the population of 
interest 
 Reduce bias by ensuring all interviews follow the same protocol  
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 If it is not possible for all interviews to be administered by the same person 
ensure that bias is reduced through adequate training of all interviewers  
 Report participation rate as the proportion of eligible people who were 
contacted and engaged in a meaningful way in the study 
 The study instrument (questionnaire) should be suited to the purpose of the 
study and capture the necessary data and include 
o Identification 
o Demographics of at least age and gender 
o Screening questions (do you have headache or not) 
o One year prevalence of headache 
o Diagnostic questions on headache that explore severity, duration, 
location, frequency, associated symptoms, aggravating and alleviating 
symptoms 
o Gathering information on only one headache type per questionnaire. 
Participants should identify and provide information on their most 
bothersome headache first and then complete a separate questionnaire 
of other headache types 
o Elements of burden related to the purpose of the study must be 
measurable 
 The questionnaire should be prepared and tested 
 The questionnaire should be validated to prove diagnostic capability 
 An algorithm developed against the ICHD criteria must be developed and used 
for classification purposes after the questionnaire is completed. 
 
Many questionnaires also gather information on medication use and comorbidities 
(Borhani Haghighi et al., 2008; Dong et al., 2012; Jull et al., 2007; Li et al., 2012; 
Pfaffenrath et al., 2009; Queiroz et al., 2009; Sjaastad & Bakketeig, 2008b; Zielman 
et al., 2012). Dong et al., (2012) and Jull et al. (2007) included questions about 
previous treatments for headache and family history of headache. A study by Li et al. 
(2012) also included questions on quality of life exploring any perceived restriction on 
daily and social activities caused by the headache. The majority of questionnaires used 
in research about headache also gather information about socio-demographics and 
utilisation of healthcare systems. 
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Pfaffenrath et al. (2009) suggest that questionnaires should be administered face-to-
face so that clarification could be provided around misunderstanding of questions. This 
is in line with the recommendation by Stovner et al. (2014). Many other studies have 
also used this method (Borhani Haghighi et al., 2008; Dong et al., 2012) although one 
study conducted in Brazil and another in Germany used a questionnaire administered 
over the telephone which may have impacted on results (Queiroz et al., 2009; Radtke 
and Neuhauser, 2009). To reduce recall bias most studies met the recommendations 
and were conducted on people who had experienced headache in the previous twelve 
months (Pfaffenrath et al., 2009; Queiroz et al., 2009).  
 
Any headache questionnaire being used to classify headache in order to determine 
prevalence, should have high agreement between the questionnaire classification and 
the eventual diagnosis (Hagen, Zwart, Vatten, Stovner, & Bovim, 2000; Jull et al., 
2007; Stovner et al., 2014). Jull et al. (2007) developed and validated such a 
questionnaire to classify headache types based on symptoms described by the ICHD.  
 
This questionnaire was designed to collect information about the frequency and 
intensity of headache as well as specifics about the location of pain, associated pain, 
accompanying symptoms, possible triggers and possible measures that provide relief 
of symptoms. The tool was used to collect data on characteristics of headache in order 
to classify intermittent MH with and without aura, TTH, medication overuse headache 
and CGH. To validate that the tool was able to distinguish between CGH and other 
headache types, after the headache was classified Jull and colleagues conducted a 
physical examination to determine presence or absence of cervical musculoskeletal 
impairments. The purpose was to find if there was a specific pattern of musculoskeletal 
impairments in CGH that could differentiate it from other headache types. To test inter-
rater reliability of the questionnaire, using an algorithm to guide classification, two 
researchers and a neurologist independently classified headache types of 11 people and 
compared classifications. There was 82% agreement (9/11). The validity of the 
questionnaire was supported by two studies both of which showed clear differences in 
neuro-musculoskeletal impairment in the upper cervical spine of subjects classified as 
having CGH compared to those with an alternative classifications (Amiri, Jull, 
Bullock-Saxton, Darnell, & Lander, 2007; Jull et al., 2007).  
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1.2.2 Differential classifications of headaches and development of an 
algorithm 
For research purposes an algorithm is important to aid classification of headache and 
it must be developed applying the criteria of the ICHD (Stovner et al., 2014). The 
algorithm must be sensitive enough to differentiate each headache into only one 
classification but at the same time comprehensive enough to be able classify every 
case (Stanton et al., 2011). 
 
It is evident that there is considerable overlap of clinical symptoms across CGH, MH 
and TTH (Fleming, Forsythe, & Cook, 2007; Frese & Evers, 2008; Sjaastad & 
Bakketeig, 2008a; Zito et al., 2006). Thirty percent of people with CGH meet ICHD 
criteria for MH and 3% of people with CGH meet the criteria for TTH (Hall, Briffa, & 
Hopper, 2008). Neck pain, which is considered a key indicator of CGH is also reported 
by 70% of headache patients with mixed intermittent headache (Hall et al., 2007) and 
69% of patients with MH (Florencio et al., 2014). Pfaffenrath et al. (2009) describe 
this situation of headache types not being mutually exclusive as a major problem of 
the ICHD classification system.  
 
Given the overlap between characteristics in different headache types it is clear that 
simple data collection is not enough to enable classification, and clinical reasoning of 
all data presented is required. Algorithms and other decision making tools have been 
used in previous studies to assist clinical decision making and guide classification. For 
headache studies the algorithm used must be comprehensive enough to facilitate 
classification of headache type into only one classification. As with the development 
of algorithms to classify back pain, an algorithm to guide classification of headache 
type from questionnaire responses may require an hierarchical system of criteria to 
help determine ‘best’ fit (Stanton et al., 2011; Stovner et al., 2014). Stovner et al. 
(2014) suggest that secondary headache should be diagnosed before primary headache 
and migraine should be diagnosed before TTH. A classification of migraine should 
only be given when all key criteria are met (Stovner et al., 2014).  
 
The first step to developing such an algorithm is identifying key defining 
characteristics of each headache type. Tables 1, 2 and 3 list the defining characteristics 
for CGH, MH and TTH used to develop the algorithm for this study. Table 1 lists 
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defining characteristics for CGH based on the classification developed by Sjaastad and 
the Cervicogenic Headache International Study Group (CHISG) in 1990 (Fleming et 
al., 2007).  
 
All people aged between 18 and 65 years in the town of Våga in Norway (n=2075) 
were invited to participate in a study exploring differences between MH without aura 
and CGH. There was a response rate of 88.6% (1838/2075). It was identified that CGH 
is the only headache where people present with unilateral pain starting posteriorly in 
the neck and moving anteriorly to the frontal region (Sjaastad & Bakketeig, 2008). 
Antonaci and Sjaastad (2011) reported cervicogenic headache almost always presents 
with unilateral pain, decreased neck range of motion, ipsilateral shoulder and/or arm 
pain brought on by either awkward neck position or pressure on the occipital structure.  
 
Table 1 - CHISG Characteristics of CGH 
Reproduced from Fleming et al. 2007.  
CHISG DIAGNOSTIC CRITERIA FOR CGH 
A Signs and symptoms of neck involvement: 
a. Precipitation of head pain similar to the usually occurring one: 
1. By  neck movement and/or sustained awkward head 
posturing, and/or 
2. By external pressure over the upper cervical or occipital 
region on the symptomatic side 
b. Restriction of the range of motion (ROM) in the neck 
c. Ipsilateral neck, shoulder, or arm pain of a rather vague non-
radicular nature or, occasionally, arm pain of a radicular nature 
B Confirmatory evidence by diagnostic anaesthetic blockades 
C Unilaterality of head pain without side shift. 
For a diagnosis of CGH to be appropriate, one or more aspects of 
Point 1 must be present, with 1a sufficient to serve as a sole 
criterion for positivity or 1b and 1c combined.  
 
Migraine with aura headache is distinguished from most other headaches by the 
associated visual and/or sensory aura. Flickering lights, spots in the field of vision, 
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numbness or pins and needles may be present and importantly are all fully reversible 
within 60 minutes (Hall et al., 2008). The headache associated with migraine with aura 
is normally unilateral with severe pulsating pain lasting 24 to 72 hours. In the case of 
migraine without aura the headache also usually presents as unilateral, pulsating or 
throbbing, moderate to severe pain lasting between 24 and 72 hours.  
 
The onset of most MH is anterior in the head and is only infrequently brought on by 
neck position, unlike CGH. In MH pain is aggravated by activities such as climbing 
stairs, standing from a lying position or bending from an upright position. Nausea, 
photophobia, phonophobia, heightened sensitivity to smell, cognitive, emotional and 
motor disturbances may also be present (Noseda & Burstein, 2013). MH sufferers 
report nausea, photophobia, phonophobia, and pulsating pain more frequently than any 
other headache group. Like Stovner et al. (2007), for the purposes of prevalence of 
MH we did not differentiate between migraine with aura and migraine without aura as 
they are not too dissimilar in terms of aetiology and impact on the individual.  
 
Table 2 – ICHD Characteristics of MH without Aura 
The International Classification of Headache Disorder – 2nd Edition (2004) 
 
CHARACTERISTICS OF MIGRAINE WITHOUT AURA 
A At least 5 attacks fulfilling criteria B-D 
B Headache attack lasting 4-72 hours (untreated or unsuccessfully treated) 
C Headache has at least two of the following characteristics 
1. Unilateral location 
2. Pulsating quality 
3. Moderate or severe pain intensity 
4. Aggravation by or causing avoidance of routine physical activity 
(eg walking or climbing stairs 
D During headache at least one of the following 
1. Nausea and/or vomiting 
2. Photophobia and phonophobia 
E Not attributed to another disorder 
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Tension Type Headache is a headache that has a diverse clinical profile, however the 
most classical symptoms include band like, mild to moderate, bilateral pressing or 
tightening pain lasting from between 30 minutes to 7 days. TTH are aggravated by 
stress and normal physical activity does not classically aggravate symptoms. Nausea, 
vomiting, photophobia and phonophobia are not normally associated with TTH, 
however, if the headaches are chronic in nature then these symptoms may be present 
in a mild form thus complicating the classification process. In some studies TTH has 
been diagnosed by an absence of features found in other headache types or as a 
headache of just head pain with no other features (Fumal & Schoenen, 2008). In this 
study we have chosen to define TTH based on the ICHD guidelines. During this study 
headache not fitting any of the above criteria for CGH, MH or TTH were classified as 
OH. 
 
Table 3 – ICHD Characteristics of TTH 
The International Classification of Headache Disorder – 2nd Edition (2004) 
CHARACTERISTICS OF TENSION TYPE HEADACHE 
(INFREQUENT EPISODIC TYPE) 
A At least 10 episodes occurring on <1/day per month on average (<12 days 
per year) and fulfilling criteria B-D 
B Headache lasting from 30 minutes – 7 days  
C Headache has at least two of the following characteristics 
5. Bilateral location 
6. Pressing/tightening (non-pulsating) quality 
7. Mild or moderate intensity 
8. Not aggravated by routine physical activity (eg walking or 
climbing stairs 
D Both of the following 
3. No nausea or vomiting (anorexia may occur) 
4. No more than one of photophobia or phonophobia 
E Not attributed to another disorder 
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1.3 Method 
1.3.1 Design 
We conducted a longitudinal cohort study on 12 people with known history of 
headache within the previous 12 months. This study received institutional ethics 
approval and all participants provided written informed consent. 
 
1.3.2 Tools 
Knowing that the questionnaire used by both Jull et al. (2007) and Amiri et al. (2007) 
was a validated tool it was taken to two experts in the psychiatric field, a Consultant 
Psychiatrist and a Mental Health Nurse who both worked across the acute inpatient 
hospital setting, the community setting and on the Psychiatric Emergency Response 
Team. Both experts reviewed the questionnaire for its suitability for use with people 
with schizophrenia and schizoaffective disorder. Both identified that the questionnaire 
was lengthy but felt that all bar one of the statements/comments exploring the 
possibility of migraine headache was suitable for this population. It was suggested to 
change the words ‘visual aura’ to ‘flashing or zigzag light’ as the words visual aura 
has specific connotations in the psychiatric community and may easily be 
misinterpreted.  
 
Based on the fact that this was a validated questionnaire and it was deemed appropriate 
for people with schizophrenia and schizoaffective disorder by mental health 
practitioners and following consultation with Professor Gwen Jull it was decided to 
use what will be referred to as the ‘Jull headache questionnaire’ as the basis for data 
collection and classification for this current study. At the time this decision was made 
the recommendations from Stovner et al. (2014) had not been published but it is 
reassuring to know that the Jull questionnaire met their recommendations for headache 
questionnaires. 
 
Questions were added to the pilot study questionnaire to gather data on the basic 
demographics of age, gender and current medication of participants. The word ‘aura’ 
was changed according to the expert’s suggestions. A copy of the final questionnaire 
used in the main study can be found in Appendix 1. 
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As is evident from the literature there are some defining characteristics unique to each 
headache type as well as many characteristics that are similar across headache types. 
No one characteristic in isolation can define a headache diagnosis. An algorithm is 
required to assist with the clinical decision making process and allow for classification 
of headaches based on the individual’s signs and symptoms as identified in their 
questionnaire responses. Researchers have developed algorithms to aid headache 
classification but these were not appropriate to be used in this study as the combination 
of specific headaches types chosen for classification did not match. The algorithm for 
this study required researchers to differentiate between the primary headaches of MH 
with and without aura and TTH, the secondary headache of CGH as well as allow for 
classification of OH for all headaches that could not be classified as MH, TTH or CGH. 
It is anticipated that within this population some of these OH may be headache 
attributed to psychiatric disorder or medication related headache.  
 
An algorithm (Figure 1) was designed to assist with the classification of headaches 
based on the ICHD classification for MH and TTH and the CHISG classification for 
CGH. OH included headache that did not fit the classification for either MH, TTH or 
CGH. Once completed this algorithm was reviewed by Professor Gwen Jull who 
determined that it was a suitable tool to aid classification and suggested no changes 
were required. 
 
The algorithm (Figure 1) was developed to be sensitive enough to allow classification 
of each participant’s headache into only one headache type but ensure that every 
headache could be classified (Stanton et al., 2011). It was divided into two sections. 
Part A included characteristics that were definitive of ‘classic’ CGH, MH or TTH. In 
the instance when responses to the questionnaires met all characteristics within Part 
A, then the headache could be classified without having to proceed to Part B. Part B 
included more detailed information derived from the ICHD, the CHISG and clinical 
studies to facilitate clinical reasoning and enable classification. It was expected that 
only a few participants would have ‘classic’ symptoms and that the information in Part 
B would be required for clinical reasoning to classify the majority of headaches.   
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Figure 1 – Algorithm for headache classification  
       Yes 
   N 
No 
           
       Yes 
   No 
        
       Yes 
   No 
Which classification best does the patient best suit? 
CGH Defining factors Migraine Defining 
factors 
TTH Defining factors Other Defining 
factors 
Less episodic 
 
Chronic/continuous 
 
*Unilateral without side shift 
 
Starts in neck 
 
Neck stiffness/injury 
 
Headache precipitated by 1 or more of 
*Neck movement 
*sustained awkward head position 
*pressure over upper cervical or 
occipital region on symptomatic side 
 
Ipsilateral neck, shoulder or arm pain 
 
Varying duration of moderate – severe 
pain 
Ache/ sharp/ non-throbbing, non-
lancinating pain or fluctuating 
continuous pain 
 
May have associated nausea, 
photophobia or phonophobia, 
dizziness, ipsilateral blurred vision, 
difficulties swallowing , 
ipsilateral eye oedema, 
 
Aggravated by sport/exercise, stress 
 
Relief with hotpacks, neck exercises, 
change of position, massage, relaxation 
Lasting 4-72 hours 
 
Episodic  
 
Time locked 
 
Fronto-temporal  location 
 
Starts in head 
 
2 of the following 
*Unilateral 
*Pulsating/throbbing/shar
p/stabbing 
*Moderate to severe 
*Aggravated by routine 
exercise, food, 
environment, stress, 
 
At least one of the 
following 
*Nausea/Vomiting 
photophobia or 
phonophobia 
 
May have associated fully 
reversible aura including 
visual –flickering lights, 
spots, lines or loss of 
vision 
Sensory-pins and needles, 
numbness 
 
Relief with medication, 
rest 
lasting 30 min – 7 days 
 
Less episodic   
 
Chronic/continuous 
 
Starts in head 
 
At least 2 of the following 
*Bilateral  
*Pressing/tightening 
pain/bandlike 
*Mild to moderate pain 
*Not aggravated by exercise 
 
Least pain 
 
Both of the following 
*no nausea/vomiting 
*no more than one of 
photophobia or phonophobia 
Unless chronic then mild 
nausea may be associated 
 
Not made worse by normal 
physical activity 
Aggravated by stress 
 
Relief with physical activity, 
relaxation, massage, rest 
alcohol 
Motor weakness 
 
Triggered by 
medication 
 
Inconsistent 
characteristics of 
other three 
headache types 
 
Aggravated by 
food, alcohol, 
lifestyle, 
environment, stress 
 
Eased by alcohol, 
street drugs 
Does this person have mild to moderate, 
pressing/tightening pain which is always bilateral and 
no neck symptoms? 
 
Cervicogenic headache 
 
Tension Type Headache 
Is the headache unilateral and side locked, precipitated 
by neck movement and/or sustained awkward neck 
position and pain starts in neck? 
 
 
 
 
Does this person have unilateral, moderate to severe, 
pulsating/throbbing, time locked pain which 
prohibits activity with associated aura? 
 
Migraine Headache with aura 
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1.3.3 Procedure 
A convenience sample of twelve people without schizophrenia or schizoaffective 
disorder known to have experienced a headache in the last 12 months were invited to 
complete the questionnaire. The inclusion criteria for participation in the pilot study 
were being over 18 years of age, proficient in written English and having experienced 
regular headache within the previous 12-months. Participants were excluded if they 
were unable to provide consent or reported any major extant medical condition for 
which headache was a likely symptom. Participants meeting selection criteria were 
given the questionnaires to complete. The questionnaires were de-identified for the 
purpose of classification. 
 
To establish the headache classification for each participant the principal researcher 
and one other physiotherapist (raters) independently reviewed the questionnaires and 
using the algorithm to guide clinical reasoning, classified each participant’s headache 
type. Results were compared. Where there was disagreement on classification of a 
participant’s headache type, discussion was undertaken to reach consensus agreement 
between the two raters. If consensus could not be reached a third physiotherapy expert 
was to be consulted to enable final adjudication. Following this process the algorithm 
was reviewed by both raters and any changes deemed necessary to improve 
classification were made. 
 
The same twelve people were asked to complete the same questionnaire again 6 weeks 
later. Following the guidelines determined by Peat (2002) to test repeatability  
 the questionnaire was administered in an identical way  
 the participants were blinded to initial results 
 a short enough time had elapsed so that the condition had not changed but long 
enough time that the respondent could not remember their original answers. 
 
A further six weeks elapsed (12 weeks in total) before the raters once again 
independently classified the headaches using the revised algorithm. Classifications 
were compared and after this a consensus classification was assigned to each 
participant using the process outlined above. It was decided that 12 weeks was an 
adequate time to elapse so that the raters would not be able to remember the previous 
classification allocated to each participant (Peat 2002). 
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Inter-rater reliability of the algorithm was determined by evaluating agreement 
between the two raters across all 24 completed questionnaires. Test/retest reliability of 
the tool was determined based on agreement of the consensus headache classification 
for the first questionnaire to consensus classification for the repeat questionnaire.  
 
At the end of this process the raters reviewed the algorithm against the disagreed 
questionnaires from both rounds and discussed their interpretations in a process of 
moderation. Some minor adjustments were made to the algorithm in an attempt to 
clarify the points of difference. 
 
1.3.4 Analysis of Data 
Each participant was allocated an individual identification number (ID) for the first 
and second rounds. Continuous data was checked for normal distribution. Descriptive 
statistics were used to describe the participant characteristics. The Kappa Measure of 
Agreement was used to quantify agreement between raters across all 24 questionnaires. 
To evaluate the test-retest reliability of the tool, comparison of the agreed 
classifications for the first questionnaire were compared against those for the second 
questionnaire also using the Kappa Measure of Agreement. In keeping with Peat 
(2002) a value of 0.5 was used to represent moderate agreement, greater than 0.7 to 
represent good agreement and greater than 0.8 to represent very good agreement.   
 
1.4 Results 
There were 4 males and 8 females in the pilot study with an age range from 17 years 
to 56 years and a mean age of 39.8 years (SD=11.8 years). One person had a comorbid 
medical condition and was taking medication for this. The medication had a possible 
side effect of headache. 
 
Agreement between raters was 87.5% with consensus reached on 21 out of 24 
headache classifications. One rater classified 8/24 headache as MH, 7/24 as TTH, 6/24 
as CHG. and 3/24 as OH while the other rater identified 8/24 as MH, 7/24 as TTH, 
7/24 as CHG. and 2/24 as OH. The Kappa Measure of Agreement value was 0.83, 95% 
CI [0.65-1.00] indicating very good agreement according to Peat (2002). 
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In the first round of testing 3/12 of the participants were classified CGH, 5/12 were 
classified MH and 4/12 were classified TTH. In the second round classifications were 
4/12 CGH, 5/12 MH, 2/12 TTH and 1/12 OH. Three of the 12 participants were 
classified differently across the two time points. The Kappa value for agreement 
between the two rounds was 0.636, 95% CI [0.28-0.99] indicating moderate test retest 
reliability across a six week interval.  
 
1.5 Discussion 
The purpose of this pilot study was to identify and refine an appropriate questionnaire 
for data collection of headache symptoms and to develop and evaluate test-retest 
reliability and inter-rater reliability of an algorithm to guide headache classification 
into CGH, MH, TTH and OH. The ‘Jull headache questionnaire’ was identified as a 
suitably validated questionnaire to use to gather clinical information to allow 
classification of headache within the general population. Two independent mental 
health practitioners deemed the ‘Jull questionnaire’ appropriate for use with people 
with schizophrenia and schizoaffective disorder with one minor adjustment to wording 
to clarify aura in the headache context. The experts identified that the tool was lengthy 
and cautioned that participants with schizophrenia or schizoaffective disorder may 
have trouble completing it. After discussions around any possible changes that could 
reduce the length of the questionnaire it was determined that any significant 
modification would impact on its validity. The experts agreed with the decision and 
gave endorsement to use it in the main study with a suggestion that the researcher be 
present and participate in the interview process rather than give the questionnaire to 
participants to complete independently. The participants for this pilot study, however, 
did not have schizophrenia or schizoaffective disorder and so while experts had 
considered the questionnaire suitable for this population it was not piloted on this 
population. Although not available at the time it was subsequently determined that this 
questionnaire met the recommendations of an expert group about the design of 
headaches questionnaires to be used for research purposes (Stovner et al., 2014).  
 
Based on classification research from the low back pain field (Stanton 2012) a two part 
algorithm was developed to assist with specific classification of headache being used 
in this study. The algorithm was designed using the ICHD and CHISG criteria to guide 
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the researchers in decision making for headache classification. Professor Jull, a world 
leader in headache diagnosis and management, reviewed and approved the algorithm 
before testing. Trials of the algorithm were encouraging with very good agreement 
between the two raters with consensus reached on 21 out of 24 headache 
classifications. There was a moderate test retest reliability of the questionnaire across 
a six week interval.  
 
To determine prevalence and characteristics of headaches for research purposes it is 
imperative that validated and reliable tools are available. This includes both a 
questionnaire to gather information about history and characteristics to enable accurate 
classification as well as a reliable algorithm to guide clinical reasoning for 
classification against the ICHD (Liebert et al., 2013; Stovner et al., 2014; Zito et al., 
2006). In this pilot study the algorithm was required to distinguish between CGH, MH 
and TTH. Unlike some previous studies TTH was not classified as being an absence 
of symptoms of MH (Kuritzky et al, 1999). The algorithm allowed for a classification 
of OH, a headache type that would not meet the characteristics of CGH, MH or TTH, 
but one that might be particularly important to consider in the mental health population 
given the potential medication side effects and the influence of the psychiatric 
condition. OH covers a range of headaches and no attempt was made to further classify 
this headache type. Understanding that some headache types that are not CGH, MH or 
TTH could be potentially serious medical conditions such as brain tumours or 
cardiovascular accidents, care was taken to review the characteristics to ensure no 
action was required to assure the safety of the participant.  
 
The first step towards developing the algorithm was to reference the ICHD and the 
CHISG to identify characteristics that differentiate headache types. This process 
emphasised the similarities and cross-over between characteristics of various headache 
types and highlighted the difficulties associated with classifying headaches. Examples 
of similarities identified included characteristics such as the presence of neck pain in 
MH or TTH (Florencio et al., 2014; Pfaffenrath et al, 2009; Sjaastad, 2008), despite 
neck pain being a key characteristic of CGH (Fleming et al., 2007; Hall et al., 2008; 
Hall et al., 2007). Nausea and vomiting are usually associated with MH but may also 
be present in some instances of TTH or CGH (Fleming et al., 2007; Florencio et al., 
2014; Frese & Evers, 2008; Hall et al., 2008; Hall et al., 2007; Pfaffenrath et al., 2009; 
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Sjaastad, 2008). These finding dictated that the algorithm should be divided into two 
sections.  
 
The first section was based on ‘classic’ presentations of CGH, MH with aura and TTH. 
The ‘classic’ CGH was defined as unilateral, side locked pain originating in the neck 
and precipitated by neck movement or awkward posture. The person whose symptoms 
were undeniably unilateral, moderate to severe pain of a throbbing or pulsating nature, 
pain that was time locked and prohibited movement or activity and was accompanied 
by aura were given a classification of MH. TTH was classified when the characteristics 
were mild to moderate bilateral pain which was pressing or band like and not 
associated with neck pain or stiffness. When characteristics did not categorically meet 
all of these criteria and classification was not straight forward the second part of the 
algorithm was used. This section of the algorithm contained more detailed information 
from the ICHD, the CHISG and clinical investigations about characteristics of each 
headache type and guided clinical reasoning to determine the headache classifications. 
 
Once the algorithm was ready to test for inter-rater reliability and test-retest reliability 
of classification of headache type, participants were approached to complete the 
questionnaire and then repeated the process six weeks later. The majority of the sample 
population in the pilot study were physiotherapists and it is possible that their clinical 
knowledge of expected signs and symptoms of some headache types might have biased 
their responses in the questionnaire and impacted on the precision of answers given. 
To reduce possible bias participants were asked to answer each question based only on 
their personal experience and not their perceived diagnosis. Participants were also 
known to the researcher and it was thought that her being present with them while they 
completed the questionnaire may inadvertently influence some participants’ answers. 
Therefore participants were given the questionnaire to complete independently without 
the researcher being present. It is recognised that this is not the preferred method 
(Pfaffenrath et al., 2009) as there is no opportunity to ask for clarification of questions 
but it was deemed appropriate for this pilot. All participants completed the 
questionnaire without any missing data. 
 
Using the algorithm developed for this pilot study agreement between raters was 
87.5% (21/24). The Kappa Measure of Agreement across all 24 responses was 0.83 
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indicating very good agreement (Peat 2002). These results are similar to those reported 
by Amiri et al. (2007), who found 82% agreement (9/11) with the same questionnaire.  
It is possible that classification may have been facilitated by the clarity of responses 
based on the fact that participants in this pilot study were mostly physiotherapists. Our 
results and the results of Amiri et al., (2007) suggest that this is a reliable tool for 
classifying headache although the performance may vary slightly in the schizophrenic 
population. 
 
To determine test/retest reliability a comparison was made between classifications 
from the first round of responses to the questionnaires compared to classification from 
the second round of responses. While six weeks was considered an appropriate gap 
between questionnaires for participants to prevent recall of previous answers, a further 
six weeks elapsed before raters independently classified the headaches of the repeat 
questionnaire. This extended time was to minimise possible recall/bias on their part 
because discussion had occurred between the raters after the initial questionnaires were 
completed. It was thought they may recognise responses if enough time had not 
elapsed. The Kappa Measure of Agreement (0.67) between the consensuses 
classifications of initial and follow up questionnaire indicated moderate agreement 
(10/12).  
 
Many researchers do not agree with asking participants to complete headache 
questionnaires independently and prefer to administer questionnaires face to face to 
assist with clarification of questions (Borhani Haghighi et al., 2008; Dong et al., 2012; 
Pfaffenrath et al., 2009). For convenience and a desire not to influence answers since 
the pilot study participants were known to the researcher, the questionnaire was given 
to them to take away and complete. It is possible that the two participants who had 
quite different clinical characteristics in their second questionnaire from their first 
might have had more consistency if there had been opportunity to get some clarity 
around specific questions. To reduce the possibility of this occurring in the main study 
it was decided to implement the suggestion of the Consultant Psychiatrist and Mental 
Health Nurse and ensure that the researcher would be present while the participants 
with schizophrenia or schizoaffective disorder completed the questionnaire. 
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1.6 Conclusion 
This pilot study succeeded in identifying a valid and reliable questionnaire tool to use 
to gather clinical characteristics to guide classification of headache into CGH, MH, 
TTH and OH. While identified as lengthy, the questionnaire was not too complicated 
and was deemed appropriate for the main study population by experts in the mental 
health field. It was decided that the researcher should be present while participants 
complete their questionnaires to clarify questions for participants in order to ensure 
accurate and reliable responses. 
 
A comprehensive two part algorithm was developed to guide clinical reasoning to 
enable classification of headaches based on the ICHD, the CHISG and clinical 
investigations. This algorithm was proven to be reliable with excellent agreement 
between reviewers classifying headaches. Test/retest agreement was good. Both 
instruments were deemed suitable for the project.  
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CHAPTER TWO 
Introduction  
This introduction focuses on the background and reasons for undertaking this cross-
sectional cohort study exploring the prevalence, characteristics, impact and 
management of headache in people with schizophrenia and schizoaffective disorder. 
 
2.1 Topic and purpose 
It has long been identified that headache is one of the most common pains reported by 
people with schizophrenia, with a prevalence rate as high as 48% (Kuritzky, Mazeh, 
& Levi, 1999; Morgan et al., 2012; Watson, Chandarana, & Merskey, 1981). Research 
has determined that people who experience chronic headache have a poorer quality of 
life than healthy people (Leiper, Elliott, & Hannaford, 2006; Solomon, Skobieranda, 
& Gragg, 1993; van Suijlekom, Lamé, Stomp-van den Berg, Kessels, & Weber, 2003; 
Vinding, Zeeberg, Lyngberg, Nielsen, & Jensen, 2007). People with schizophrenia or 
schizoaffective disorder have also been identified as having reduced quality of life 
(Cuyún Carter, Milton, Ascher-Svanum, & Faries, 2011). It could be suggested that 
people with schizophrenia or schizoaffective disorder who also experience chronic 
headache may have an even poorer quality of life (Pompili et al., 2009; Smitherman & 
Baskin, 2008) and that treatment directed towards alleviating headache could 
importantly contribute to improving life quality. The first step in providing effective 
management is identifying the cause of the problem; that is classifying the type of 
headache. To date very little research has been conducted attempting to characterise 
and classify the headache type suffered by people with mental illness (Dworkin, 1994; 
Watson et al., 1981). 
 
Reactions and/or responses to noxious input are diminished among people with 
schizophrenia and schizoaffective disorders (Bonnot, Anderson, Cohen, Willer, & 
Tordjman, 2009; Lévesque et al., 2012a; Potvin & Marchand, 2008; Wojakiewicz et 
al., 2013). Despite diminished sensitivity to nociception the prevalence of reported 
headache appears to be equivalent to that seen in the general population (Kuritzky et 
al., 1999). While there are a number of explanations for this paradox, one possibility 
is that the aetiological factors contributing to headache are present to a greater extent 
in people with schizophrenia, that is, the factors which drive the headache experience 
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are more marked in this population. There is evidence for this phenomenon from as 
long ago as the 1950’s where multiple cases were documented of people with 
schizophrenia experiencing perforated peptic ulcers, ruptured appendix and 
myocardial infarction with no associated report of pain (Marchand et.al. as cited in 
Dworkin 1994). These incidents suggest that early recognition of any other pain related 
disorder including headache is particularly important in the schizophrenic population.   
 
The International Headache Society (IHS) developed a classification for headaches in 
the late 20th Century to provide diagnostic criteria for different types of headaches (The 
Headache Classification Subcommitee of the International Headache Society, 2004). 
Numerous headache types are defined by this classification system, however, the three 
with the most significant burden of disease are TTH, MH (Jensen & Stovner, 2008; 
Stovner et al., 2007) and CGH (van Suijlekom et al., 2003). Cervicogenic headache is 
headache that originates from a disorder within the musculoskeletal structures of the 
cervical spine (Sjaastad & Bovim, 1991) and is a problem that can be successfully 
managed with physiotherapeutic treatment directed towards normalising 
neuromusculoskeletal function in the cervical spine (Chaibi & Russell, 2012; Hall et 
al., 2007; Zito et al., 2006). Prevalence of CGH in the general population is estimated 
at about 4% (Bogduk & Govind, 2009; Sjaastad & Bakketeig, 2008b), though may be 
as high as 20% in the headache population or those attending headache clinics (Evers, 
2008; Fernández-de-las-Peñas, Alonso-Blanco, San-Roman, & Miangolarra-Page, 
2006; Frese & Evers, 2008). No studies to date have determined the prevalence of 
CGH amongst people with schizophrenia or schizoaffective disorders despite the high 
reported incidence of headache in this group and the fact that they demonstrate known 
risk factors for the development of cervicogenic headache such as poor posture and 
poor postural control (Jull, Sterling, Falla, Treleaven, & O'Leary, 2008; Marvel, 
Schwartz, & Rosse, 2004).    
 
The purpose of this research is to determine the prevalence and characteristics of 
headache, in particular possible cervicogenic headache, and the perceived impact on 
aspects of quality of life of people with schizophrenia or schizoaffective disorder. It is 
also to determine how people manage their headache and whether they receive 
appropriate assessment and/or treatment from a health professional. This information 
will help identify whether changes could be implemented to better address this 
 28 
manageable physical illness and possibly favourably effect general wellbeing. This 
may include expanding the role of physiotherapy in mental health services. 
 
2.2 Background  
The link between good physical health and good mental health is widely accepted. The 
role of physiotherapy in maintaining or achieving good physical health is also widely 
accepted. The Australian Physiotherapy Association (APA) identifies that 
physiotherapists are experts in the treatment of musculoskeletal conditions and chronic 
pain, helping people with these conditions achieve better physical health (Australian 
Physiotherapy Association, 2012). Physiotherapists also play a significant role in the 
management of many preventable and/or chronic diseases including heart disease, 
diabetes and respiratory diseases such as asthma, enabling people to achieve better 
physical health outcomes (Australian Physiotherapy Association, 2008, 2009).  
 
People with mental illness, in particular people with psychotic illnesses, have poorer 
physical health than those without mental illness and increased morbidity and 
mortality from preventable diseases (Coghlan, Lawrence, Holman, & Jablensky, 2001; 
Griswold et al., 2008; McLennan, 1998; Morgan et al., 2012; Richardson et al., 2005; 
Stubbs et al., 2014; Vancampfort et al., 2011). People with schizophrenia are generally 
less physically active than the general population (Vancampfort et al, 2012; Morgan 
et al., 2011). Morgan et al. (2011) determined that in Australia 66% of people with 
psychosis smoke compared to the rate of 25.3% in the general population (Morgan et 
al., 2012). People with inactive lifestyles who also smoke are at high risk of many 
preventable diseases such as chronic pain, asthma, heart and circulatory problems and 
diabetes. In Australia almost one third of people with a psychotic illness have asthma 
(30.1%), over one quarter (26.8%) of people experience heart or circulatory problems 
and a further 20.5% having diabetes (Morgan et al 2011). All these conditions 
contribute significantly to mortality and morbidity of people with psychosis (Morgan 
et al., 2011).  
 
Reporting of chronic pain is common among people with mental illness (Gureje, 2008) 
and as many as one in four people with a musculoskeletal condition report a comorbid 
mental illness (Australian Institute of Health and Welfare, 2010). Chronic back, neck 
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or other pain was reported by 31.8% of people in Australia with psychosis and severe 
headache or migraine reported by 25.4% (Morgan et al 2011).  
 
With the high prevalence of musculoskeletal conditions and chronic disease it might 
be expected that physiotherapists would be integral to any mental healthcare team. In 
Australia this is not the case. Physiotherapy is not considered a primary profession in 
the Australian Mental Health Workforce and is not recognised as a discipline that has 
a significant role in delivering services to mental health consumers (Health Workforce 
Australia, 2013). In general physiotherapists play either no or an insignificant role in 
mental health care teams (Australian Physiotherapy Association, 2011) and as a result 
many people who access the mental healthcare systems are missing out on key 
treatment and/or preventative health measures to address their physical wellbeing. 
While these services are available through the general healthcare systems there are 
challenges and barriers that make accessing these services difficult for mental health 
consumers (Fagiolini, 2008). Ongoing and unmanaged poor physical health for these 
people could result in a further compromise to their mental health. 
 
The omission of physiotherapists in mental health teams suggests that directors of 
mental health services are either unaware of the benefits to consumers of including 
physiotherapists as part of the multidisciplinary team or overlook the impact poor 
physical health has on mental health. Either way within Australia there is a need to 
promote the role of physiotherapy and the benefits of employing physiotherapists 
within mental healthcare. 
 
One approach to highlight the value of physiotherapy as an integral profession in 
mental healthcare is to evidence the impact of physiotherapeutic interventions to the 
overall health of the person with mental illness. Research is beginning to emerge in 
Europe that demonstrates the positive effects of physiotherapy on the mental and 
physical wellbeing of people with schizophrenia (Vancampfort et al., 2012). Another 
approach is to identify situations where people with psychotic illness are being 
disadvantaged by not being able to access best practice treatment for conditions in 
which physiotherapists are considered experts. One such condition is headache which 
has already been identified as one of the most common pains reported by people with 
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schizophrenia (Kuritzky, Mazeh, & Levi, 1999; Morgan et al., 2012; Watson, 
Chandarana, & Merskey, 1981).  
 
Physiotherapeutic intevention is considered the treatment of choice for CGH (Chaibi 
& Russell, 2012; Hall et al., 2007; Zito et al., 2006). Physiotherapists are trained not 
only to diagnose and treat CGH but also to differentially  diagnose CGH from MH, 
TTH and other headache types. Physiotherapy has also been shown to play a role in 
the holistic management of the person with TTH (Fernández-de-las-Penos et al., 2006). 
Physiotherapists are not experts in the management of MH but will refer clients to 
health professionals who can provide best practice treatment of these headache types. 
Physiotherapy is a treatment of choice to assess and if appropriate manage neck pain 
and postural problems that may be present alongside MH or TTH. Without access to 
physiotherapy, clients of mental health services experiencing headache are likely be 
disadvataged by not receiving best practice, holistic management that will improve 
their physical health which in turn could impact positively on their mental well being. 
 
While this study was initially conceived as a vehicle to highlight just one small way in 
which physiotherapists can contribute to the holistic care of people with mental illness 
is was also inspired by a desire to help address the much bigger issue of headache that 
has long been regarded as a problem for people with psychotic illness (Kuritzky, 
Mazeh, & Levi, 1999; Morgan et al., 2012; Watson, Chandarana, & Merskey, 1981). 
It was thought that a better knowledge of the prevalence and impact of headache on 
this population might be useful to highlight the need for mental health workers to 
address this significant physical health problem.  
 
2.3 Potential significance 
This research is significant to all the people with schizophrenia or schizoaffective 
disorder who experience headache. Information that leads to a better understanding of 
the nature, characteristics and impacts of these headaches will provide a basis to 
determine better management and probable improvement in wellbeing. This 
information could also benefit other users of mental health services. 
 
Diminished responses to or reduced reporting of pain in this population may suggest 
that the impairments driving a headache need to be severe before the person will report 
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it to their health professional. No literature is currently available that examines the 
characteristics of the headache experienced by this population and compares them to 
the general population. If this research determines that headache characteristics are at 
least the same or more severe than in the general population it will provide an argument 
for better management strategies to be considered and implemented.  
 
People with chronic headache experience a poor quality of life (Leiper et al., 2006; 
Solomon et al., 1993; van Suijlekom et al., 2003; Vinding et al., 2007) as do people 
with schizophrenia or schizoaffective disorder (Cuyún Carter et al., 2011). It is 
possible that headache experienced by people with schizophrenia or schizoaffective 
disorder may further impact negatively on quality of life. There is very little research 
investigating the impact of headache on the quality of life of people with schizophrenia 
or schizoaffective disorder who experience chronic headache (Pompili et al., 2009; 
Smitherman & Baskin, 2008). It is important to better understand the impact headache 
is having on the quality of life of a population that has already been identified with a 
reduced quality of life. The results could highlight a greater need to better manage 
headaches in this population. 
 
Poor posture and impaired postural control is associated with schizophrenia and poor 
posture is associated with cervicogenic headache (Marvel et al., 2004; Zito et al., 
2006). It is possible that this population may be at greater risk of developing 
cervicogenic headache than the general population. Determining the characteristics of 
headache and exploring prevalence of possible CGH may provide basis for further, 
more detailed research into the impacts of poor posture associated with schizophrenia.  
 
Treatment protocols and guidelines have been researched and instigated for the 
management of headaches including physiotherapeutic intervention for CGH and 
TTH. Within the general population people presenting to a medical practitioner with 
frequent or chronic headaches are referred to the appropriate health practitioner for 
treatment based on the characteristics and diagnosis of their headache. Within the 
psychiatric population it would appear that screening and referrals for further 
investigation of physical health issues including headache is less common than for the 
general population (Griswold et al., 2008; Happell, Scott, & Platania-Phung, 2012). 
Happell et al, (2012) suggested that there is a tendency for many mental health workers 
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to undervalue complaints about physical illness and view their consumer only in terms 
of their mental illness. The result is that these mental health workers do not act on the 
reports of physical illness but dismiss them as a part of the mental illness. It was noted 
that if this behaviour is repeated frequently that it may result in people eventually not 
reporting the presence of a physical illness. It is unclear if this is occurring in the case 
of headache amongst people with schizophrenia or schizoaffective disorder. Kuritzky 
et al. (1999) suggest that people with schizophrenia do not report headache because 
they do not want to bother anyone, have a fear of hospitalisation or simply do not have 
anybody to complain to. It is possible that any of these reasons mean that treatable 
headache, including CGH and TTH is underreported in this population. If CGH and 
TTH has the same or greater prevalence in this population as in the general population 
then it further strengthens the argument that physiotherapists should be included as 
integral members of the mental health teams.  
 
A screening tool for headache could help case managers identify when their client 
experiences headache and when referral or follow up of reported headache is indicated. 
Information about management of headache types and the role of physiotherapy could 
guide them towards the most appropriate referral pathway and raise the awareness of 
the value of physiotherapy in the care of this client group. This process would enable 
more timely and appropriate intervention for the mental health consumer thus 
preventing needless suffering and discomfort and hopefully improving both their 
mental and physical wellbeing. 
 
This research aims to identify the prevalence, characteristics and determinants of 
headache amongst people with schizophrenia or schizoaffective disorder and compare 
them against the general population. It will determine the impact comorbid headache 
has on their quality of life and the current management of the headache. A better 
understanding of these could result in better management of headache amongst this 
population.   
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2.4 Research Questions 
1. What is the prevalence of headache amongst people with schizophrenia and 
schizoaffective disorder? 
2. What are the prevalence rates of specific headache types amongst people with 
schizophrenia and schizoaffective disorder? 
3. Are any clinical characteristics different between people with schizophrenia 
and schizoaffective disorder who experience headache and those who don’t? 
4. Are any clinical characteristics different between people with schizophrenia 
and schizoaffective disorder who experience specific headache types? 
5. Are there any perceived impacts of headaches on quality of life of people with 
schizophrenia and schizoaffective disorder? 
6. How are headaches managed in this population? 
7. Is the management appropriate for the headache classification? 
8. Is physiotherapy used as a treatment option where indicated? 
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CHAPTER THREE 
Review of Literature  
This literature review will be presented in eight sections providing information about 
headache and schizophrenia and schizoaffective disorder as described below. 
 
3.1 Overview of headache 
This section will provide information about the prevalence of headache in both the 
general population and in the population of people with schizophrenia and/or 
schizoaffective disorder. 
 
3.2 Cervicogenic Headache 
This section will report literature findings on the prevalence, clinical characteristics, 
mechanisms behind and management of CGH. 
 
3.3 Migraine Headache 
This section will examine the prevalence, clinical characteristics, mechanisms behind 
and management of MH. 
 
3.4 Tension Type Headache 
In this section literature about the prevalence, clinical characteristics, mechanisms 
behind and management of TTH will be reviewed. 
 
3.5 Overview of schizophrenia and schizoaffective disorder 
This section will provide an overview of schizophrenia and schizoaffective disorder. 
It will also review the literature on people with schizophrenia’s response to pain and 
explore postural anomalies, both of which could have significant implications on the 
presentation and characteristics of their headache experience.  
 
3.6 Physical health of people with mental illness and role of physiotherapy 
This section will provide some more information on the poor overall physical health 
of people with mental illness and the insight into the role of physiotherapy in overall 
management of physical health. It will also highlight the lack of physiotherapy input 
into this management within this population.  
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3.7 Factors that impact on quality of life 
This section will provide an overview of the impact schizophrenia and/or 
schizoaffective disorder has on the quality of life of an individual. It will also report 
on the impact of headache on quality of life in the general population and investigate 
any literature on effect of headache on quality of life of people with schizophrenia and 
schizoaffective disorder.   
 
3.8 Summary of literature review 
This section will provide a summary of the above information. 
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3.1  Overview of Headache 
The World Health Organisation (WHO) rates headache as a common disorder of the 
nervous system that is underestimated, under-recognised and under-treated (World 
Health Organisation, 2012). Headache is listed as one of the 10 most disabling 
conditions world-wide (Martelletti, Birbeck, et al., 2013; Martelletti, Mitsikostas, et 
al., 2013; Stovner et al., 2007). Four percent (4%) of medical practitioner consultations 
and 20% - 30% of referrals to neurological departments in the United Kingdom are for 
headaches (Kristoffersen, Lundqvist, Aaseth, Grande, & Russell, 2013) and in 
America, headache is the fourth most common presentation at emergency departments 
with between 1.4 - 3.3 million visits per year (Kelley & Tepper, 2012a). 
 
Despite this, it has been identified that up to 50% of headache sufferers do not seek 
medical advice for headache and when they do many are wrongly diagnosed and 
wrongly treated. The WHO (2012) identified that worldwide an average of four hours 
of undergraduate medical training is dedicated to education on headache disorders. In 
contrast The University of Notre Dame Australia Physiotherapy undergraduate 
programme has 16 hours dedicated to assessment and management of the upper 
cervical spine and cervicogenic headache alone, suggesting physiotherapists are well 
prepared to be involved in the management of headache and in particular CGH (Wand, 
2014). Martelletti et al. (2013) advocate for better headache health-care services and 
improved training of physicians within these services to deliver more comprehensive 
and accessible services to headache sufferers (Martelletti, Mitsikostas, et al., 2013).  
 
Headaches are classified in the ICHD into primary and secondary headache. Primary 
headaches are those with a vascular or muscular origin occurring in the absence of any 
organic disorders while secondary headaches are attributed to other disorders such as 
inflammation or injury (Cathcart, Winefield, Lushington, & Rolan, 2010; Racicki, 
Gerwin, Diclaudio, Reinmann, & Donaldson, 2013). Secondary headache symptoms 
either resolve or reduce following treatment of the causative disorder.  
 
The most prevalent primary headaches found in the adult population are TTH and MH 
(Cathcart et al., 2010; Fernández-de-las-Peñas et al., 2006; Fumal & Schoenen, 2008). 
The most common secondary headaches include those triggered by alcohol, fever and 
medication overuse (Kristoffersen et al., 2013). Cervicogenic headache is considered 
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a secondary headache type with a quality of life burden similar to that of people 
experiencing MH and TTH (van Suijlekom et al., 2003). While less prevalent than 
TTH and MH the mechanisms behind CGH are some of the best understood (Bogduk 
& Govind, 2009). 
 
Each type of headache has a different pathogenesis and logically each respond to 
treatment specifically targeted to that headache type. Incorrect diagnosis and therefore 
inappropriate treatment can mean poor outcomes for the headache sufferer (Bogduk & 
Govind, 2009; Hall et al., 2008; Hall et al., 2007; Li et al., 2012). To complicate 
diagnosis and treatment even further some people will experience more than one 
headache type (Hall et al., 2008; Stovner et al., 2014). 
 
3.1.1  Prevalence of headache in the general population 
The WHO Global Burden of Headache study identified that headache affects 47% of 
the world’s population (Jensen & Stovner, 2008; Stovner et al., 2007). This figure was 
calculated to be the mean value of prevalence of headaches found in numerous 
headache studies conducted across North and South America, Asia and Europe 
(Stovner et al., 2007). Data on prevalence in these studies was collected from 
questionnaire or personal interview. The lifetime prevalence (47%) of headache was 
determined to be similar to the 1 year prevalence of 46%.  
 
There are some significant differences in prevalence of headache in recent studies. In 
Brazil in 2009, during a routine home visit by health officials, face to face surveys 
were conducted to determine a one year prevalence of headache in the entire 
population of one town (Junior et al., 2009). The response rate was 98.4% (n=1605). 
Participants were asked if they had any headache episodes in the previous twelve 
months. An overall twelve month prevalence of headache of 65.4% was found with a 
higher prevalence in women (69.5%) than men (60.9%) and prevalence of headache 
diminishing in people over 60 years of age. A slightly higher twelve month prevalence 
of 72.1% was documented by Queiroz et al. in a study undertaken 3 years earlier using 
the same questionnaire (Queiroz et al., 2009). Unlike Junior et al. (2009) this survey 
was not limited to one town but conducted across 27 states in Brazil with 3,848 people 
participating. Recruitment and was through randomised ‘cold call’ telephone calls and 
interviews were conducted over the telephone. The response rate was only 49.9%. 
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Junior et al. (2009) surmise that discrepancies in headache prevalence between these 
two studies may be attributed to the different response rates stemming from the two 
differing recruitment methods, that of the personal home visit, face to face approach 
versus the impersonal ‘cold call’ telephone approach. They suggest that in the case of 
‘cold call’ telephone recruitment, people without headache were less likely to engage 
thus creating a bias in the participant cohort resulting in a higher prevalence of 
headache. They also suggest that cultural and ethnic differences across the different 
regions of Brazil may have had an impact on prevalence of headache.  
 
Reza et al. (2012) asked an all-female population in Hawaii if they had been ‘bothered’ 
by headache in the preceding two weeks and found the two-week headache prevalence 
was 47% (Reza, Sievert, Rahberg, Morrison, & Brown, 2012). While it might appear 
that this prevalence is in line with the WHO Global Burden of Headache study (Jensen 
& Stovner, 2008; Stovner et al., 2007) for twelve month prevalence of headache no 
such assumption can be made. It is known that women have a higher prevalence of 
headache than men (Stovner et al., 2007) which might suggest that this two week 
prevalence is in fact less than the WHO twelve month prevalence. It is not possible to 
make a comparison between two week and twelve month prevalence, supporting the 
need for uniformity in methodology of headache research (Stovner et al., 2014). This 
study did support the theory of ethnicity contributing to variances in headache 
prevalence proposed by Junior et al. (2009) identifying that there was a higher 
prevalence of headache among Caucasian women (42%) compared to Chinese (30%) 
and Japanese (37%). 
 
The Norwegian Nord-Trondelag Health Studies (HUNT 2 and HUNT 3) determined 
the mean 1-year prevalence of headache was 38% (Linde, Stovner, Zwart, & Hagen, 
2011). Participants were asked in a mailed survey if they had ‘suffered’ from a 
headache in the past year. Linde et al. (2011) hypothesised that this low prevalence 
could be attributed to the number of people who responded ‘no’ to suffering from 
headache, who then continued to either complete some of the headache questions about 
characteristics of their headaches or record a headache in their diary. It could be 
surmised that some participants did not respond ‘yes’ because although they 
experienced headache they may not have felt that they actually ‘suffered’ from the 
headache. If the people who responded ‘no’ to suffering from headache but went on to 
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complete information about headache had been included with those responding ‘yes’ 
to suffering from headache the prevalence of 12 month headache would have been 
more comparable to the findings of Junior et al. (2009). 
 
Radtke and Neuhauser (2009) determined that 60.2% of Germans experienced 
headache in the previous twelve months. Data was collected via telephone interview 
with a 52.3% response rate comparable to that of Queiroz et al. (2009). Like the Linde 
et al. (2011) study, participants in this survey were also asked if they ‘suffered’ from 
headache. Unlike the Linde et al. (2011) study there was a high ‘yes’ response rate. 
Although not identified by the authors it is possible that similar to the Brazilian study 
by Queiroz et al. (2009) there may have been some bias in the recruitment process in 
that people who experience headache may have been more likely to engage in the 
telephone interview than those who do not. This study did identify that headache 
created a significant burden to the individual and society with reduced quality of life, 
loss of productivity and an increased use of healthcare resources (Radtke & Neuhauser, 
2009). Nearly one quarter of people who reported severe headache were seen by a 
physician equating to 8% of the population.  
 
The twelve month prevalence of headache in the Italian city of Parma was found to be 
42.8%, more comparable to the Burden of Headache study (Torelli et al., 2010). 
Participants in this study were asked in a face to face interview ‘did you have headache 
in the past year?’ It was determined in this study that most people only experience one 
type of headache with the number of headaches never greater than 2. Torelli et al. 
(2010) reported that this finding was in agreement with a previous 1999 study by 
Schwartz et al. who identified that 80% of headache sufferers only experience one type 
of headache. 
 
Headache is a global disorder associated with a significant level of disability. While 
headache is widespread throughout all continents, cultural and ethnic consideration 
may account for local variations in prevalence. Methodological variations including 
the recruitment process, the framing of questions about presence or absence of 
headache and the interpretation of the responses used to allocate participants into 
‘headache’ or ‘non-headache’ cohorts, the length and validity of questionnaires and 
factors such as whether the interview is conducted face to face, over the telephone or 
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by post impact on prevalence of headache cited in different studies. It also needs to be 
recognised that most people who have headache only experience one type but some 
people may experience two different headaches which may be problematic when 
trying to estimate prevalence rates of individual headache types.  
 
Prevalence rates for CGH, MH and TTH are of particular interest to this study. TTH 
is recognised as the most prevalent of headaches and has prevalence ranging from 20% 
to 70% with global 12 month prevalence of 42%. (Bezov, Ashina, Jensen, & Bendtsen, 
2011; Dong et al., 2012; Fernández-de-las-Peñas et al., 2006; Queiroz et al., 2009; 
Steiner, Stovner, & Birbeck, 2013; Stovner et al., 2007; World Health Organisation, 
2012). The second most common form of primary headache is MH with one year 
prevalence rates of between 11% -31% and the most current WHO figure of 14.7% 
(Kelley & Tepper, 2012a; Noseda & Burstein, 2013; Sjaastad & Bakketeig, 2008a; 
Stovner et al., 2007; World Health Organisation, 2012). One year prevalence of CGH 
is between 0.17% - 4.6% and estimated to account for between 15% and 20% of all 
chronic headache (Chaibi & Russell, 2012; Diener, Kaminski, Stappert, Stolke, & 
Schoch, 2007; Liebert et al., 2013; Racicki et al., 2013). Each of these headache types 
will be reviewed in more detail later in this literature review. 
 
3.1.2 Prevalence of headaches in people with schizophrenia and 
schizoaffective disorder 
In a study exploring pain in schizophrenia, Watson et al. (1981) recognised that as long 
ago as 1911, Bleuler in ‘Textbook of Psychiatry’ identified headache as the most 
common pain experienced by people with schizophrenia. In their own study of 78 
people with schizophrenia, Watson et al. (1981) too determined that headache was the 
pain problem most commonly experienced by this population and that all people who 
reported multiple pain sites included head pain as one of the sites. There is limited 
description of the methodology of data collection employed in this study of 46 men 
and 32 women, but it is likely that it was via face to face interview. This study was 
undertaken prior to the introduction of the International Classification for Headache 
(Sjaastad, Fredriksen, & Pfaffenrath, 1998) and no attempt was made to classify 
headache types although it was noted that no participant described their headache pain 
as tight, gripping or vice-like suggesting that TTH might have been uncommon.  
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Dworkin (1994) conducted a literature review investigating pain insensitivity in people 
with schizophrenia and cited previous studies stating that headache was the most 
common pain reported in this population (Dworkin, 1994). No data on prevalence was 
presented. In 1999 a controlled study of 108 people with schizophrenia and 100 healthy 
controls was undertaken by Kuritzky et al. (1999). Using a questionnaire to gather 
information in a face to face interview about headache prevalence, characteristics, 
management and impact the study determined that the prevalence of headache in 
people with schizophrenia was 48% while the prevalence in the control group was 
41%. This study focused on MH and TTH and found the prevalence of MH in the study 
group was 19.4% (21/108) and in the control group was 24% (24/100) while TTH in 
the study group was 28.7% (31/108) compared to 17% (17/100) in the control group. 
The study found no statistically significant differences in overall headache prevalence 
or prevalence of either headache type between the sample and control group. There 
was no consideration of CGH.  
 
There are methodological factors that may have impacted on the results of this study 
by Kuritzky et al. (1999). Firstly, like Linde et al. (2011), underreporting of prevalence 
of headache may be attributed to the process used to determine who experienced 
headache and who did not experience headache. People where asked if they were 
‘subject to headache’ and if they responded ‘no’ were asked no further questions. 
However, people may interpret ‘subject to headache’ in different ways and respond 
differently as it is a statement open to a number of interpretations. It is possible that 
people who experienced infrequent headache may have answered ‘no’, believing that 
they would only be ‘subject to headache’ if headaches were frequent. Secondly, 
prevalence may be affected by the gender distribution of the participants. The only 
demographic questions in this study were age and socioeconomic background so it is 
unknown if both males and females participated. As previously noted, females have a 
higher prevalence of headache so if either very few or no females were in this study 
then the prevalence could be affected (Stovner et al., 2007). There is a need for more 
investigation of prevalence of headache in a cohort that can be identified as a true cross 
section of people with schizophrenia to be able to provide accurate estimates on the 
actual prevalence of headache in this population.  
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The second Australian National Survey of Psychosis surveyed a random cross section 
of people identified with psychotic illness and conducted interviews with 1,825 people 
(Morgan et al., 2012). Almost one third (32%) reported chronic back, neck or other 
pain and 25.4% reported frequent or severe headaches and migraine (Morgan et al., 
2012). No explanation was given as to what severe headache meant or how a diagnosis 
of migraine was determined, nor was it possible to specifically identify prevalence 
rates within the schizophrenic or schizoaffective disorder population. Although 
interesting, this survey does not provide accurate representation of headache within 
this population. 
 
Lake et al. (2005) noted that since 1999 very little research has been conducted into 
the prevalence and characteristics of headache experienced by people diagnosed with 
psychiatric illnesses. It is their opinion that despite an IHS classification for headache 
attributed to psychotic disorder (ICHD-2 12.1) where headache is a delusional belief; 
there are in fact very few instances where headache truly is a psychotic phenomenon. 
This is consistent with Watson et al. (1981) who reported that hallucinated pain was 
uncommon among people with schizophrenia. Lake et al. (2005) suggest more 
research is required to accurately identify both the psychiatric diagnosis and the 
headache diagnosis to determine true prevalence and characteristics of headache in this 
population.   
 
Kuritzky et al. (1999) determined that 40% of the people with schizophrenia who 
experienced headache had not ever reported it to a health practitioner and suggest that 
this might be for fear of hospitalisation or simply because they have no-one to 
complain to. In comparison Watson et al. (1981) found that 80% of people with 
schizophrenia who experienced pain had reported it to a health professional. Neither, 
Kuritzky et al. (1999) nor Watson et al. (1981) report on whether appropriate treatment 
was implemented or if there was any follow up once the pain was reported. As 
suggested by Lake et al. (2005), a headache screening tool for people attending 
psychiatric clinics would be useful to help guide management and better treatment 
outcomes for this group of people.  
 
Developing a simple screening tool that identifies presence of headache is not 
sufficient to guide management because different headache types manifest in response 
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to different mechanisms. To develop a screening tool to help guide the user towards 
the pathway to access appropriate expert assessment and management of headache 
there needs to be an understanding of the mechanisms driving the particular headache 
type. The following sections will focus on prevalence, characteristics, mechanisms 
driving impairment and management of CGH, MH and TTH. 
 
3.2  Cervicogenic Headache 
The Cervicogenic Headache International Study Group have developed the clinical 
diagnostic criteria of CGH and provided the information and detail about the condition 
for the 2004 ICHD operational criteria (Chaibi & Russell, 2012). CGH is a secondary 
headache that presents as unilateral pain originating in the neck, usually without side 
shift and is triggered by a sustained awkward neck position or pressure over the upper 
cervical joints. Symptoms can be reduced through physiotherapy involving manual 
therapy and exercise.  
 
3.2.1  Prevalence of CGH 
The prevalence of cervicogenic headache in the general population varies from 0.17% 
to 4.6% depending on the characteristics of the study (Knackstedt et al., 2010). 
Prevalence of CGH within the headache population has been identified as between 
14% - 20% (Fleming et al., 2007; Liebert et al., 2013; Zito et al., 2006). Studies have 
shown that the mean age of onset of CGH is 33 years with people experiencing them 
for between 7 and 17 years (Antonaci & Sjaastad, 2011; Hall et al., 2008). A significant 
difference exists between hospital based studies and community based studies in the 
preponderance of CGH experienced by females versus males, with females having a 
higher prevalence of CGH in hospital settings. This gender difference is not apparent 
in community settings (Anthony, 2000; Chaibi & Russell, 2012; Diener et al, 2007; 
Sjaastad & Bakketeig, 2008b). No studies have been conducted to identify prevalence 
of CGH in people with schizophrenia and schizoaffective disorder. 
 
3.2.1  Clinical characteristics of CGH 
Characteristics of CGH include unilateral, side locked headache originating from the 
neck, exacerbated by neck movement and/or sustained awkward neck position and/or 
external pressure over the occipital region on the side of pain. Moderate to severe pain 
refers from the neck to frontal regions supplied by the trigeminal nerve (Frese, 
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Schilgen, Edvinsson, Frandsen, & Evers, 2005; Vincent, 2010). There is usually 
restriction in ROM of the upper cervical segments. Neck, shoulder and arm pain may 
also be present. In general a forward head posture is associated with cervicogenic 
headache although this has also been observed in those with migraine and tension type 
headache (Jull et al., 2008).  
 
Diagnostic anaesthetic blocks can be used to provide further diagnostic information, 
(Anthony, 2000; Narouze, Casanova, & Mekhail, 2007) although as identified in the 
pilot study, many people with MH and TTH also complain of neck pain (Fernández-
de-las-Peñas et al., 2014). The value of diagnostic blocks for diagnosis is discussed 
later.  
 
3.2.3  Mechanisms behind CGH 
Cervicogenic headache is a problem of referred pain (Bogduk & Govind, 2009). 
Painful dysfunction of somatic structures within the cervical spine give rise to the 
experience of head pain due to the convergence of afferent information within the 
trigemino-cervico nucleus. The exact nature of somatic tissue dysfunction is not clear 
and may in fact represent different processes in different individuals. However, there 
is now substantial evidence that people with CGH demonstrate impairments in the 
articular, muscular and proprioceptive function of the upper cervical spine (Bogduk & 
Govind, 2009; Frese & Evers, 2008; Narouze et al, 2007; Vincent, 2010).   
 
When a noxious input is generated from structures within the upper cervical spine it 
may be expected that pain would be localised to this region and not manifest as 
headache. However, according to Bogduk (1993) pain from the skin is the only pain 
that is felt locally, relating back to a basic human instinct where survival may be 
dependent on the brain receiving accurate information from external noxious stimuli 
and implementing an appropriate and immediate response. When actual or potential 
damage occurs to the skin the nociceptive afferent impulse is relayed to the ventral 
posterior lateral (VPL) nucleus of the thalamus and then to higher centres including 
the parietal lobe via the highly organised neospino-thalamic pathway. At the same time 
information from non-nociceptive receptors such as touch and pressure are also 
transmitted to the VPL nucleus of the thalamus via the even more organised posterior 
columns. The thalamus is thus receiving two highly specific and complementary 
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messages that can accurately define and localise the source of noxious input. As the 
noxious stimulation is superficial it is also likely that visual information is available to 
further aid localisation. 
 
In the case of tissue other than skin, the information reaching the thalamus and cortex 
about the localisation of noxious stimuli is less well defined so in many instances the 
pain is often felt at a distance from the source or may be felt to radiate from the source. 
This is called referred pain (van Griensven, 2005). The exact mechanism of referred 
pain is not fully understood, however, the projection-convergence model is the most 
widely discussed. This model proposes that messages about noxious stimuli from deep 
tissues are relayed through the spino-reticular system which is less well organised than 
the neospino-thalamic pathway. At the same time the brain is not receiving additional 
information about touch and/or pressure to enable localisation of the noxious source. 
Visual information may also be lacking. As a result of receiving less specific 
information the brain cannot pinpoint the location of the source of nociceptive input. 
According to Galea (2002) the brain is probably able to localise the source of 
nociceptive input from deep tissue only to the level of a particular spinal segment 
(Galea, 2002). Armed only with this information the individual then attempts to 
localise the source of afferent traffic further based on other available information 
including other sensory information, past experiences and general knowledge.   
 
Anatomy of the innervation and neural pathways around the upper cervical segments 
is essential to understanding the mechanism of headache associated with noxious 
stimuli in this region. The spinal trigeminal nucleus is a column of cells that descend 
through the pons and medulla where upper cervical segments combine to form the 
trigemino-cervico nucleus within the posterior horn of the upper cervical cord 
(Anthony, 2000). Nociceptive afferents of the trigeminal nerve and C1, C2 and C3 
spinal nerves converge onto the second order neurones in the trigemino-cervical 
nucleus in the upper cervical cord (See Figure 2) (Bogduk & Govind, 2009; Chaibi & 
Russell, 2012; Knackstedt, Kråkenes, Bansevicius, & Russell, 2012).  
 
With the convergence of spinal and cranial nerve afferents in the trigemino-cervical 
nucleus nociception from upper cervical region can be experienced as referred pain in 
the areas of sensory distribution for the cervical nerves, the occiput and auricular  
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Figure 2 - Mechanism of pain referral from the cervical spine to the head. 
(Reproduced from Bogduk & Govind, 2009) 
 
  
 
regions of the head, as well as to sensory distributions of the trigeminal nerve, in 
particular the ophthalmic branch which innervates the parietal, frontal and orbital 
regions (Bogduk & Govind, 2009; Fleming et al., 2007). Anthony (2000) calls this a 
‘cervico-trigeminal relay’ and suggests through it nociception from any structures 
innervated by C1, C2 or C3 spinal nerves can be experienced as referred pain from the 
neck to the frontotemporal region of the head and vice-versa (Anthony, 2000). 
Fleming, Forsythe and Cook (2007) suggest that pain can arise from theatlanto-
occipital, median atlanto-axial, lateral atlanto-axial and C2/3 zygapophyseal joints, 
C2/3 intervertebral discs, musculature of the suboccipital, upper posterior cervical and 
upper paravertebral regions, the trapezius and sternocleidomastoid muscles (Anthony, 
2000; Fleming et al., 2007). According to Bogduk and Govind (2009) the source of 
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noxious input in 70% of cases is the C2/3 zygapophyseal joint. They claim to have 
provided complete pain relief by using fluoroscopically guided diagnostic blocks of 
the third occipital nerve where it crosses the C2-3 zygapophyseal joint (Bogduk & 
Govind, 2009).  
 
Identifying the primary source of noxious input is a key element in the diagnostic 
criteria of the ICHD and the CHISG, listed in both as ‘confirmatory evidence by 
diagnostic anaesthetic blockades’. The most accurate diagnostic anaesthetic blockade 
procedure is still to be determined. In an editorial in The Spine Journal, Carragee et al. 
(2007) cite many invasive diagnostic tests which have been used to diagnose CGH, 
including single joint injection, tests using both provocative and anaesthetic injections 
(similar to that used by Bogduk and Govind in 2009), tests comparing anaesthetics 
with varying pharmacologic-range effects and tests that include placebo-controlled 
injections. They maintain that none are fully validated and most studies do not meet 
the British Medical Journal and the Journal of the American Medical Association 
criteria for low risk of bias diagnostic studies (Carragee, 2007). The main criticisms 
are the inconsistency in what might constitute a positive block and the lack of a true 
gold standard against which the blocks themselves might be validated. 
 
Physiotherapists maintain that they can diagnose CGH through examination of the 
upper cervical spine thus eliminating the need for invasive testing (Zito et al, 2006). 
Bogduk and Govind (2009) discount these claims saying they have not been validated, 
though how they might be validated is still an unresolved issue. While Carragee et al. 
(2007) do not discredit physiotherapeutic examination as a clinical test they do not 
support the notion that it has high levels of accuracy (Carragee et al., 2007). There is 
obviously a need for more rigorous studies to be undertaken on the physical assessment 
of CGH.  
 
Dysfunctions in the structures innervated by the ‘trigeminal relay’ are not only evident 
in CGH but can be found in people with MH (Knackstedt et al., 2012; Vincent, 2010). 
When exploring the differences between MH and CGH, Sjaastad and Bakketeig (2008) 
determined that the restrictions in the average range of motion of the neck was 
significantly greater in people with CGH with 93% of people experiencing limitations 
of ≥15° compared to only 16% of people experiencing MH. Sjaastad and Bakketeig 
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(2008) also found that ‘cervicogenic factors’ (CF) were more significant in people 
experiencing CGH than MH. These CF included pain provocation through pressure on 
the tendon insertion in the occipital area or facet joints, ipsilateral shoulder discomfort, 
radicular arm pain, posterior onset of headache and unilateral pain. They determined 
there was clear distinction between MH and CGH and any neck involvement in MH 
was more subtle and of a different nature. 
 
It is worth noting that Frese & Evers (Frese & Evers, 2008; Frese et al., 2005) 
demonstrated there is no increase of calcitonin gene-related peptide, an indicator of 
trigeminal-neurovascular activation found in MH, in people with CGH. This further 
supports the theory that the trigeminal nerve involvement is via the ‘cervico-trigeminal 
relay’ thus providing a biological marker that differentiates between CGH and MH 
and discredits the theory that CGH and MH are on a continuum as proposed by Watson 
and Drummond (2012). MH will be discussed in more detail in the next section.   
 
Noxious input from upper cervical muscles, facet joints, and ligaments has been shown 
to produce head pain (Chaibi & Russell, 2012; Knackstedt et al., 2012) but 
dysfunctions in these structures does not necessarily mean presence of CGH clinically. 
Dysfunction in musculoskeletal function need not be nociceptively active and not all 
nociceptive activity is interpreted as pain. Vincent (2010) suggests that while 
dysfunction within the cervical structures is necessary for CGH to occur the headache 
response may not be triggered without an essential ‘central disposition’. While the 
experience of pain is often associated with noxious input, the two are not synonymous. 
For the perception of pain to emerge into consciousness, nociceptive information is 
integrated with other sensory inputs and scrutinised in relation to relevant 
psychological and contextual influences. The pain experience is constructed if the 
individual feels that the body is under threat and that survival/recuperation is best 
served by the construction of the pain experience. In the case of CGH this means 
recognising noxious input from the cervical region as a threatening stimulus. This 
cortical recognition will vary from one person to the next because psychological, 
emotional, behavioural and physical factors all contribute to the perception of and 
response to pain (Galea, 2002). A person’s previous experience with pain, their 
understanding of the pain mechanism and what pain represents to them all impact on 
their responses to input from cervical structures. These factors have been extensively 
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explored in people with low back pain. The role psychological factors play in 
experience of CGH is poorly researched and not well understood. It is also unclear 
how theoretical models such as fear avoidance belief model would relate to pain in the 
head. 
 
3.2.4  Management of CGH 
Both invasive procedures and non-invasive rehabilitative approaches have been 
advocated for the management of CGH (Bogduk & Govind, 2009). Invasive 
procedures include surgery and injection of blocking agents while non-invasive 
techniques include massage, exercise, manipulation and/or mobilisations. 
 
A review conducted by Tobin and Flitman (2009) proposed that occipital nerve block 
is effective in the treatment of CGH citing the double blinded randomised controlled 
trial (RCT) conducted by Naja et al. (Naja, El-Rajab, Al-Tannir, Ziade, & Tawfik, 
2006). It was noted, however, that the selection criteria for participants in the Naja et 
al. study was based on the 1988 ICHD criteria rather than the 2004 ICHD criteria 
suggesting that some participants may not have actually had CGH but could have had 
occipital neuralgia thus impacting on results. Three other studies where participants 
showed some improvement post treatment were included in the review but none of 
these studies were RCT’s (Tobin & Flitman, 2009). The authors identified a significant 
lack of RCT’s exploring the efficacy of nerve blocks in the management of CGH. 
 
A systematic review by Ashkenazi et al. (2010) further highlighted the lack of evidence 
supporting the efficacy of peripheral nerve blocks for treatment of CGH (Ashkenazi 
et al., 2010). They identified that the most common site for nerve block injection is the 
greater occipital nerve. The authors pointed out once again that very few studies 
evaluating the use of nerve blockades in headache management were RCT’s. They 
highlighted that any studies undertaken thus far have limitations including small 
patient numbers or were retrospective designs without controls (Ashkenazi et al., 
2010). While the Naja et al. (2006) study was acknowledged as a double blinded, 
randomised controlled study, Ashkenazi and colleagues were critical of the use of 
polypharmacy which could have confounded results. The Ashkenazi et al. (2010) 
review identified a lack of uniformity and consistency across trials in the techniques 
used for nerve blockade, the types of anaesthetic used, the dose and volume 
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administered and the location of the injection making it difficult to compare results. It 
is evident that more rigorous research needs to be undertaken to determine the efficacy 
of this treatment. 
 
In 2010 Zhou et al. conducted a retrospective evaluation of facet joint injections in a 
study of 31 people following injections into C1/C2 and C2/3 facet joints using a 
mixture of anaesthetic (bupivacaine) and corticosteroid (betamethasone) for treatment 
of CGH (Zhou, Hud-Shakoor, Hennessey, & Ashkenazi, 2010). Data was collected 
retrospectively by looking through medical charts of people who attended a medical 
centre for headache. At the clinic patients had been seen for follow up 14 days after 
injection and then once a month for between 3 and 24 months. The researchers found 
that 90% of participants had greater than 50% relief of their headache immediately and 
then for an average of 21 days following injection (Zhou et al., 2010). They 
acknowledged that their study had limitations with no control group, a small sample 
size and that data was collected retrospectively.  
 
A 2015 review of studies of facet joint injections by Ng and Wang discussed only three 
trials (Ng & Wang, 2015). These included the retrospective medical chart reviews by 
Zhou et al. (2010), another by Narouze et al. (2007) and a prospective study by Bovim 
et al. (1992) (Ng & Wang, 2015). The Narouze et al. (2007) review of 32 patients 
diagnosed with CGH highlighted that there was insufficient data to support the use of 
atlanto-axial joint injection for long term relief of CGH. In 1992 Bovim et al. 
conducted a small prospective study on 14 females who underwent C2/C3 facet joint 
injections and C2-C5 nerve blocks determining that C2 nerve block was the more 
effective treatment. Based on only these three reviews Ng and Wang (2015) 
determined that there is limited efficacy in the use of facet joint injections for the 
management of CGH. 
 
No RCT’s examining the efficacy of surgery in the management of CHG. could be 
found. In 2009 Riina et al. conducted a retrospective analysis of 1,004 patients, 2 years 
after they had undergone either an upper cervical arthrodesis or a disc arthroplasty for 
CGH (Riina et al., 2009). They determined that there was improvement in headache 
pain following both procedures with 64% of patients undergoing arthroplasty and 58% 
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of patients undergoing arthrodesis reporting reduction in pain scores of at least one 
point on a visual analogue scale.  
 
Research on non-invasive management of CGH is more prolific and robust than for 
invasive management. Fleming, Forsythe and Scott (2007) identified in a limited 
retrospective review of patient charts (n=44) that participants had best outcome from 
manual therapy and exercise for treatment of CGH (Fleming et al., 2007). They also 
highlight the importance of including an holistic approach to patient care. A systematic 
review undertaken in 2011 went one step further to suggest there is no evidence to 
support the use of spinal manipulation alone as an effective treatment for CGH 
(Posadzki & Ernst, 2011). Another review by Chaibi and Russell (2012) identified 
physiotherapy treatment of exercises in combination with spinal manipulation as an 
effective treatment for CGH although highlighted that all RCT’s considered were 
based on participants who experienced only infrequent CGH and could not comment 
on people with more chronic CGH (Chaibi & Russell, 2012). A more recent systematic 
review by Racicki et al. (2013) of RCT’s exploring the efficacy of conservative 
management of CGH proposes that a combination of mobilisation, manipulation and 
exercises to strengthen the cervico-scapular mechanisms is the most effective 
conservative therapy.   
 
In 2013 Liebert et al. (2013) undertook an investigation to explore physiotherapist’s 
perceptions of why some people were non-responsive to physiotherapeutic treatment 
for CGH. A survey was distributed to 290 registered physiotherapists with a mean 24.4 
years of experience. There was a 31% response rate (90/290). They determined that 
factors associated with poor treatment outcomes were a history of severe trauma such 
as motor vehicle accident and a family history of any headache type. Responses to 
open ended questions provided some qualitative data suggesting that physiotherapists 
also perceived psychosocial factors such as depression and anxiety contribute to non-
responsiveness. 
 
3.3  Migraine Headache 
Migraine is a primary headache and ranks seventh highest globally in the causes of 
disability, being responsible for 2.9% of all years of life lost to disability (Steiner et al, 
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2013). Attributed to being a common neurovascular disorder, MH is characterised by 
unilateral, pulsating pain of a moderate to severe nature, lasting up to 72 hours 
(Zielman et al., 2012). MH is often associated with vomiting, nausea and/or 
photophobia or phonophobia 
 
3.3.1  Prevalence of MH 
Prevalence of MH varies considerably between studies and regions. Kelley and Tepper 
(2012a) have identified that Europe has the highest prevalence of MH with 15% 
prevalence, followed closely by North America with 13%. Africa has the lowest 
prevalence of MH at 5%. According to Noseda and Burstein (2013) around 16% of the 
global population experience MH while Stovner et al. (2007) found a global 
prevalence of 11%. The World Health Organisation (WHO), Global Burden of Disease 
Survey 2010 estimated the worldwide prevalence of MH as 14.7% (Steiner et al., 
2013). Differences in prevalence across studies can be attributed to discrepancies in 
data sampling used, diagnostic criteria applied for classification, data management and 
statistical analysis (Stovner et al., 2014). Guidelines are being developed by an expert 
panel to try and better standardise studies exploring prevalence of headache (Stovner 
et al., 2014).   
 
Uniformly there is a higher prevalence of MH in females than males. The American 
Migraine Prevalence and Prevention (AMPP) study identified the prevalence of 
migraine in females to be 17.1% compared to males 5.6% (Stewart, Wood, Reed & 
Lipton, 2008). Junior et al. (2012) found a difference in the prevalence of MH with 
prevalence in females of 26.4% and males of 8.5%. The AMPP study also determined 
that women experience greater symptomology and increased disability associated with 
the MH than males (Stewart et al., 2008). No studies have been conducted to identify 
prevalence of MH in people with schizophrenia and schizoaffective disorder. 
 
3.3.2  Clinical Characteristics of MH 
The two categories of MH considered in this study are Migraine without Aura and 
Migraine with Aura. Migraine without aura has some characteristics similar to both 
CGH and TTH. Pain is usually unilateral, as is the case in CGH, but studies have 
identified that this is in only about 60% of cases with pain in the remaining 40% being 
bilateral, similar to the distribution for TTH. To complicate classification, the location 
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of the pain varies between individuals and in some instances even varies between 
attacks experienced by the same person (Hussain, Stiles, & Oshinsky, 2010). Pain 
characteristics, however, are different from CGH and TTH as pain is pulsating or 
throbbing, is usually more severe and generally of a shorter, relatively fixed duration. 
MH pain is aggravated by general physical activities such as climbing stairs, 
something not associated with other headache types. Nausea, photophobia, 
phonophobia, heightened sensitivity to smell, cognitive, emotional and motor 
disturbances are also more commonly present with MH (Hall et al., 2008; Noseda & 
Burstein, 2013).  
 
About one third of MH are preceded by an aura which commonly presents as flickering 
lights or spots in the field of vision, numbness or pins and needles before the onset of 
pain. These symptoms are fully reversible within 60 minutes (Hall et al., 2008) and if 
aura symptoms do not subside in that time they may be an indicator of more serious 
medical conditions. The presence of an aura is a strong indicator of a MH. 
 
Comorbid neck pain has been observed in people with MH but variations in headache 
classification, data sampling and data collection across different studies means that 
there is no consensus on the prevalence. With neck pain being a dominant feature of 
the unilateral CGH it can be challenging when trying to differentiate between CGH 
and MH. An example of this challenge can be found in Calhoun et al. (2010) who 
made a differentiation between CGH and MH by classifying those participants 
presenting with a cervical mechanical precipitation to their headache or with reduced 
cervical range of motion as CGH (Calhoun et al., 2010). As previously discussed 
presence of dysfunction in the cervical spine does not necessarily mean a diagnosis of 
CGH and it is possible that people were wrongly classified (Vincent, 2010).  Calhoun 
et al. (2020) did however include people in the MH cohort who experienced neck pain 
(without a mechanical precipitation) that radiated forward so it is possible that these 
people were indeed experiencing CGH as pain starting in the neck is a defining feature 
of CGH (Frese & Evers, 2008; Sjaastad, 2008; Sjaastad & Bakketeig, 2008a). Some 
studies on MH do not consider or do not recognise CGH as a possible differential 
diagnosis while others view CGH as being on the continuum of MH (Ashina et al., 
2014; Fernández-de-las-Peñas et al., 2006; Florencio et al., 2014; Watson, 2012). 
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3.3.3  Mechanisms behind MH 
Migraine headache is often considered an inherited condition with many people 
experiencing MH having a first degree relative who also experience MH (Ashina & 
Bendsten 2013). Pain is not believed to be related to tissue damage or any detectable 
pathology but can be triggered by environmental factors such as fatigue, lack of sleep, 
certain foods, smoke, hunger, menstrual cycle and even bright light (Landy, Rice, & 
Lobo, 2004). 
 
It is thought that the causative mechanism in migraine is an altered excitability in the 
brain in response to these environmental triggers activating the trigemino-vascular 
system (Hall et al., 2008; Noseda & Burstein, 2013). Theories have been proposed 
about the possible over excitability (dysexitability) of different cortical areas and 
Cosentino et al. reported findings that supported cortical hyper-responsivity as an 
explanation for susceptibility to migraine (Cosentino et al., 2014).  
 
A phenomenon called cortical spreading depression (CSD) occurs spontaneously once 
a critical threshold of neurochemical changes has occurred in the brainstem in response 
to the environmental stimuli and prior to the onset of headache. During CSD neural 
activity across the cortex diminishes as does the cortical blood flow and this is thought 
to trigger visual aura and other prodome associated with MH (Kelley & Tepper, 
2012a). Following CSD dural blood flow increases and the vessels dilate. At this stage 
meningeal nociceptors are activated releasing calcitonin gene-related peptide and other 
neuropeptides which in turn trigger further vasodilation and an inflammatory reaction. 
 
Innervation of the meninges and intracranial vasculature originates in the trigeminal 
ganglion and passes along the trigeminal nerve with additional innervation arising 
from the neurons in the upper cervical dorsal root ganglion (Noseda & Burstein, 2013). 
Activation of nociceptors in the dura mater, meningeal vessels, intracranial segments 
of V, IX and X cranial nerves as well as intracranial segments of the basilar, vertebral 
and carotid arteries, trigger signals which are transmitted to the spinal trigeminal 
nucleus in the medulla and the dorsal horn of the upper cervical spine. Similar to CGH 
headache pain experienced in MH is referred through the trigeminal nerve pathways, 
predominately the ophthalmic branch but to a lesser extent the maxillary and 
mandibular branches too (Noseda & Burstein, 2013). It has been noticed that that once 
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a MH has begun, neuroplastic changes may alter the response profile of nociceptive 
neurons such that pain may continue without further noxious stimuli (Landy et al., 
2004).  
 
3.3.4  Management of MH 
MH is associated with a significantly decreased quality of life so it is no surprise that 
people experiencing MH would ideally like a treatment that provides long lasting and 
complete pain relief, without side effects (Kelley & Tepper, 2012b; Zielman et al., 
2012). Medication is the first choice of treatment for most migraine sufferers (Wells 
et al., 2014). The European Headache Federation identifies two steps in management 
of MH 
 Step One - symptomatic therapy  
 Step Two - specific therapy  
It is advised that Step Two should not be considered unless Step One has been tried 
three times without success (World Health Organisation, 2012). 
 
Symptomatic therapy includes administration of medication to target the symptoms of 
migraine including simple analgesics, non-steroidal anti-inflammatory drugs 
(NSAIDs) and antiemetic medication. Pain killers such as paracetamol and 
acetylsalicylic acid are taken to relive headache pain. NSAIDs such as ibuprofen and 
naproxen act to reduce the inflammatory responses associated with migraine and 
therefore reduce the activation of nociceptors and subsequently pain. Use of 
antiemetic’s can reduce the symptoms of nausea and vomiting.  
A systematic review by Kelley and Tepper (2012a) noted that over half of people 
suffering from MH use ‘over the counter’ analgesics such as paracetamol and 
acetylsalicylic acid to treat their headache. A Cochrane Review of the efficacy of 
paracetamol in the management of MH highlighted that paracetamol is superior to 
placebo in reducing pain from moderate or severe to mild or no pain in 2 hours (Derry 
& Moore, 2013). There is not enough data to determine its efficacy beyond 2 hours 
(Derry & Moore, 2013) resulting in the WHO guidelines for symptomatic therapy 
advising that paracetamol has limited efficacy in the management of MH. Another 
Cochrane Review identified that 1,000mg of effervescent acetylsalicylic acid is more 
effective in the management of MH providing a 2 hour pain free response similar to 
Sumatriptan (a specific therapy which will be discussed later), however, there were no 
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studies to provide data for 24 hour relief so the longer term benefits are unknown 
(Kirthi, Derry, & Moore, 2013). 
 
Ibuprofen is an ‘over the counter’ NSAID used to manage MH. The Cochrane Review 
described Ibuprofen as an effective medication in the management of MH providing 
significant pain relief to half of the people who take it (Rabbie, Derry, & Moore, 2013). 
It was noted, however, that very few people experienced complete pain relief. Another 
NSAID used in the management of MH is Naproxen. The Cochrane Review 
investigating the efficacy of Naproxen for treatment of MH identified that the 
medication was better than a placebo but is not clinically useful being effective in less 
than 1 in 5 people (Law, Derry, & Moore, 2013). Kelly and Tepper’s Systematic 
Review (2012c) identified that intramuscular or intravenous Ketoprofen provides 
temporary relief of MH symptoms, however, this requires the person to present 
themselves to a medical practitioner to receive treatment.  
WHO guidelines for Step One are 
 use soluble analgaesics 
 take early in the attack 
 use antiemetic medication as required 
 rectal administration of medications may be preferable if vomiting is present. 
 
When Step One has been implemented three times and is not successful in managing 
the MH then Step Two, specific therapy of either triptans or ergotamines should be 
instigated. The WHO recommends that triptans should be offered as a first option of 
treatment. Triptans act to constrict blood vessels and inhibit the release of the 
vasodilator calcitonin gene-related peptide responsible for further vasodilation. 
Triptans also inhibit the release of anti-inflammatory peptides in the meninges which 
subsequently reduces pain. Ergotamine acts similarly to triptans but also block 
activation of the trigeminal nucleus caudalis reducing headache (Kelley & Tepper, 
2012a).  
 
The two most common triptans are Sumatriptan and Rizatriptan. Sumatriptan was the 
first marketed and is used extensively world-wide (Derry, Derry & Moore 2014). An 
overview of four Cochrane reviews of Sumatriptan indicates it provides fast acting 
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pain relief and in the case of subcutaneous administration can provide relief within 2 
hours (Derry, Derry, & Moore, 2014; Kelley & Tepper, 2012a). The WHO suggest 
that up to 40% of people who initially respond to triptans have their symptoms return 
within 48 hours at which time a second dose may be administered (WHO 2012). 
Subcutaneous administration provides more rapid response but comes with increased 
adverse effects which include chest pressure, neck tightness, limb heaviness, tingling, 
dizziness and flushes and its use is only recommended with caution.  
 
The WHO (2012) recommends that triptans should not be used more than 10 
days/month. Triptans have very varied efficacy on individuals and in many instances 
patients may need to try several before finding the most effective one for them. It has 
been identified that triptans are more effective when taken during the mild phase of 
the headache. 
 
Dihydroergotamine (DHE) provides slower but longer lasting relief than Sumatriptan. 
Unfortunately there are side effects of which nausea is the most common, followed by 
diarrhoea, abdominal cramps, vasoconstriction and leg pain (Kelley & Tepper, 2012a). 
The WHO (2012) found that while ergotamines has a longer duration of action which 
can provide longer relief of symptoms than Sumatriptan, in many instances this also 
results in poor tolerability in the long term. 
 
WHO guidelines for Step Two are 
 use of triptans first 
 do not use triptans for more than 10 days/month 
 begin with only one tablet and administration of a second tablet is not 
recommended if non responsive to the first 
 triptans are more effective if administered while headache is mild 
 
Landy et al. (2011) noted that when treatment for MH is instigated within the first hour 
of the episode that the MH lasts a significantly shorter time than when treatment is 
commenced more than an hour after symptoms manifest (Landy, Runken, Bell, Higbie 
& Haskins, 2011). This finding is consistent with the WHO recommendations. Not 
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having medication available was the most common response for not taking medication 
within the hour (Landy et al, 2011).   
 
When MH manifests more than two days a month, and acute therapy as described 
above does not prevent this, prophylactic medication should be considered (WHO 
2012). Zielman et al. (2012) found that only 18% of people who met the criteria for 
prophylactic treatment referred to neurologists in The Netherlands where actually 
taking prophylactic medication. There exists significant variation between countries in 
the number of people taking prophylactic treatment for MH, although is it recognised 
that the number of people taking prophylactic medication is much lower than the 
number of people who actually meet the criteria for prophylactic treatment (Zielman 
et al., 2012). It is not known if this is because people are not prescribed the medication 
or if they chose not to take it. It appears that anti-emetic medication is also underused.  
 
Two medications recognised by the WHO as effective prophylactic medication for MH 
are the mood stabiliser sodium valproate, a medication used extensively in the 
management of schizoaffective disorder and the antidepressant drug amitriptyline used 
in the management of depression associated with schizoaffective disorder or 
schizophrenia. It may be possible that people taking these medications for their mental 
illness are inadvertently receiving prophylactic medication for MH thus impacting on 
the prevalence of MH manifesting in this population.  
 
Non pharmaceutical treatment may be considered by people experiencing MH either 
in isolation or in combination with pharmacological based treatments. A systematic 
review of RCT’s exploring the efficacy of spinal manipulation in the management of 
MH has identified a serious lack of reliable research that will either support or refute 
this form of treatment for MH (Fernández-de-las-Peñas et al, 2006). Neck pain, 
however, is often experienced by people with MH and is seen as a confounder that 
may affect treatment choice (Ashina et al., 2014; Florencio et al., 2014).  
 
Other non-pharmacological treatments and/or preventative measures considered in the 
US Headache Consortium guidelines (Wells et al., 2014) include relaxation training 
and cognitive behavioural therapy (CBT). These conservative therapies have evidence 
to support their use in the preventative management of MH based on evidence from 
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39 controlled trials (Wells et al., 2014). Although there is no evidence to support the 
efficacy of meditation and yoga about half of Americans who experience MH report 
using them to assist with management (Wells et al, 2014). A more recent technique 
considered is mindfulness training which has been shown to assist in management of 
chronic pain. Despite some positive trends from a recent small RCT pilot study there 
is no evidence to support the use of mindfulness an effective treatment for MH (Wells 
et al., 2014). 
 
3.4  Tension Type Headache 
TTH is considered one of the most prevalent primary headaches yet the 
pathophysiology behind the headache is less well understood than MH and CGH 
(Cathcart et al., 2010;  Jensen, 2003). Unlike all other headache types, diagnosis of 
TTH relies entirely on clinical symptoms and is often diagnosed by the absence of 
features of other headache types (Fumal & Schoenen, 2008). ICHD characteristics 
include band like bilateral, pressing or tightening pain of a mild to moderate intensity.  
 
3.4.1  Prevalence of TTH 
Tension Type headache has been identified as the most prevalent headache (Li et al., 
2012; Queiroz et al., 2009) with a global point prevalence estimated at 20% (Steiner 
et al., 2013) and a 12 month prevalence of 42% (World Health Organisation, 2012). 
Prevalence of TTH is higher in women than men and tends to decrease with age in 
both genders (Fumal & Schoenen, 2008), although one study by Queiroz et al. (2009) 
determined prevalence was higher in men with a higher education. 
 
Kuritzky et al. (1999) determined the prevalence of TTH amongst people with 
schizophrenia to be 28.7% using the criteria that all headaches not fitting the definition 
for MH were classified as TTH. This cannot be an accurate figure of TTH but simply 
a figure of all headaches that were not MH. No other studies have explored the 
prevalence of TTH in this population.  
 
3.4.2  Clinical characteristics of TTH 
Characteristics of TTH include bilateral mild to moderate pain most frequently in the 
frontal region but also experienced in the parietal and occipital regions (Li et al., 2012). 
Headache may last from 30 minutes to up to seven days (The Headache Classification 
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Subcommitee of the International Headache Society, 2004). TTH has sometimes been 
called a ‘featureless headache’ being simply an experience of pain predominately 
described as pressing or tight (Fumal & Schoenen, 2008). The presence of neck pain 
has been associated with TTH and in one limited cross-sectional study a prevalence of 
88% neck pain in TTH was found with a strong correlation between frequency of neck 
pain and TTH (Ashina et al., 2014).  
 
3.4.3  Mechanisms behind TTH 
Independent reviews investigating the pathophysiology of TTH undertaken by Fumal 
and Schoenen in 2008 and Cathcart et al. in 2009 produced similar findings. Both 
described studies that identified an increase in muscle activity in pericranial muscles 
of people who experience TTH. This increase in muscle activity was not shown to 
have an association to the presence or intensity of headache, suggesting it might be an 
epiphenomenon (Fumal & Schoenen, 2008; Cathcart et al., 2009).  
 
Fumal & Schoenen (2008) also reported on a series of blinded controlled studies that 
indicated there is an increased number of active and latent myofascial ‘trigger-points’ 
in the head, neck and shoulders of people who experience TTH (Fumal & Schoenen, 
2008). It was considered possible that continued activation of these hypersensitive 
areas within pericranial and cervical muscles could lead to sensitisation of the 
nociceptors in the spinal trigeminal nucleus. More recently Bezov et al. (2011) 
reviewed literature on the pathophysiology of TTH and hypothesised that frequent 
nociceptive input from ‘trigger points’ within pericranial muscles induces sensitisation 
of the sensory afferents and second order neurones in the trigeminal nucleus. They 
propose it is plausible to conceive that if this process is not stopped through 
prophylactic measures then neuroplastic changes within the central nervous system 
could lead to a maladaptive sensitivity state and the precipitation of chronic TTH. 
However, in 2014 Quintner, Bove and Cohen undertook a review of literature about 
‘trigger points’ and surmised that the concept of ‘trigger points’ is an invention with 
no specific scientific basis to support it (Quintner, Bove, & Cohen, 2014). They cited 
a lack of diagnostic certainty to support the concept of ‘trigger points’ with limited 
inter-rater reliability of physical examination findings. They also cited a lack of 
recognised pathogenesis to explain ‘trigger points’ with a deficiency of unique specific 
tissue biochemistry and EMG or imagery findings. The authors did suggest that a 
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plausible hypothesis is emerging with new insight into the neurobiology of nociception 
and pain that should better explain the phenomena currently attributed to the ‘trigger 
point’ concept. 
 
Both the review by Fumal and Schoenen (2008) and that by Cathcart et al (2009) 
reported the findings of an investigation using electrical stimulation into pain 
sensitivity in people with chronic TTH. This study found that there is a generalised 
increase in pain sensitivity in this population suggesting a central nervous system 
abnormality in processing pain. Both reviews also referred to a study published by 
Schmidt-Wilke in 2008 that found that people who experience chronic TTH have 
decreased cortical grey matter density in particular the pons, anterior cingulate cortex, 
insular cortex, temporal lobe, orbito-frontal cortex and the hippocampus. They 
hypothesise that this reduction in tissue density suggests supra-spinal sensitisation as 
a result of constant activation of these pain related areas.  
 
Based on these reviews the authors hypothesised that TTH is the result of pain elicited 
by peripheral mechanisms such as overloaded pericranial muscles combined with 
sensitisation of nociceptors in the spinal trigeminal neurones and abnormal pain 
processing in the CNS, possibly as a response to stress. It is accepted that physical and 
emotional stress, increased nociception from pericranial muscles, lack of sleep and 
fatigue are common triggers for TTH (Cathcart et al., 2010; Fumal & Schoenen, 2008; 
Li et al., 2012).  
 
3.4.4  Management of TTH 
The majority of people who experience TTH do not consult a doctor, rather treat 
themselves with ‘over the counter’ medication resulting in many people with more 
frequent TTH overusing medications and developing associated medication overuse 
headaches (Fumal & Schoenen, 2008; Li et al., 2012). The European Headache 
Federation has indicated that pharmacological intervention is appropriate for the acute 
care management of people who experience infrequent TTH episodes but has limited 
scope in the management of chronic TTH (World Health Organisation, 2012). ‘Over 
the counter’ analgesic medications such as paracetamol, ibuprofen and acetylsalicylic 
acid are effective for relief of pain, however, caution is advised because if TTH 
becomes frequent and this treatment regime continues there is a risk of developing 
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medication overuse headache. If TTH presents on more than 2 days per week 
prophylactic treatment is recommended.  
 
Verhagen et al. (2010) undertook a systematic review of 41 RCT’s that provided 
evidence that paracetamol and ibuprofen are both effective for short term pain relief 
in the case of episodic TTH. Another systematic review by Moore et al. (2014) 
provided the same result (Moore, Derry, Wiffen, Straube, & Bendtsen, 2014). An 
earlier study by Steiner, Lang and Voelker (2003) demonstrated in a double blinded, 
placebo controlled trial of 638 people that there was no difference between taking 
acetylsalicylic acid or paracetamol for the management of TTH and that both were 
effective in the management of episodic TTH (Steiner, Lange, & Voelker, 2003).  
 
In 2006 Fernández-de-las-Penos et al. undertook a systematic review of RCT’s 
examining the efficacy of spinal manipulation in the management of TTH, CGH and 
MH. They reviewed 3 papers relating to TTH and noted that in general the 
methodological quality was low indicating a need for more rigorous research. 
Physiotherapy was found to play a role in the holistic management of the person with 
TTH by providing ergonomic and postural education combined with muscle 
strengthening exercises to reduce stresses on the myofascial tissues involved in the 
generation of the headache. Physiotherapy can also be effective in managing neck pain 
that may be present in conjunction with TTH. As identified by Fernández-de-las-Penos 
et al. (2006) more robust research would need to be undertaken to determine if these 
physiotherapeutic measures impact on the frequency and intensity of TTH.  
 
There is consensus that initial treatment of infrequent episodic TTH is the use of simple 
‘over the counter’ analgesics, but when headache becomes frequent and the trigger for 
headache cannot be avoided then prophylactic measures should be implemented to 
avoid the development of medication overuse headaches. After reviewing 44 clinical 
trials on prophylactic pharmacological intervention Verhagen et al. (2010) found that 
preventative medications for TTH are either no more effective than a placebo or there 
was conflicting or limited evidence to support their effectiveness. If prophylactic 
pharmacological intervention is not effective then a more multidisciplinary approach 
may be required for best results. The review by Verhagen et al. (2010) examined 
another 44 RCT’s exploring the effectiveness of CBT and another 12 trials exploring 
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physiotherapy as preventative measures for TTH. No conclusions could be drawn as 
there were either inconsistent results or trials did not have adequate power to 
demonstrate a significance for the use of the specific intervention (Verhagen et al., 
2010). The WHO Global Campaign to Reduce the Burden of Headache Worldwide 
recommends some self-management strategies of relaxation, exercise, seeking help for 
stress management and seeking help for depression if identified as a problem (World 
Health Organisation, 2012).  
 
Ashina and Bendsten (2013) have reviewed systematic and Cochrane reviews on non-
pharmaceutical management of TTH including behavioural treatments, spinal 
manipulation and physiotherapy and acupuncture (Ashina & Bendsten, 2013). They 
found the following 
 Cognitive Behavioural Therapy is effective in the management of TTH 
 People taking antidepressants and receiving non pharmaceutical treatment for 
stress management had a 50% decrease in the number of TTH experienced 
 A combination of physical therapy and exercise provides reduced frequency 
and intensity of TTH 
 Acupuncture was not found to be superior to physical therapy 
 
‘Over the counter’ medications such as paracetamol, acetylsalicylic acid and ibuprofen 
are recognised as effective form of management of infrequent episodic TTH (Fumal 
& Schoenen, 2008; Li et al., 2012; Moore et al., 2014; Steiner et al., 2003; Verhagen 
et al., 2010; World Health Organisation, 2012). In the case of frequent TTH these 
medications must be used with care to prevent the development of medication overuse 
headache (Fumal & Schoenen, 2008; World Health Organisation, 2012). There is some 
evidence to support the use of a combination of CBT and physiotherapeutic 
interventions as preventative measures for more frequent episodic or chronic TTH 
(Ashina & Bendsten, 2013; Verhagen et al., 2010; World Health Organisation, 2012).  
 
3.5  Overview of Schizophrenia and schizoaffective disorder 
Schizophrenia is considered one the most debilitating mental illnesses having been 
identified worldwide as the fifth leading cause of disability in people aged between 15 
- 44 years (Sawa & Snyder, 2002; Vancampfort et al., 2012). Schizophrenia symptoms 
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include positive symptoms of psychotic episodes such as delusions, hallucinations and 
bizarre thoughts and negative symptoms such as apathy, social withdrawal and 
flattened affect (Kuswanto, Teh, Lee, & Sim, 2012; Sawa & Snyder, 2002). 
Schizoaffective disorder has features of both schizophrenia and mood disorders and 
can be classed as manic or depressive depending on the symptoms that are present. 
Prognosis is better for people with schizoaffective disorder than it is for people with 
schizophrenia (Essali, Al-Haj Haasan, Li, & Rathbone, 2009; Jäger, Bottlender, 
Strauss, & Möller, 2004).  
 
3.5.1  Prevalence of schizophrenia and schizoaffective disorder 
Schizophrenia is a disease that affects 0.4 - 1.4% of the population (Carter, 2012; 
Castle & Buckley, 2011; Vancampfort et al., 2012). Symptoms usually first appear in 
young adults with males making up nearly 60% of the patient population (McGrath, 
Saha, Chant, & Welham, 2008). To date there have been no large scale studies to 
determine the prevalence of schizoaffective disorder but according to Malhi et al. 
(Malhi, Green, Fagiolini, Peselow, & Kumari, 2008) prevalence has been estimated to 
be between 0.5% and 0.8% in the general population. The onset of thirty percent of 
cases is before age 25 and a further 30% between age 25 and 35 and occurs more 
frequently in females (Abrams, Rojas, & Arciniegas, 2008).   
 
In the 2010 Australian National Survey of people living with a psychotic illness, 47% 
of people with a psychotic illness had a diagnosis of schizophrenia and 16.1% a 
diagnosis of schizoaffective disorder (Morgan et al, 2011). Nearly 65% of people with 
a psychotic diagnosis in Australia develop this illness between the ages of 25 and 34 
years of age (Morgan et al., 2012). 
 
3.5.2  Clinical Characteristics of schizophrenia and schizoaffective 
disorder 
Emil Kraepelin was the first person to describe ‘dementia praecox’ or schizophrenia 
as we now call the illness. This condition is characterised by positive symptoms, 
negative symptoms and/or stereotypical behaviours that are evident for a period of at 
least one month in conjunction with a noted decline in function over a 6 month period. 
Positive and negative symptoms and cognitive deficits alter the person’s sense of 
reality which in turn may affect personal, social and occupational functioning. Positive 
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symptoms include psychoses such as delusions, hallucinations, bizarre thoughts, 
suspicion and disorganised speech and behaviour. Negative symptoms are 
characterised by poor motivation, apathy, flattened affect and social withdrawal. 
Kraepelin clearly identified a decline in cognitive function through his use of the word 
‘dementia’ to describe what he was witnessing in patients. The cognitive deficits 
include attention, memory and executive functions (Kuswanto et al., 2012). 
 
WHO ICD-10 identifies that schizoaffective disorder has symptoms of both 
schizophrenia and mood disorders which are present at the same time or within a few 
days of each other. The patient’s symptoms do not meet the specific criteria for either 
schizophrenia or depressive/manic episode. To be diagnosed with schizoaffective 
disorder a person must experience a major depressive episode for at least two weeks 
or a manic episode for one week either concurrently or within a few days of 
experiencing positive symptoms of schizophrenia. Two of the following must be 
present for more than two weeks – delusions, hallucinations, disorganised speech, 
disorganised behaviour or negative symptoms (Malhi et al., 2008). Schizoaffective 
disorder will be defined as bipolar schizoaffective disorder if mania is part of the 
presentation or depressive schizoaffective disorder if depression is the only mood 
disorder observed.  
 
3.5.3  Mechanism behind schizophrenia and schizoaffective disorder 
Schizophrenia is a complex condition in which the pathophysiology is still not clearly 
understood. It is believed that schizophrenia develops in response to specific stressors 
in vulnerable people. Stressors can be either biological factors such as infections or 
substance abuse and/or environmental such as death and trauma (Castle & Buckley, 
2011).  
 
Genetics are believed to contribute to a predisposition or vulnerability of an individual 
to develop schizophrenia. (Arnedo et al., 2014; Castle & Buckley, 2011; Lowry, 2014). 
Research is being undertaken to better understand the role of genetics in the 
development of the illness. In recent years attempts have been made to find a 
‘schizophrenia gene’ without success and the complex nature of the genetic links 
suggest that there may not be such a gene but rather a series of gene-gene interactions 
(Arnedo et al., 2014). Castle and Buckley (2011) tabled a ‘gradient of genetic risk for 
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schizophrenia’ which evaluates the risk of developing schizophrenia based on the 
proximity of the genetic relationship to a person who has a diagnosis of schizophrenia. 
Table 4 presents information on the chances of developing schizophrenia based on this 
genetic link.   
 
Table 4 - Chances of developing schizophrenia   
Relationship Chance of developing schizophrenia 
General population 1% 
Sibling with schizophrenia 8% 
One parent with schizophrenia 12% 
Fraternal twin with schizophrenia 14% 
Both parents with schizophrenia 39% 
Monozygotic twin with schizophrenia 47% 
 
Castle and Buckley (2011) identified that early life environmental factors contribute 
to vulnerability of developing schizophrenia but emphasise that in isolation these are 
not the cause of the development of schizophrenia. These factors include, but are not 
limited to, maternal infection, maternal anaemia or malnutrition, maternal Vitamin D 
deficiency, birth complications and maternal stress during pregnancy.  
 
Karlsgodt et al. (2012) propose a more specific neurodevelopmental hypothesis where 
brain lesion caused by a combination of genetic and environmental factors interferes 
with the normal growth and development in the brain resulting in schizophrenia 
(Karlsgodt, Ellman, Sun, Mittal, & Cannon, 2012). The theory recognises three 
specific elements 
1. Conception - genetic make-up 
2. Early development - pre and peri-natal brain development which may be 
influenced by environmental factors identified above such as maternal 
infection and other obstetric complications 
3. Later development - late adolescent and young adult stresses resulting in the 
structural changes to grey and white matter noted previously. Studies are 
currently being undertaken in an attempt to better understand the role of stress 
in the onset of psychosis (Mondelli & Pariante, 2012). 
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This complex interaction is explained in Figure 3. 
 
Figure 3 – Neurodevelopmental model of schizophrenia 
 
Reproduced from Karlsgodt, K., Ellman, L., Sun, D., Mittal, V & Cannon, T. 
(2012). The neurodevelopmental hypothesis of schizophrenia. In A. David, S. 
Kapur & P. McGuffin (Eds), Schizophrenia: The Final Frontier - A Festschrift for 
Robin M. Murray (p4.). East Sussex: Psychology Press 
 
While the mechanisms behind the development of schizophrenia are still not fully 
understood there is an understanding of the structural changes within the brain of a 
person with schizophrenia. A systematic review of brain MRI anatomy of people with 
schizophrenia by McCarley et al. (1999) and a review of Diffusion Tensor Imaging 
studies by Kuswanto et al. (2012) have found enlarged lateral ventricles, enlarged third 
ventricle, reduced overall grey matter and widespread cortical and cerebellar atrophy. 
There is also noted volume reduction of the inferior prefrontal cortex and the 
amygdala, hippocampus and parahippocampal gyrus particularly on the left side 
(Kuswanto et al., 2012; McCarley et al., 1999). 
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Along with structural changes within the brain, an increase in dopamine D2 receptors 
has long been associated with schizophrenia (Madras, 2013). With the development of 
imaging technology (SPECT) it has now been determined that there is an increase in 
presynaptic dopamine D2 receptors as well as the previously identified increased 
levels in response to a ‘challenge’ (Howes, 2012). A new theory of the involvement of 
dopamine in schizophrenia as the final common pathway for schizophrenia has been 
proposed by Howes (2012). He suggests that multiple ‘hits’ on risk factors described 
above lead to increased dopamine levels and in particular presynaptic dopamine 
dysregulation through abnormalities with the function and regulation of dopamine cell 
bodies in the midbrain. It is unknown if there is dysregulation in other neurons within 
the midbrain or if they are limited to the dopaminergic cell bodies.  
 
Malhi et al. (2008) highlight the dearth of studies into biological mechanism associated 
with schizoaffective disorder although some have shown enlarged ventricles, reduced 
white matter and asymmetry of the parahippocampal gyrus as well as an increased in 
dopamine D2 receptors. They also have been shown to have striatal regional 
abnormalities similar to those seen in people with bipolar affective disorder.  
 
3.5.4  Management of schizophrenia and schizoaffective disorder 
The main treatment of antipsychotic medication aims to reduce symptoms of 
schizophrenia and maintain and improve patient functioning and quality of life. 
Neuroleptic medication reduces positive symptoms of the illness through blocking of 
the dopamine D2 receptors unfortunately with neurological side effects mimicking 
Parkinson’s disease (Sawa & Snyder, 2002). Atypical neuroleptics have been 
developed that target serotonin receptors to a greater extent than dopamine D2 
receptors and do not have these Parkinsonian side effects. These drugs have been 
shown to be effective in reducing both positive and negative symptoms of 
schizophrenia; however, these drugs have adverse metabolic side effects including 
weight gain.  
 
Schizoaffective disorder is usually treated with a combination of antipsychotic 
medication and mood stabilisers but there is a lack of evidence to support that this is 
the optimum treatment for the condition (Murru et al., 2011). The systematic review 
undertaken by Murru et al. (2011) highlights this lack of research with only one 
 69 
antipsychotic medication having been tested in a placebo controlled trial and no 
placebo controlled trials of mood stabilisers. Murru et al. (2011) noted that the basis 
for prescribing these medications for the treatment of schizoaffective disorder was 
from extrapolation of data from trials of these drugs in other populations such as 
bipolar disorder or schizophrenia. They cautioned this practice and proposed the need 
for more specific, robust RCT’s exploring the efficacy of these medications for the 
management of schizoaffective disorder.   
 
Many people with schizophrenia and schizoaffective disorder are non-adherent to their 
treatment regime and non-compliance of medication is thought to be the biggest factor 
contributing to relapse (Carter, 2012; Lammers, Zehm, & Williams, 2013). Depot 
injections have been identified as a safe and effective way of ensuring compliance 
(Olivares et al., 2009; Sim et al., 2004). Some studies have associated the use of depot 
with males and people who have aggressive behaviour (Sim et al., 2004) while other 
have identified depot users as people more likely to have alcohol or substance abuse, 
higher involvement with police and more frequent hospitalisation (Ascher-Svanum, 
Peng, Faries, Montgomery, & Haddad, 2009; Rubio et al., 2006). For many users, 
however, the convenience of not having to remember to take medication is appealing 
and they voluntarily choose to receive their medication in depot form (Sim et al., 
2004).  
  
3.5.5  Pain and schizophrenia 
Early pioneers in the study of schizophrenia, Kraepelin and Bleuler noted that people 
with schizophrenia have a reduced sensitivity to nociception (Potvin & Marchand, 
2008). In 1982 Fishbain warned about the importance of clinicians exploring pain 
reported by people with psychoses to prevent misdiagnosis of medical conditions and 
even death (Fishbain, 1982). A review of literature relating to pain experienced by 
people with schizophrenia and psychoses conducted by Singh et al. (2006) uncovered 
that many people experiencing psychosis fail to respond to noxious input from life 
threatening conditions such as myocardial infarction, ruptured appendix and 
perforated bowels (Singh, Giles, & Nasrallah, 2006).  
 
A study by Atik et al. (2007) explored the differences in pain threshold, pain tolerance 
and pain endurance between people with schizophrenia, bipolar affective disorder and 
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controls (Atik, Konuk, Akay, Ozturk, & Erdogan, 2007). The study used the cold 
pressor test (immersing the hand in iced water) on the non-dominant hand and recorded 
when the cold began to hurt (pain threshold), when participants removed their hand 
(pain tolerance), their pain score out of 10 using a visual analogue scale at the point 
where they removed the hand (pain magnitude) and then the time that elapsed before 
pain resolved (pain endurance time). They determined there was no statistical 
difference between time to pain threshold between the group with schizophrenia 
(mean=144.4sec) and the control group (mean=112.5sec) and measured pain 
magnitude (schizophrenia mean=6.85/10 and control group mean=6.94/10). It was 
determined, however, that people with schizophrenia had higher pain tolerance 
(mean=199.4sec) in that they could leave their hand in the cold for longer than the 
control group (mean=137.5sec) before pain forced them to remove it. In what appears 
to be a contradiction people with schizophrenia had longer pain endurance times 
(mean=56.4 sec) than the control group (mean=25.0 sec). It was suggested that this 
discrepancy existed because report of pain resolution was based on subjective 
evaluation and delay in reporting could be attributed to affective abnormalities. 
However, no consideration was given to the fact that having left their hand in the iced 
water for longer periods of time other physiological changes associated with prolonged 
cold might have meant it could have taken longer for pain to resolve after emersion.   
 
In 2008 Potvin and Marchand conducted a meta-analysis of twelve studies conducted 
between 1966 and 2007comparing experimental pain responses in people with 
schizophrenia to healthy controls (Potvin & Marchand, 2008). Six studies related to 
thermal stimulation of pain with two using the cold-pressor test, five studies related to 
electrical stimulation and one study used mechanical stimulation through pressure on 
the deltoid, tibia and finger to stimulate pain. They determined that people with 
schizophrenia had a diminished sensitivity to experimentally induced pain from 
electrical and thermal stimulation. An important aspect of their report was that this 
diminished sensitivity was present in people taking medication as well as those not 
taking medication suggesting antipsychotic medication alone cannot be responsible for 
diminished pain sensitivity in people with schizophrenia. Hooley and Delgado 
evaluated pain responses in relatives of people with schizophrenia using finger 
pressure algometer (Hooley & Delgado, 2001). They determined that relatives of a 
person with schizophrenia had a higher threshold to pressure pain than people who did 
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not have a relative with schizophrenia. This could suggest a genetic predisposition to 
hypoalgesia amongst people with schizophrenia.  
 
A systematic review of literature by Bonnot et al. (2009) focused on differences 
between behavioural responses to pain and physiological responses to pain. Fifty-
seven articles were reviewed under the following sub headings  
 Case reports of people with schizophrenia who reported no pain in known 
painful medical conditions  
 Clinical and epidemiological studies where a high prevalence of people with 
schizophrenia experiencing headaches was noted 
 Experimental studies with varied results, some showing higher pain threshold 
in people with schizophrenia and others not showing this phenomenon.   
 Previously reviewed articles.  
 
A decrease in behavioural responses to pain was found which was attributed to 
cognitive impairments (Bonnot et al., 2009). Bonnot et al. (2009) and Potvin and 
Marchand (2008) suggest that poor communication and cognitive impairments as well 
as negative symptoms such as blunted responses experienced by this population group 
could contribute to altered pain expression. They hypothesise that noxious stimuli will 
still provoke a pain response but the expression of the pain response may be blunted. 
The research evaluated in these two reviews focused on cutaneous pain and not deep 
tissue sensitivity which is more likely to be associated with medical conditions and 
musculoskeletal dysfunction. 
 
A more recent study not included in the above systematic reviews examined responses 
of people with schizophrenia to both acute and prolonged painful stimuli elicited by 
transcutaneous electrical stimulations of the sural nerve (Lévesque et al., 2012). They 
determined that people with schizophrenia have a unique response to noxious input 
with increased sensitivity to acute nociception and decreased sensitivity to prolonged 
nociception when compared to a control group of people with no family history of 
schizophrenic spectrum disorders. The fact that participants had different responses to 
different types of noxious input might suggest that communication and blunted 
responses are not the limiting factors to pain expression. There is some consistency 
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between this study and that of Atik et al. (2007) mentioned above who found that 
people with schizophrenia have higher pain endurance and tolerance.  
 
Engels et al. (2014) conducted a systematic review on fourteen studies on clinical pain 
in schizophrenia reflecting that responses to nociception induced in experimental 
conditions are very different from those of clinical pain experienced in daily life 
(Engels et al., 2014). Clinical pain included surgical pain, chronic pain and pain 
experienced in daily life. It appeared that prevalence and intensity of pain associated 
with medical causes is lower in people with schizophrenia than controls. When pain 
was not related to a medical cause both prevalence and intensity were the same as 
healthy people. Possible explanations were presented for the lower prevalence and 
intensity of medical related pain and these include 
 Not actually reporting the pain for fear of hospitalisation or to avoid being a 
burden 
 Diminished processing of motivational-affective aspects of pain due to 
dysfunction in the frontal lobe. The person may feel pain but not exhibit pain 
behaviour  
 Decline in cognitive functioning 
 Use of antipsychotic medication.  
The question of whether lower prevalence and intensity of medically caused pain is a 
result of being less sensitive to nociception or having a blunted response to pain was 
not resolved. A possible explanation, not suggested by the authors, is that medical pain 
could be more prolonged whereas experimental pain may be more acute and as 
identified by Lévesque et al., (2012) there appears to be a reduced sensitivity to 
prolonged pain in people of this population.  
 
According to Wojakiewicz et al. (2013) people with schizophrenia not only have a 
reduced response to their own pain but also that they have difficulty recognising when 
other people are in pain (Wojakiewicz et al., 2013). The hypothesis for this study was 
that response to pain is both physiological and emotional. Wojakiewicz et al. (2013) 
evaluated the emotional aspects of pain recognition by comparing responses to facial 
expressions, videos of pain sequences and a situational pain questionnaire. They 
compared responses of 29 people with schizophrenia against 27 controls matched on 
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age, gender and IQ. They found differences that suggest people with schizophrenia 
lack an ability to recognise basic emotions from facial expressions and are not able to 
differentiate between imaginative painful and non-painful situations and have an 
altered ability to recognise pain and pain behaviours.  
 
Regardless of the underlying mechanism it is acknowledged that people with 
schizophrenia do have a diminished response to noxious input especially in the chronic 
stages of their illness (Bonnot et al., 2009; Engels et al., 2014; Guieu, Samuélian, & 
Coulouvrat, 1994; Potvin & Marchand, 2008). All researchers agree that more research 
into the responses of people with schizophrenia to noxious stimuli is required.  
 
The concept that people with schizophrenia experience reduced pain responses but 
have a high incidence of pain and a prevalence of headache the same if not greater than 
the general population raises questions about the nature and characteristics of the 
headaches that they may experience. Are the headaches different or are the 
impairments driving the conditions more severe than the general population in order 
to provoke a response? If this is the case then it is important that headache can be 
identified and treated in a timely manner.  
 
3.5.6  Posture and schizophrenia  
As already noted a forward head posture has been associated with headache and in 
particular cervicogenic headache. Poor trunk stability and diminished postural control 
can be a factor in forward head posture (Beinert & Taube, 2013). There is evidence 
that people with schizophrenia have structural abnormalities of their cerebellar vermis 
a neural structure that plays an important role in maintaining postural control 
(Nopoulos, Ceilley, Gailis, & Andreasen, 1999). Using MRI it has been determined 
that the proportional relationship between volumes of grey and white matter in the 
cerebellar vermis region of people with schizophrenia is different compared to a 
healthy control group (Lawyer, Nesvag, Varnas, Okugawa, & Agartz, 2009). 
Diminished postural control and balance has been observed in people with 
schizophrenia and are often referred to as neurological soft signs (Ho, Mola, & 
Andreasen, 2004; Marvel et al., 2004; Picard, Amado, Mouchet-Mages, Olié, & Krebs, 
2008; Varambally, Venkatasubramanian, & Gangadhar, 2012; Varambally, 
Venkatasubramanian, Thirthalli, Janakiramaiah, & Gangadhar, 2006).  
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In an experiment comparing postural sway in people with schizophrenia to healthy 
individuals the people with schizophrenia demonstrated more sway in the anterior-
posterior plane which was even more pronounced when feet were together and arms 
raised (Marvel et al., 2004). In this study it was suggested that medication could be a 
potential confounder. Ho et al. (2004) compared cerebellar signs of 155 neuroleptic 
naïve people with schizophrenia against 155 healthy volunteers of similar age and 
gender. The tests included finger-nose, rapid alternating pronation-supination, heel-
knee-shin, muscle tone, Rhomberg and tandem gait tests. It was determined that about 
one fifth of the study group (neuroleptic naïve) displayed positive cerebellar sign, 
particularly in gait and stance indicating that neuroleptic medication cannot be totally 
responsible for positive cerebellar signs. A possible limitation to this study was that 
examiners were not blinded to participant’s diagnosis. These findings of Ho et al. 
(2004) were reproduced in a later study by Varambally et al. (2006) in a cohort 
screened for comorbid alcohol abuse or dependence. People with known alcohol 
dependence were excluded from the study thus eliminating the possibility of alcohol 
abuse as a reason for cerebellar abnormalities.  
 
Reviewing clinical, cognitive and functional literature on the role of cerebellum in 
schizophrenia, Picard et al. (2008) found nothing to refute the concept of cerebellar 
involvement in schizophrenia resulting in anomalies in postural control and 
equilibrium (Picard et al., 2008). A later review of current literature also supports the 
belief that cerebellar signs are part of the syndrome of schizophrenia and determined 
that their presence may have some link to poorer prognosis (Varambally et al., 2012).  
 
3.6  Managing the physical health of people with mental illness and 
role of Physiotherapy 
There is a strong connection between physical wellbeing and good mental health. 
Good mental health is fundamental to the wellbeing of individuals, families and 
communities (Department of Health and Aging, 2009). Good health is a result of a 
complex interaction of biological, psychological, social, environmental and economic 
factors. When any of these factors are compromised so is the health of the individual. 
It is widely accepted that people with mental health disorders have poorer physical 
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health than the general population with higher levels of mortality and morbidity from 
physical illness (Coghlan et al., 2001; Happell et al., 2012; McLennan, 1998; 
Richardson et al., 2005). 
 
The importance of maintaining good physical health of mental health clients is 
recognized in the Australian National Mental Health Policy (2008). Australian mental 
health teams are comprised of psychiatrists, psychologists, mental health nurses, social 
workers, occupational therapists and Aboriginal and Torres Strait Islander mental 
health workers (National Mental Health Policy, 2008). Unfortunately it has been 
identified that people working in mental health often discount physical complaints as 
side effects of medication or a psychotic event and do not investigate further often 
resulting in poor outcomes for the client (Cuyún Carter et al., 2011; Happell et al., 
2012).  
 
In order to access holistic health care all mental health consumers are encouraged to 
visit a general practitioner (GP), someone who is responsible for their overall 
management including physical health issues. Unfortunately Morgan et al. (2011) 
reported that only 35.5% of people with psychotic illness who visited their GP had a 
general health examination. This was not a surprising finding when most GP visits 
(65.4%) lasted between 10 and 19 minutes allowing very limited time to address both 
mental and physical health issues (Morgan et al., 2011).  
 
It would appear that mental health consumers are not getting adequate access to health 
practitioners who can evaluate and manage their physical health issues. Many papers 
recommend that better assessment and diagnosis of physical complaints of people with 
schizophrenia and schizoaffective type disorders is necessary (Connaughton, Patman, 
& Pardoe, 2013; Fagiolini, 2008; Galletly et al., 2012; Jeste, 1996; Morgan et al., 
2012). Within the general healthcare system, physiotherapists play significant roles in 
the assessment, treatment and ongoing management of many of the more common 
physical health issues experienced by people with schizophrenia or schizoaffective 
disorder (Australian Physiotherapy Association, 2011, 2012). These include chronic 
back, neck or other pain (Galletly & Murray, 2009; Gureje, 2008; Morgan et al., 2012; 
The Chartered Society of Physiotherapy, 2008), cardiovascular disease, ischaemic 
heart disease, hypertension, diabetes, respiratory disease (Fagiolini, 2008; Morgan et 
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al., 2012; Richardson et al., 2005), and illnesses associated with obesity (Morgan et 
al., 2012). Given that the National Mental Health Policy (2008) advocates for good 
holistic health of mental health consumers it could be argued that physiotherapists 
should be included as integral members of mental health teams.  
 
Physiotherapeutic interventions of aerobic exercise, muscle strengthening and 
relaxation have been shown to have positive effects on psychiatric symptoms, 
psychological distress and anxiety of people with schizophrenia as well as improving 
health related quality of life (Gorczynski & Faulkner, 2010; Vancampfort et al., 2012). 
A limited systematic review of the effects of physical exercise in schizophrenia (n=3 
articles) has determined that exercise can lead to an increase in hippocampal volume, 
increased cardio-respiratory fitness and has been associated with an increase in cortical 
thickening in the left hemisphere (Vancampfort et al., 2014). It is becoming evident 
that physiotherapy has a bigger role to play in the holistic management of people with 
schizophrenia and schizoaffective disorder than just addressing their physical health, 
further strengthening the argument to include them as a profession within mental 
health workforce. 
 
3.7  Factors affecting quality of life 
Quality of life (QOL) is no longer measured by the presence or absence of disease and 
survival but covers a more holistic view of the person (Magnusson, Riess, & Becker, 
2012). Most quality of life questionnaires explore a person’s perceptions of their 
physical and social functioning, their psychological status and disability attributed to 
disease related symptoms (Magnusson et al., 2012; Manhalter, Bozsik, Palásti, 
Csépány, & Ertsey, 2012).  
 
3.7.1  Impact of headache on quality of life 
The WHO identified in the document ‘Lifting the Burden’ (2012) that many people 
‘belittle’ the impact headache can have on a person. It is often overlooked by medical 
health professionals because almost every one experiences headache from time to time 
and is not usually a life threatening illness (Stovner et al., 2007; Stovner, Zwart, 
Hagen, Terwindt, & Pascual, 2006). Headache has been recognised as one of the 
world’s top 10 causes of disability, is among the top 3 most prevalent diseases globally 
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and has been identified as the top neurological cause of years lived with disability 
(Martelletti, Mitsikostas, et al., 2013; Martelletti, Birbeck, et al., 2013).   
 
The presence of headache impacts on a person’s function and quality of life. Solomon 
and colleagues (Solomon et al., 1993) undertook a study of 208 people attending a 
headache clinic using the Medical Outcomes Study Short Form Health Survey (SF-36) 
to determine the impacts chronic headache has on quality of life. People with 
headaches recorded significantly worse scores for physical, social and role functioning 
components and had worse mental health than people with chronic diseases such as 
arthritis and diabetes. The reduced quality of life results were comparable to those of 
people who had experienced myocardial infarction.  
 
A Dutch study was undertaken in 2003 using the SF-36 to explore the health related 
quality of life of 118 people attending a headache clinic who had either CGH, TTH or 
MH diagnosed by neurologists against the ICHD (van Suijlekom et al., 2003). They 
found that people experiencing CGH had a quality of life burden greater than the 
normal population but similar to that of people experiencing MH without aura and 
TTH (van Suijlekom et al., 2003). The 2007 study by Vinding and colleagues 
examining the impact of headache in a Danish Headache centre population found 
people experiencing frequent headaches also made greater use of the healthcare 
system, had more time off work and were less effective when at work than the general 
population (Vinding et al., 2007). The need for early intervention was highlighted to 
reduce the burden and improve quality of life.  
 
Wiendels et al conducted a population based survey exploring prevalence and risk 
factors of chronic frequent headaches (Wiendels et al., 2006). This postal survey was 
sent to 21,440 people who were registered with a GP in two regions of The 
Netherlands. There was a response rate of 76% (n=16,232). Researchers wanted to 
minimise selective responses so it was not identified that headache was their primary 
focus. They found that fifty percent of people experiencing chronic frequent headaches 
had significant comorbidities and reported moderate disability. The most prevalent 
comorbidities were gastrointestinal and musculoskeletal conditions including arthritis, 
back pain, neck pain and fibromyalgia. The majority of people attending headache 
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clinics also had comorbid mental health issues the most common of which were 
depression and anxiety disorder. 
 
In a qualitative study exploring the experiences and perceptions of people with 
headache it was found that presence of headache had negative effects on work, family 
life, social activities and mood (Leiper et al., 2006). A significant worry for headache 
sufferers was the cause of the headache and it was identified that there was a desire for 
investigations to determine the cause to rule out sinister origins. There is nothing to 
suggest this is any different for people with schizophrenia or schizoaffective disorder.  
 
3.7.2  Impact of schizophrenia and schizoaffective disorder on quality of 
life 
People with schizophrenia and schizoaffective disorder are known to have poor quality 
of life and global functioning (Morgan et al, 2011). Worldwide, schizophrenia has 
been found to be the fifth leading cause of disability (Vancampfort et al., 2012). A 
study conducted over a three year period by Cuyún Carter et al. (2011) found that only 
10% of people with a diagnosis of schizophrenia had good QOL outcomes including 
an improved quality of life, increased daily activities and global functioning. This 
agrees with the Australian Government Report, People Living with Psychotic Illness, 
2010 (Morgan et al, 2011) which determined that 90% of people in Australia with 
psychotic illness report deterioration in their occupational and social functioning after 
their diagnosis (Morgan et al, 2011). Two thirds of people were identified as having a 
severe dysfunction in their ability to socialise and about one third were severely 
impaired in their ability to look after themselves and undertake basic activities of daily 
living.    
 
Ritsner, Lisker and Grinshpoon (2014) highlight that poor quality of life in people with 
schizophrenia and schizoaffective disorder is linked to presence of depressive 
symptoms, side effects of antipsychotic medication and emotional distress (Ritsner, 
Lisker, & Grinshpoon, 2014). In their study Ritsner et al., (2014) only focused on 
psychological features that may contribute to emotional stress and overlooked impacts 
of physical factors such as pain (Ritsner et al., 2014). 
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3.7.3  Impact of headache on quality of life of people with mental illness 
Presence of a psychiatric comorbidity is known to complicate the management of 
headache (Bera, Khandelwal, Sood, & Goyal, 2014). Verri et al. (1998) identified the 
most common comorbidity of people who experience chronic daily headaches were 
anxiety and mood disorders (Verri et al., 1998). A more recent study determined that 
the most common psychiatric comorbidity associated with headache is depression with 
Bera et al. (2014) finding depressive symptoms present in 37.5% of people 
experiencing MH and 30% of those with TTH compared to 10% in a headache free 
control group. The study examined the QOL of people experiencing different headache 
types but no comparisons were made in the QOL between those with depression and 
those without depression.  
 
People experiencing headaches with a comorbid psychiatric condition incur increased 
medical costs, a higher headache related disability and a reduced quality of life 
(Smitherman & Baskin, 2008; Wang & Juang, 2002). Pompili et al. (2009) found that 
a psychiatric disorder among people with headaches decreased quality of life, resulted 
in poorer prognosis and response to treatment and resulted in an increased chronicity 
of the disease (Pompili et al., 2009). The presence of migraine or chronic non migraine 
headaches increased the risk of developing depression. The study found 
pharmaceutical intervention targeting mental health comorbidities improved mental 
health but did not impact on headache number or intensity. No physiotherapeutic 
assessment or intervention was considered. 
It is already known that management of physical complaints of people with mental 
illness is poorer than the general population (Coghlan et al., 2001; Fagiolini, 2008; 
Morgan et al., 2012) and it could be suggested that people with schizophrenia and 
schizoaffective disorder are not receiving assessment and treatment for their headaches 
equivalent to the general population. Already considered a burden on the healthcare 
systems the addition of headaches on a person with schizophrenia or schizoaffective 
disorder could compound this. 
 
3.8  Summary of literature review 
Headache is recognised as one of the top ten disabling conditions worldwide yet up to 
50% of headache sufferers in the general population do not seek medical advice. 
Prevalence of headache amongst people with schizophrenia has been determined at 
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48% which is comparable to that of the general population. Headache is reported to be 
the most common pain experienced by people with psychotic illness. People with 
mental illness have poorer physical health than the general population and for many 
reasons do not receive appropriate care. It is suggested that fewer people with 
schizophrenia or schizoaffective disorder report the presence of headache to their 
health professional which would also suggest that they do not receive appropriate 
assessment and treatment.  
 
Headache of particular interest to physiotherapists is CGH. The prevalence of 
cervicogenic headache is about 4% in the general population and roughly 15-20% of 
patients suffering from ongoing headache. No studies have been undertaken to 
determine if this is the same for people with schizophrenia or schizoaffective disorder. 
Physiotherapy plays an important role in the management of CGH.  
TTH and MH are also of interest to physiotherapists. Physiotherapy plays a role in the 
management of TTH and although not a key treatment for MH, physiotherapy has a 
role to play when comorbid neck pain exists. Physiotherapists are able to differentially 
diagnose between CGH, TTH and possible MH and refer people to appropriate health 
professionals for the management of MH. Prevalence of TTH is 42% and MH 14.7% 
in the general population. Only one study has looked at the prevalence of TTH and 
MH in people with schizophrenia but this study did not use the ICHD to classify TTH 
and it is unknown how MH was classified. More research is needed to determine the 
prevalence of these headache types in people with psychotic illness. 
 
Schizophrenia and schizoaffective disorder affects about 1% of the population. These 
disorders are associated with a diminished response to pain which could have 
significant implications on the presentation and characteristics of their headache 
experience. The cerebellum vermis is involved with postural control and can be 
impaired in people with schizophrenia. Poor posture can be a contributing factor to 
headache and in particular CGH. It could be possible that people with schizophrenia 
who already have poor postural control may be more at risk of developing headache 
than the general population.  
 
The literature has identified that the general physical health of people with mental 
illness is poorer than the general population. Despite recognition of the relationship of 
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one to the other there is increased mortality and morbidity from preventable diseases 
and ailment in this population. There is a need for better assessment and diagnosis of 
physical complaints of people with schizophrenia and schizoaffective disorder. 
Physiotherapy plays an important role in the management of chronic pain, 
musculoskeletal conditions, cardiovascular, neurological and metabolic conditions and 
it could be argued that they should be more involved in the holistic management of 
mental health clients to address both the physical and mental wellbeing of people with 
mental illness 
 
It has been noted that chronic or regular headache reduces quality of life with particular 
impact on physical, social and role functioning. People with schizophrenia experience 
reduced quality of life in relation to global functioning. It could be suggested that the 
presence of headache could further reduce an already poor quality of life of the person 
with schizophrenia or schizoaffective disorder. There are very few studies 
investigating the impact on quality of life of people with schizophrenia and 
schizoaffective disorder who experience headache. 
 
The purpose of this research is to determine the prevalence and characteristics of 
headache, in particular possible CGH, and the perceived impact on aspects of quality 
of life of people with schizophrenia or schizoaffective disorder. It is also to determine 
how people manage their headache and whether they receive assessment and/or 
treatment from a health professional. This information will help identify whether 
changes could be implemented to better address this manageable physical illness and 
possibly favourably effect general wellbeing. This may include expanding the role of 
physiotherapy in mental health services. 
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CHAPTER FOUR 
Design and Methodology 
4.1 Study Design 
A cross-sectional observational cohort study was undertaken surveying patients 
attending the Fremantle Mental Health Services (Alma Street). Ethical approval was 
provided through the Human Research Ethics Committee of both The University of 
Notre Dame Australia (HREC Ref 012113F) and the South Metropolitan Area Health 
Service (HREC Ref 12/390). All participants provided informed consent and all 
procedures adhered to the declaration of Helsinki. 
 
Based on a headache prevalence of 48% (Kuritzky et al., 1999) with a 95% certainty 
it was estimated that 97 participants would be required to provide a level of absolute 
precision for our estimate of the prevalence to be within 10% of the population 
prevalence. It was decided to oversample by 3 for a final recruitment target of 100 
participants. 
 
4.1.2 Participants 
One hundred participants with a medically confirmed diagnosis of schizophrenia or 
schizoaffective disorder were recruited from a cross section of people attending the 
Fremantle Hospital Mental Health service between 2nd July and 28th November 2013. 
Recruitment occurred in the outpatient depot clinic in July and the open wards at the 
Fremantle Hospital Mental Health complex between August and November.  
 
Participants were not selected according whether they experienced headache or not 
rather they were selected using the following criteria. 
 
Inclusion criteria  
People who 
 Had a confirmed psychiatric diagnosis of schizophrenia or schizoaffective 
disorder 
 Were over 18 year of age 
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 Were consumers of Fremantle Hospital Mental Health Services in either an 
inpatient open ward or as an outpatient  
 Were deemed stable in their recovery process so that a researcher asking 
questions about clinical characteristics and headache would not potentially 
jeopardise their recovery progress 
 
Exclusion Criteria 
People who 
 Had a history of psychosis but the psychiatric diagnosis was not yet verified  
 Were in the secure wards 
 Were deemed cognitively impaired by their case manager/nurse to the extent 
they would not be able to complete the questionnaire 
 Were in critical time of their recovery which could potentially be destabilised 
by attending an interview about headache 
 Were assessed as a potential safety risk to the researcher by nurse or case 
manager 
 
The first cluster of recruitment of outpatient participants was via the facility’s twice 
weekly depot clinic. The majority of clients attending the depot clinic have a diagnosis 
of schizophrenia or schizoaffective disorder which has been confirmed by a 
psychiatrist. Posters in the waiting room and depot injection treatment room advertised 
the project. The depot nurses invited everyone attending the clinic over the month of 
July 2013 who met the selection criteria to participate in the study. Those agreeable 
were introduced to the principal researcher and invited to complete a questionnaire. 
Recruitment saturation was achieved after one month, with all eligible attendees 
having been approached regarding participation by this time.  
 
The second cluster for recruitment of inpatient participants was via the open wards at 
the Fremantle Hospital Mental Health Complex from August to November 2013. The 
Fremantle Mental Health Services have five inpatient wards comprised of two secure 
wards and two open wards on the main campus as well as a ‘step up/step down’ ward 
in a facility within short walking distance of the hospital. In the ‘step up/step down’ 
ward patients are monitored by medical staff while transitioning towards discharge or 
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avoiding admission into the hospital proper. They remain overnight in this facility but 
during the day are responsible for their own activities of daily living and are 
encouraged to return to daily activities such as working and socialising. Patients in the 
two secure wards did not meet selection criteria due to the acuity of their illness. The 
nurse manager on the three open wards initially alerted the researcher as to which 
inpatients had a diagnosis of schizophrenia or schizoaffective disorder. Discussion 
with the nurse manager or the patient’s ward nurse manager identified those who met 
the selection criteria and these people were approached by the researcher to participate 
in the study.  
 
4.2 Procedure 
Once an outpatient was identified by the depot nurse as a suitable candidate, and 
following their injection, they were introduced to the researcher in a private interview 
room. The researcher explained the purpose of the project to them as well as the 
research process. If still interested participants were given the opportunity to read the 
plain language statement (PLS) and sign a consent form prior to completing the 
questionnaire. In the inpatient setting once possible participants were identified the 
nurse case manager introduced the researcher to them and once again the researcher 
went through an explanation of the purpose and process of the study. If the patient was 
still interested a private area was found on the ward and the participant was offered a 
copy of the PLS to read prior to gaining written informed consent.  
 
Based on previous research (Kuritzky et al., 1999; Pfaffenrath et al., 2009), the 
researcher’s personal experience of working with this client group and on the advice 
of experts consulted during the pilot study, the researcher offered the first seven 
outpatient participants the option of either independently completing the questionnaire 
in her presence or have her ask the questions and fill in the form. All seven people 
specifically requested that the researcher ask the questions and so for consistency all 
subsequent participants were not offered that option (Stovner et al., 2014).  
 
This method proved to be essential as some participants needed clarification of 
questions and prompting as to what was being asked. When some participants 
appeared to be losing interest the researcher could speed up the interview. This 
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facilitated both participation in the study and participant’s attention to questions and 
task. 
 
4.2.1 Demographics and Clinical characteristics  
Questions to capture demographics of age and gender to enable comparisons to normal 
population studies were included (Stovner et al., 2014). Previous headache 
questionnaires had identified comorbidities and medication as variables to consider 
and questions about these were included along with data about inpatient/ outpatient 
status.  
 
To evaluate the impact of chronicity of mental illness a question was initially included 
asking the participant how long ago they had been diagnosed with schizophrenia or 
schizoaffective disorder. This question was removed from the questionnaire in 
accordance with one ethics committee’s recommendation. This information was then 
determined from the case notes. It should be noted that the majority of clients 
volunteered this information without being asked and referral to the notes was not 
always necessary.  
 
Body Mass Index (BMI) was considered a possible variable impacting on presence of 
headache. To determine BMI, participants were asked to give their height and weight 
a method that has been found to be reliable in other studies (Queiroz et al., 2009). 
Participants who were unsure of their height or weight were measured in the clinic or 
on the ward.  
 
4.2.2 Headache characteristics 
It was acknowledged that there is a low participation rate of people with schizophrenia 
and schizoaffective disorder in psychiatric research with a participation rate in 
interviews of between 53% and 85% (Haapea, 2007). When compared to a depressed 
population, people with schizophrenia are less willing to participate in questionnaires 
(Schäfer et al., 2011). Bearing this in mind important aspects of the data collection 
process were to collect all the necessary data in a timely manner, not overwhelm 
participants with too many questions and exclude irrelevant questions in order to limit 
losing participants (Stovner et al., 2014). The pilot questionnaire formed the basis of 
the study to collect data about the prevalence and characteristics of headaches. In both 
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inpatient and outpatient settings if a person identified more than one headache type 
they were initially asked to complete the questionnaire on their most worrying 
headache and only when this was finished were they invited to complete a second 
questionnaire on the other headache. 
 
4.2.3 Headache impact 
Recurrent headache is known to impact on a person’s quality of life and general health 
so one additional feature of this study was to determine the impact headache had on 
the quality of life of the participants (van Suijlekom et al., 2003). Questionnaires 
evaluating Quality of Life for people with schizophrenia and schizoaffective disorder 
can be lengthy. In order to collect data in a timely manner and to try and prevent 
participants from losing interest during the interview only selected questions from the 
SF-36 were included in the questionnaire. These were to gauge the perceived effects 
recurrent headache have on role-physical, social functioning and bodily pain.  
Questionnaires evaluating impact of headache on QOL must be specific enough to be 
sure they are capturing only impacts from the headache and not from other physical 
and psychological factors (Stovner et al., 2014). It was suggested that people with 
schizophrenia and schizoaffective disorder may consider the impairment to their 
functional role more important than actually considering what may be causing it and 
have difficulty answering the question (Picard et al., 2008). However, as suggested by 
Magnusson et al. (2012) including a qualifying phrase about headache allowed for 
better interpretation of the questions. The researcher found that by asking all the 
questions she was able to emphasise to participants that these QOL questions related 
only to impairments from headache not from their mental illness.  
 
There has been mixed views on the validity of the SF-36 to evaluate quality of life of 
people with schizophrenia and other severe mental illnesses (Papaioannou, Brazier, & 
Parry, 2011). Leese et al. (2008) determined that people with schizophrenia were just 
as able to use the SF-36 as the general population, however, highlighted the importance 
that participants correctly interpret the questions providing further evidence for the 
researcher to present the questionnaire in person (Leese et al., 2008).  
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4.2.4 Headache Classification 
The algorithm described in the pilot study was used to assist with the classification of 
headaches. A copy of the questionnaire and algorithm can be found in the Appendix 1 
and Appendix 2. 
 
4.3 Data Analysis 
4.3.1 Preparing and processing data 
Each participant was allocated an individual identification number (ID) from 1-100. 
People who experienced more than one type of headache and completed two 
questionnaires were allocated a second ID for the second questionnaire starting from 
101. A variable coding table was developed to list all the variables in the questionnaire 
and assign each a numerical code. All data were double entered and screened for errors. 
Analysis was undertaken using IBM SPSS statistics version 22. Continuous variables 
were screened for normality of distribution using Kolmogorov-Smirnov test and the 
influence of outliers was investigated using the 5% Trimmed Mean. 
 
Monthly Index of Medical Speciality (MIMS) searches were conducted on all 
medication to determine how they should be rated in relation to impacting on 
possibility of developing headache. All participants were taking antipsychotic 
medication due to the nature of their illness. Medications were divided into groups of  
 antipsychotic medication only,  
 all other mental health medication that did not include antipsychotics,  
 all other medication that did not include any for mental health conditions.  
 
The groups were further divided into two subgroups  
 headache as a common or very common side effect 
 headache as an uncommon or rare side effect 
 
In every instance the highest rating of headache side effect of any of the drugs being 
taken by that participant was considered. So for example if a person was taking an 
antipsychotic medication which rated headache as a rare side effect but was taking 
another mental health medication such as venlafaxine which has a common side effect 
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of headache then when considering if the person was taking medication with headache 
as a common or rare side effect the rating was ‘common’.  
 
4.3.2 Analysing data 
Descriptive statistics were used to describe participant’s demographic, general health 
and psychiatric clinical characteristics. Where possible the clinical and demographic 
characteristics were compared to normative data.   
 
The 12-month prevalence rate for headache was calculated for the whole sample. A 
series of univariate logistic regressions were conducted to determine if there were any 
demographic or clinical characteristics that impacted on the likelihood of participants 
reporting headache. Headache was the dependent variable and explanatory variables 
explored were gender, age, inpatient/outpatient status, BMI, length of illness, 
medication with headache as side effect and diabetes. A Pearson product-moment 
correlation was conducted to determine if there was a linear relationship between 
reported pain from headache and chronicity of mental illness. 
 
Two researchers independently screened each headache questionnaire and classified 
each individual’s headache as MH, TTH, CGH or OH. The responses of the two raters 
were then compared and inter-rater agreement was assessed using the Kappa Measure 
of Agreement. Any disagreements between the raters headache classifications were 
discussed and a consensus reached on the most appropriate classification for that 
person. In situations where a consensus could not be reached a third review would be 
asked to review the questionnaire and a majority decision would be made. Prevalence 
rates for each of the headache types were also calculated. Within the population who 
experienced headache the proportion of participants experiencing each headache type 
was calculated.  
 
To explore the likelihood of any demographic and/or clinical characteristics impacting 
on participants experiencing specific headache types a series of logistic regression 
analyses were undertaken, one within the whole sample and then another within the 
headache only population. For example when investigating the influence of clinical 
and demographic factors on the presence of MH, the whole sample was dichotomised 
into migraine or not migraine such that the non-migraine cohort contained some 
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headache free participants as well as headache patients who suffered from non-
migrainous headache. Univariate logistic regression analyses were performed in this 
way for each headache type using the whole sample with the dependent variable of 
presence or absence of specific headache type. Explanatory variables explored were 
gender, age, inpatient/outpatient status, BMI, length of illness, medication with 
headache as side effect and diabetes. This process was repeated for each specific 
headache type as well as OH. To model the combined influence of significant 
explanatory variables on headache status a multivariate logistic regression was 
conducted using explanatory variables identified in the univariate logistic regression 
with p<0.2. No multivariate logistic regression was conducted is no variable recorded 
p<0.2. 
 
Then to further explore the influence of demographic general health and psychiatric 
clinical characteristics on specific headache status the same series of univariate logistic 
regressions using the headache only population, meaning no headache free participants 
were included in the sample. A multivariate logistic regression was also conducted 
using the same parameters as described for the whole population.  
 
Correlations were used to explore the impact of headache on quality of life. If data was 
normally distributed a Pearson correlation was used or if data was not normal a 
Spearman’s correlation was undertaken to determine if there was a relationship 
between quality of life scores (QOL) for Bodily Pain, Social Functioning, Role 
Physical and length of headache (LOH), frequency of headache (FOH) and pain 
(VAS). One way group analysis of variance (ANOVA) for parametric data or a 
Kruskal-Wallis Test for non-parametric data was used to explore if a specific headache 
type impacted on quality of life scores (QOL) for BP, SF and RP.  
 
Themes of management strategies for headache were identified and ranked in order of 
prevalence. 
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CHAPTER FIVE 
Results 
5.1 Participation 
Across the five months of recruitment 148 people met selection criteria and were 
approached regarding participation. There was a 68% participation rate with 48/148 
people (32%) declining to participate. The final cohort consisted of 100 people with a 
diagnosis of schizophrenia or schizoaffective disorder confirmed by a psychiatrist. All 
subjects completed most aspects of the questionnaire – there was minimal missing data 
and specifics of missing data are detailed below. A flow chart detailing the recruitment 
process can be found in Figure 4. 
 
During the recruitment period 85 people who met selection criteria attended the 
outpatient depot clinic and were invited to participate. Fifty five people (55/85) agreed 
to participate making a participation rate of 65% in this setting. Participation rate for 
males was 63% (31/49) and 67% (24/36) for females. The main reasons given to 
decline participation included   
 I’m not interested (n=13) 
 No reason given (n=4) 
 I’m in a hurry (n = 4) 
 I would but I don’t want to sign a consent form (n=3) 
 My children are in the waiting room (n=2) 
 I don’t want to (n=2) 
 I have just completed a medical appointment and am not feeling good (n=1) 
 I’m too tired (n=1) 
 
During the inpatient recruitment phase 63 people met selection criteria and 45 people 
agreed to participate giving a participation rate of 71% in this setting. The participation 
rate for males was 80% (35/44) and 53% (10/19) for females. Main reasons given to 
decline participation included   
 I’m not interested (n=12)  
 I would but I don’t want to sign a consent form (n=4) 
 I want to go to sleep (n=2) 
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Figure 4 - Flow chart of recruitment rate in inpatient and outpatient settings 
  
5.2 Demographics 
Sixty six percent of participants were male (66/100) and 34% were females (34/100). 
Participation rate for males was 71% (66/93) and 61.8% for females (34/55). 
Recruitment of males was distributed reasonably evenly between inpatient (53%, 
35/66) and outpatient settings (47%, 31/66). In contrast, of the 34 women recruited, 
71% were from the outpatient setting (24/34) with only 29% recruited from the 
inpatient setting (10/34). Figure 5 shows the distribution of males to females in both 
approached and participated groups.  
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Figure 5 – People approached and participated by setting and gender 
 
 
Age ranged from 19 years to 60 years with a mean age of 38.8 years (SD=10.39 years). 
As can be seen in Figure 6 there was a slight skew to the left with scores clustered 
around the lower ages.  
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Figure 6 – Age distribution of participants 
 
 
Figure 7 shows that BMI ranged from 16.8 to 55.5 with a mean score of 29.4 
(SD=6.62). A normal BMI range is from 20-25, the overweight range is 25-30 and 
over 30 is deemed obese. The mean score for this sample population is therefore at the 
upper end of the overweight range. When compared to previous studies of a similar 
population the distribution of BMI is comparable, however, there is quite a discrepancy 
between BMI distribution in these two samples and the general population as indicated 
in Figure 8 (Morgan et. al., 2012).  
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Figure 7 – BMI distribution of participants 
 
 
Figure 8 – Comparisons of BMI in the general population, people living with 
psychotic illness population and the sample population.  
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Based on results of People living with psychotic illness 2010, Australian Government. 
The length of time a person had been diagnosed with their psychotic illness ranged 
from 6 months to 50 years with a mean of 14.5 years (SD=9.2 years). It is evident from 
Figure 9 that more people access the mental health services in the early stages of their 
illness. The age on onset of mental illness ranged from self-reported 6 years of age to 
51 years of age with 62% of participants having developed their illness before age 25. 
 
Figure 9 - Length of time since diagnosis of mental illness 
 
 Medications were grouped according to antipsychotic medication, other mental 
health medications and all other medications. All patients were on antipsychotic 
medication due to the nature of their illness, 53/100 participants were taking other 
mental health medication including mood stabilisers and antidepressants and 39/100 
participants were taking other medication for conditions amongst which were 
diabetes, high blood pressure and high cholesterol. Two thirds (66/99) of people 
were taking some form of medication with headache as a common or very common 
side effect.  
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Diabetes was the most common co-morbidity identified with 15% (15/100) people 
reporting this condition. Only 3/100 people identified co-morbid musculoskeletal 
problems.  
 
5.3 Headache characteristics 
The prevalence of headache within the last twelve months was 57% (57/100). 
Prevalence rates by gender were very similar with 58% (38/66) of males and 56% 
(19/34) of females reporting headache in the last 12 months.   
 
Within the headache population 23% (13/57) experienced a headache on the day of 
interview and 68.5% (39/57) had experienced a headache in the last month. The 
majority of participants who experienced headache only reported having one type of 
headache (81%, 46/57). Of those people who did experience more than one type of 
headache (11/57) only one person completed a second questionnaire. Participants had 
started experiencing headaches from as recently as 5 months ago to as long as 50 years 
ago with a median value for length of time experiencing headaches of 20 years 
(IQR=5.5-24.5 years). Participants started getting headaches from as young as 6 years 
of age through to 58 years of age with a median age of 19 years (IQR=13-31.3 years). 
Four participants were missing data for this part of the questionnaire as they reported 
finding it too hard to remember when they first started experiencing headache.  
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Figure 10 - Length of time participants have been experiencing headaches 
 
 
Table 5 records how frequently people experienced headache. Sixty percent of people 
only experienced a headache once a month or less. Twelve percent (7/57) people 
experienced headache daily with a further 18% (10/57) experiencing headache at least 
weekly.  
  
Table 5 - Frequency of headaches 
Frequency Percentage of headache sufferers 
Daily 12% (7/57) 
3-4/week 3.5%  (2/57) 
1-2/week 14%  (8/57) 
1/fortnight 10.5% (6/57) 
1/month 31% (18/57) 
Less than once a month 29% (16/57) 
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Headaches were reported to last from as short a time as 10 seconds to being continuous 
with no relief. Figure 11 highlights that this distribution is not normal with a significant 
skew toward headaches of shorter duration times.  When people with continuous 
headache are excluded the median value for length of headache time was 3 hours 
(IQR=1– 8 hours). 
 
Figure 11 – Length of time headache lasts in hours 
 
 
Analysis of the intensity of headache pain using the 0-10 Visual Analogue Scale 
(VAS) showed (Figure 12) that average headache pain intensity ranged from 0.5/10 to 
10/10 with a mean of 5.8 (SD=2.1). A negative skewness value (-0.35) indicates a 
clustering of scores to the higher end of the scale. All participants completed this 
section of the questionnaire including the person who completed two questionnaire 
giving a total of 58 responses. Forty one percent (24/58) reported having neck pain or 
stiffness at the time of their headache. 
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Figure 12 – Average headache pain intensity scores  
 
 
5.4 Relationship between clinical characteristics and headache 
Males made up 67% (38/57) of people experiencing headache. Within both the male 
and female population there was a 58% and 56% prevalence respectively of 
participants who experienced headache (male 38/66, female 19/34). The univariate 
logistic regression found no significant association between gender and headache 
(p=.87) with an odds ratio of 1.07, 95% CI [0.47–2.47].  
 
The mean age of people experiencing headache was 37.7 years (SD=9.4 years) and 
40.2 years (SD=11.5 years) for people who did not experience headache. There was 
no significant relationship between age and presence of headache (p=.25) with an odds 
ratio of 0.99, 95% CI [0.94-1.02].  
 
Within the headache population 53% were inpatients (30/57) and 47% (27/57) were 
outpatients. Inpatient/outpatient status did not impact significantly on presence of 
headache (p=.08) with an odds ratio of 2.07, 95% CI [0.92-4.68].  
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There was no significant relationship between length of time from diagnosis of mental 
illness and presence of headache (p=.61). The odds ratio for length of illness is 0.99, 
95% CI [0.95-1.03]) suggesting no significant link between chronicity of 
schizophrenia or schizoaffective disorder and headache.  
 
Those participants experiencing headache had a mean BMI of 29.67 (SD=7.4) 
compared to those not experiencing headache M=28.96 (SD=5.48). BMI did not have 
a significant impact on headache status (p=.58) with an odds ratio of 1.02, 95% CI 
[0.96-1.08].  
 
All medications listed by participants were examined to determine the impact 
medication usage might have on headache status. Figure 13 shows the number of 
people taking medications with headache as either a common or rare side effect. It is 
apparent that almost two thirds of participants (66/99) were taking some form of 
medication that lists headache as a common or very common side effect. One person 
had missing data about their medications and was not included in this or any 
subsequent medication calculations. This person did not experience headache. Within 
the headache only population these figures were almost the same 64% (37/57) taking 
any medication with side effect of headache. 
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Figure 13 – Medication with headache as side effect 
 
 
 
Taking medication with headache as a common or very common side effect was not 
significantly related to headache status (p=.89). The odds ratio was 0.94 with 95% CI 
[0.40-2.19] suggesting no difference between taking medication with headache as a 
common side effect or medication with headache as a rare side effect.  
 
Diabetes was the most commonly occurring comorbid health problem, though only 
10% of headaches sufferers reported having diabetes. Diabetes did not impact on 
presence of headache (p=.15) with an odds ratio of 0.44 and 95% CI [0.14-1.37].  
A multivariate logistic regression was performed to model the combined explanatory 
power on potentially significant variables. Variables with p<.2 from the univariate 
analysis were considered as explanatory factors in the multivariate analysis. The 
variables included were inpatient/outpatient status and diabetes. This model was not 
statistically significant X²(2,n=100)=5.36,p=.07 indicating the model had difficulty 
distinguishing between those who had headache and those who didn’t. This model 
explained between 5.2% (Cox and Snell R square) and 7.0% (Nagelkerke R square) of 
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variance in headache and classified 60% of cases correctly. As can be seen in Table 6 
neither variable had a unique significant influence on headache. 
 
Table 6 - Logistic Regression predicting likelihood of headache 
 B S.E Wald df p 
Odds 
Ratio 
95% CI for 
odds ratio 
Lower Upper 
Inpatient/ 
outpatient 
.76 .42 3.21 1 .07 2.13 0.93 4.86 
Diabetes -.86 .58 2.15 1 .14 .43 0.14 1.33 
 
To evaluate the strength of the relationship between pain and chronicity of 
schizophrenia or schizoaffective disorder, a Pearson product-moment correlation was 
performed using headache pain intensity and length of illness. There was no 
significant relationship between pain intensity and length of illness detected (r=.098, 
p=.465).  
 
5.5 Headache classification 
Using the algorithm developed in the pilot study two physiotherapists independently 
classified all the headaches into migraine (MH), tension type (TTH), cervicogenic 
(CGH) and other (OH) headache. There was agreement on 47 out of 58 questionnaires. 
One rater classified 20/58 headache as MH, 17/58 as TTH, 5/58 as CHG. and 16/58 as 
OH while the other rater identified 15/58 as MH, 20/58 as TTH, 5/58 as CHG. and 
18/58 as OH. The Kappa Measure of Agreement value was 0.74, 95% CI[0.59-0.88] 
with significance of p<0.0005 indicating good agreement according to Peat (2002). 
Following this the physiotherapists met together and discussed and reached agreement 
on all participants without needing to refer to a third person. 
 
Classification of headache determined OH to be the most common type of headache 
experienced followed by MH and TTH. As expected CGH was the least prevalent. 
Prevalence rates are listed in Table 7.  
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Table 7 – Prevalence of headache by classification 
Headache type Total Sample Population Headache population only 
Migraine 17.8% 31.0% 
TTH 15.8% 27.6% 
CGH 4.85% 8.6% 
Other 18.8% 32.8% 
 
5.6 Relationship between clinical characteristics and specific 
headache types 
5.6.1 – Cervicogenic Headache 
The age of people experiencing CGH ranged from 37 years to 59 years with a mean 
age of 47.2 years (SD=8.3 years). Gender was evenly divided with 2 females and 3 
males. Two people were inpatients and 3 were outpatients. The mean BMI was 27 
(SD=6.6) with a range from 21.2 to 38. People with CGH had been diagnosed with a 
mental illness from as recently as 2 years ago to as long as 23 years ago with a mean 
of 16 years (SD=8.3 years). The age range of onset of headache was from 13 years of 
age to 58 years of age with a mean of 37 years of age (SD=14.5 years). Three of the 5 
people experiencing CGH were taking medications that listed headache as a common 
or very common side effect. No people experiencing CGH had a history of diabetes. 
 
As can be seen in Table 8 none of the variables age, gender, BMI, LOI, diabetes or 
medication had statistically significant impact on presence of CGH. No multivariate 
logistic regression was performed as age was the only variable that had a p<.2.  
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Table 8 Univariate models for explanatory variables for CGH in the total 
population 
Variable P value 
Odds 
Ratio 
95% CI 
Lower Upper 
Inpatient Outpatient .82 .81 .13 5.05 
Age .08 1.08 .99 1.19 
Gender .77 .76 .12 4.79 
LOI .71 1.02 .93 1.12 
BMI .41 .93 .79 1.10 
Medication .75 .74 .12 4.65 
Diabetes 1.0 .00 .00  
 
Within the headache only population age impacted significantly on CGH (p=.03) with 
an odds ratio of 1.14, 95% CI [1.01–1.29]. This suggests that there is relationship with 
age and CGH (Table 9). This is consistent with the clinical characteristics of CGH in 
the general population. 
 
Table 9 Univariate models for explanatory variables for CGH in the headache 
only population 
Variable P value 
Odds 
Ratio 
95% CI 
Lower Upper 
Inpatient Outpatient .53 .55 .09 3.58 
Age .03 1.14 1.01 1.29 
Gender .79 .77 .12 5.04 
LOI .66 1.02 .93 1.12 
BMI .40 .93 .79 1.10 
Medication .81 .79 .12 5.19 
Diabetes 1.0 .00 .00  
 
A univariate logistic regression using the variable aged² in the headache only 
population was also conducted to determine if the relationship between CGH and age 
followed a linear progression (Table 10). The impact of aged² on CGH was also 
significant p=.03 indicating that the association of age and CGH is not linear meaning 
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that while age impacts on presence of CGH there is not a direct association with each 
year of aging.  
 
Table 10 - Logistic Regression predicting likelihood of CGH by age in headache 
only population. 
  B S.E Wald df p 
Odds 
Ratio 
95% CI for 
odds ratio 
Lower Upper 
Total 
population 
Age .081 .046 3.095 1 .08 1.084 .991 1.187 
Headache 
only 
population 
Age .135 .062 4.707 1 .03 1.144 1.013 1.293 
Age² .001 .001 5.010 1 .03 1.001 1.000 1.003 
 
5.6.2 – Migraine Headache 
Thirteen males and 5 females experienced MH with inpatient/outpatient status evenly 
spread with 9 in each setting. The mean age of people with MH was 24.8 years (SD=6.7 
years) and ranged from 24 years to 57 years. BMI of people with MH ranged from 
21.5 to 55.5 with a mean BMI of 29.8 (SD=8.0). The most recent diagnosis of mental 
illness was 1 year previously with the longest being 27 year earlier. Mean time from 
diagnosis was 11.4 years (SD=7.5 years). The youngest age that anyone with MH 
started experiencing their headache was 6 years old and the oldest was 36 years. The 
average age of onset of MH was 19 years (SD=9.0 years) with average age of onset 
for males 19.4 years (SD=9.3 years) and 18.2 years (SD-10.1 years) for females. 
Fifteen of the people experiencing MH were taking medication that listed headache as 
a common or very common side effect. Thirty three percent (6/18) of the migraine 
population reported neck pain or stiffness when they have a headache. Three people 
(3/18) reported the comorbidity of diabetes.  
 
The logistic regression results presented first are based on the total population. Table 
11 summarises the information from univariate logistic regression models exploring 
the impact of the explanatory variables of age, gender, BMI, LOI, medication and 
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diabetes on MH within the total sample population. Taking medication with headache 
as a common or very common side effect was significant (p=.05) within the total 
population. 
 
Table 11 - Univariate models for explanatory variables for MH in the total 
population 
Variable P value 
Odds 
Ratio 
95% CI 
Lower Upper 
Inpatient Outpatient .64 1.28 .46 3.55 
Age .08 .95 .90 1.01 
Gender .54 1.42 .46 4.39 
LOI .12 .95 .89 1.01 
BMI .79 1.01 .94 1.09 
Medication .05 4.56 .98 21.30 
Diabetes .83 1.17 .29 4.65 
 
A multivariate logistic regression was performed using variables with p<.2 to 
determine the combined effect they might have on the presence of headache (Table 
12). The variables included were age (p=.08), LOI (p=.12) and medication (p=.05). 
This model was statistically significant X²(2,n=99)=7.694,p=.05 indicating the model 
could distinguish between those who had MH and those who didn’t. The model 
classified 82.8% of cases correctly and could explain between 7.5% (Cox & Snell R 
square) and 12.5% (Nagelkerke R Square) of the variance in MH. Within this model 
no variable had a statistically significant impact on presence of MH. 
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Table 12 - Logistic Regression predicting likelihood of MH by medication, age 
and LOI in total population. 
 B S.E Wald df p 
Odds 
Ratio 
95% CI for odds 
ratio 
Lower Upper 
Medication -1.520 .794 3.662 1 .06 4.57 .964 21.684 
Age -.034 .037 .881 1 .35 .966 .899 1.038 
LOI -.019 .042 .205 1 .65 .981 .903 1.066 
 
Amongst the headache only population the univariate logistic regression model found 
the impact of medication with headache as a common side effect was statistically 
significant (p=.03) with an odds ratio of 6.14, 95% CI [1.24-30.44]. This indicated that 
people experiencing headache who are taking medication with headache as a common 
or very common side effect are 6.14 times more likely to experience MH. None of the 
other variables age, gender, BMI, LOI and diabetes had statistically significant impact 
on presence of MH (Table 13).  
 
Table 13 Univariate models for explanatory variables for MH in the headache 
only population 
Variable P value 
Odds 
Ratio 
95% CI 
Lower Upper 
Inpatient Outpatient .72 .82 .27 2.49 
Age .13 .95 .89 1.01 
Gender .47 1.56 .46 5.25 
LOI .13 .95 .88 1.02 
BMI .96 1.00 .93 1.08 
Medication .03 6.14 1.24 30.44 
Diabetes .30 2.47 .45 13.63 
 
A multivariate logistic regression was conducted exploring the impact of age, LOI and 
medication on MH within the headache only population (Table 14). The logistic 
regression model was statistically significant (X²(1,N=57)=9.797,p=.02). It could 
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explain between 15.8% (Cox & Snell R square) and 22.4% (Nagelkerke R Square) of 
the variance in MH and correctly classify 61.4% of cases. Within this model 
medication remained statistically significant (p=.02) with and odds ratio of 7.47, 95% 
CI [1.39-40.02] indicating that a person taking medication with headache as a common 
or very common side effect was 7.47 times more likely to experience MH.  
 
Table 14 – Multivariate logistic regression for impact of medication, age and LOI 
on MH within the headache only population 
 B S.E Wald df p 
Odds 
Ratio 
95% CI for odds 
ratio 
Lower Upper 
Medication -2.011 .856 5.512 1 .02 7.468 1.394 40.016 
Age -.049 .044 1.273 1 .26 .952 .874 1.037 
LOI -.020 .044 .200 1 .66 .981 .900 1.068 
 
5.6.3 – Tension Type Headache 
People experiencing TTH ranged in age from 23 years to 51 years (Mean=50 years, 
SD=8.4 years). Of the 6 females and 10 males classified with TTH, 5 were inpatients 
and 11 were outpatients. BMI of this group ranged from 18 to 38.7 with a mean BMI 
of 29 (SD=5.8). The length of time since diagnosed with mental illness ranged from 
as recently as 2 years to 21 years with a mean time of 13.7 years since diagnosis 
(SD=5.4 years). People with TTH started experiencing them from as young as 10 years 
old to as old as 35 years old with a mean age of onset of headache 19 years (SD=8.1 
years). A large proportion of the participants with TTH (11/16) were taking medication 
that listed headache as a common or very common side effect. One quarter (4/16) of 
people with TTH had neck pain or stiffness at the time of their headache. No people 
experiencing TTH reported a history of diabetes. 
 
Univariate logistic regressions were conducted on the total population using the 
explanatory variables of age, gender, BMI, LOI, diabetes and medication. No one 
variable had a statistically significant impact on the presence of TTH within this 
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population. (Table 15) No multivariate logistic regression was conducted as no 
variables had a p<.2.  
 
Table 15 Univariate models for explanatory variables for TTH in the total 
population 
Variable P value 
Odds 
Ratio 
95% CI 
Lower Upper 
Inpatient Outpatient .23 .50 .16 1.56 
Age .60 .99 .94 1.04 
Gender .75 .83 .28 2.53 
LOI .69 .99 .93 1.05 
BMI .81 .99 .91 1.08 
Medication .85 1.12 .35 3.54 
Diabetes .99 .00 .00  
 
The univariate logistic regression models exploring the impact of these variables on 
TTH within the headache only population determined that inpatient/outpatient status 
was the only variable that was statistically significant (p=.04) (Table 16). The odds 
ratio of 0.28, (95% CI [0.08-0.95]) being less than 1, indicates that as an inpatient the 
odds of headache being TTH was 0.28 less likely.  
 
Table 16 Univariate models for explanatory variables for TTH in the headache 
only population 
Variable P value 
Odds 
Ratio 
95% CI 
Lower Upper 
Inpatient Outpatient .04 .28 .08 .95 
Age .96 1.00 .94 1.06 
Gender .77 .83 .25 2.77 
LOI .77 .99 .93 4.06 
BMI .68 .98 .90 1.07 
Medication .71 1.27 .37 4.36 
Diabetes 1.0 .00 .00  
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5.6.4 – Other Headache 
Demographics of the group of people experiencing other headaches were 12 males and 
7 females ranging in age from 19 years to 56 years with a mean age of 38 years 
(SD=11.3 years). Fifteen of this group were inpatients with only 4 in the outpatient 
setting. The mean BMI of this group was 30.8 (SD=8.3) with a range from 17 through 
to 54. This group of people had the largest distribution of length of illness ranging 
from 6 months since diagnosis to 50 years with a mean length of time from diagnosis 
of schizophrenia or schizoaffective disorder of 16.9 years (SD=12.7 years). There was 
also a large variation in age of onset of headaches from as young as 6 years old to 48 
years old with a mean age of 14.5 years (SD=6.8 years). Less than half of the people 
experiencing OH were taking medication which listed headache as a common or very 
common side effect (9/19). Almost half (9/19) of people experiencing OH reported 
feeling neck pain or stiffness when they had a headache. Three people in this cohort 
reported having diabetes. 
 
The impact of age, gender, inpatient/outpatient status, BMI. LOI, medication and 
diabetes on OH amongst the whole population was explored using univariate logistic 
regressions. Two variables were statistically significant (Table 17). With a p<.01 and 
an odds ratio of 5.76, 95% CI [1.74-19.07] the chances of developing OH is 5.76 times 
more likely as an inpatient. Taking medication with headache as a common or very 
common side effect was also significant (p=.03) with an odds ratio of 0.32, 95% CI 
[0.11-0.90] meaning a person taking this medication was 0.32 times less likely to 
experience OH. The odds ratio for a person taking medication that does not have 
headache as a side effect is 3.15, 95% CI [1.11-8.99] means that a person taking 
medication without headache as a side effect is actually 3.15 times more likely to 
experience OH. 
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Table 17 - Univariate models for explanatory variables for OH in the total 
population 
Variable P value 
Odds 
Ratio 
95% CI 
Lower Upper 
Inpatient Outpatient .00 5.76 1.74 19.07 
Age .83 .99 .95 1.05 
Gender .95 1.04 .35 3.06 
LOI .28 1.03 .98 1.08 
BMI .26 1.04 .97 1.12 
Medication .03 .32 .11 .90 
Diabetes .83 1.16 .29 4.65 
 
A multivariate logistic regression exploring the impact of inpatient/outpatient status 
and medication on OH was undertaken to explore how they impacted on OH in 
combination with each other (Table 18). This model was statistically significant 
(X²(1,N=99)=14.095,p=.001) being able to explain between 13.3% (Cox and Snell R 
square) and 21.7% (Nagelkerke R square) of the OH variance and classify 81.8% of 
cases correctly. Within the total population an inpatient (p=.01) is 5.85 (95% CI [1.71-
19.98]) times more likely to experience OH and a person taking medication with 
headache as a common or very common side effect (p=.04) is 0.30 (95% CI [0.10-
0.92]) times less likely to experience OH. The odds ratio for a person taking 
medication that does not have headache as a side effect is 3.32, 95% CI [1.09-10.09] 
means that a person taking this medication is 3.3 times more likely to experience OH.  
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Table 18 - Logistic Regression predicting likelihood of OH by medication and 
inpatient/outpatient status in total population. 
 B S.E Wald df p 
Odds 
Ratio 
95% CI for odds 
ratio 
Lower Upper 
Medication 1.199 .568 4.453 1 .04 .302 .099 .918 
Patient 1.766 .627 7.941 1 .01 5.849 1.712 19.982 
 
Within the headache only population the univariate logistic regression model found 
only two variables to have a statistically significant impact on OH (Table 19). Once 
again inpatient status had a statistically significant impact on OH (p=.01) and when 
considered within the headache only population the odds ratio of 5.39 (95% CI [1.51-
19.28]) indicates that as an inpatient the odds of headache being OH was 5.39 more 
likely. Taking medication with headache as a common or very common side effect 
(p=.01) meant a person in the headache only population was 0.23 (95% CI [0.07-0.77]) 
times less likely to experience OH. Once again when looking at medication where 
headache is not a side effect the odds ratio is 4.43, 95% CI [1.36-14.40] meaning that 
a person taking medication that does not have a side effect of headache is 4.4 times 
more likely to experience OH. 
 
Table 19 Univariate models for explanatory variables for OH in the headache 
only population 
Variable P value 
Odds 
Ratio 
95% CI 
Lower Upper 
Inpatient Outpatient .01 5.39 1.51 19.28 
Age .88 1.01 .95 1.07 
Gender .79 .86 .27 2.70 
LOI .14 1.05 .99 1.12 
BMI .48 1.03 .96 1.11 
Medication .01 .23 .07 .77 
Diabetes .35 2.25 .41 12.38 
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A multivariate logistic regression was also undertaken in the headache only population 
exploring the impact of inpatient/outpatient status and medication on OH as can be 
seen in Table 20. This model was statistically significant (X²(1,N=57)=12.395,p=.002) 
being able to explain between 19.5%% (Cox and Snell R square) and 27.1% 
(Nagelkerke R square) of the OH variance and classify 71.9% of cases correctly. 
Within the total population an inpatient (p=.02) is 4.8 times more likely to experience 
OH (95% CI [1.27-18.27]) and a person taking medication where headache is a 
common or very common side effect (p=.03) is 0.24 times less likely to experience 
OH (95% CI [0.07-0.85]). Similarly to previous examples the person taking 
medication that does not have a side effect of headache is more likely to experience 
OH (OR=4.11, 95% CI [1.18-14.37]). 
 
Table 20 - Logistic Regression predicting likelihood of OH by medication and 
inpatient/outpatient status in headache only population. 
 B S.E Wald df p 
Odds 
Ratio 
95% CI for odds 
ratio 
Lower Upper 
Medication 1.413 .639 4.896 1 .03 .243 .070 .851 
Patient 1.571 .681 5.324 1 .02 4.811 1.267 18.269 
 
5.5 Hospital admission 
Only seven people (12%, 7/58) associated headache with being admitted to hospital 
suggesting that unlike previous studies this is not a reason for people to fail to report 
the existence of headache. The following table (Table 21) indicates the headache types 
experienced by these people. 
 
Table 21 – Association to hospital admission based on headache classification 
 MH TTH CGH OH 
Number 2/18 3/16 0/5 2/19 
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5.6 Quality of Life 
Quality of Life relating to Bodily Pain (BP), Role Physical (RP) and Social 
Functioning (SF) of the 36 people who had experienced headache in the previous four 
weeks and completed the questionnaire were scored used the RAND 36 Item Health 
Survey 1.0 scoring system (Ware & Sherbourne, 1992).  
 
5.6.1   Impact of headache on QOL  
The scoring system used in the RAND 36-Item Health Survey is designed to deliver a 
score between 0 and 100. The closer the score is to 100 the less impact there is on 
QOL. Analysis of each of the individual SF-36 items showed normality as did the 
category of calculated BP scores with a mean of 60.8 (SD=19.98). The categories SF 
and RP calculated scores were not normally distributed with the median for SF=75 
(IQR 50-100) and the median for RP=50 (IQR 0-100). The high and low scores of all 
headache types are represented in Figure 14. The mean scores for BP and median score 
for SF are above 50 suggesting less impact on functioning from headache while the 
median score for RP is 50 suggetsing moderate impact.  
 
Figure 14 - High/low and mean/median scores of BP, SF and RP 
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A Pearson correlation was undertaken to determine if there was any correlations 
between quality of life scores (QOL) for BP and length of headache (LOH), frequency 
of headache (FOH) and pain (VAS). Spearman correlations were undertaken to 
determine if there was any relationship with QOL scores for SF, RP and length of 
headache (LOH), frequency of headache (FOH) and pain (VAS). Frequency of 
headache was the only factor that had a statistically significant correlation to QOL. 
There was a medium correlation between FOH and SF (ρ=-.44, n=56, p=.00), BP (r=-
.41, n=56, p=.00) and RP (ρ=-.32, n=56, p=.01). The more frequent the headache the 
more impact on SF, BP and RP. 
 
5.6.2   Impact of specific headache on QOL  
Comparing the mean score for BP and the median scores for SF and RP against each 
headache type it is clear to see that CGH and OH scored significantly worse on all 
three measures but in particular, along with OH, on role physical (Figure 15).  
 
Figure 15 - Mean score for BP, and median score for SF and RP of each headache 
classification 
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Tests were conducted to determine if there were any relationships between quality of 
life scores for BP, SF, RP and headache classification. A one way between groups 
analysis of variance was conducted to explore if any headache type of MH, TTH, CGH 
or OH impacted on BP. There is no significant relationship between bodily pain scores 
and any specific headache classification F(3,32)=.21, p=.89. A non-parametric 
Kruskal-Wallis test was conducted to explore if any headache type impacted on SF. 
No significant differences were found x²(3, n=36) =3.43, p=.33. A non-parametric 
Kruskal-Wallis test was also conducted to explore if any headache type impacted on 
RP. Once again no significant differences were found x²(5, n=36) =9.07, p=.11.  
 
FOH was shown to have an impact on QOL within the headache population of the 
sample. However, there was no significant connection between QOL scores and any 
specific headache classification suggesting frequency of headache rather than the type 
of headache has more impact on QOL for the individual with schizophrenia and 
schizoaffective disorder who experiences headache.  
 
5.7 Management 
Table 22 provides a summary techniques used by participants to relieve their 
headaches. The table is presented in order of most common to least common.  
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Table 22 – Management of Headache 
Strategies used to manage Headache Number 
Medication  47 
Sleep 40 
Massage 12 
Heat or Ice 7 
Drink of water 6 
Relaxation 5 
Physical activity and stretching 4 
Neck exercises 3 
Cannabis or other drugs 3 
Pressure points on thumb or head 3 
Alcohol 2 
Chiropractic 2 
Unknown 2 
Correct posture 1 
Eat 1 
Depot 1 
 
Eighty nine percent (16/18) of people experiencing MH took medication to relieve 
their headache and 78% (14/18) used sleep. The most common management for TTH 
was also medication with 75% (12/16) using medication for relief of symptoms. Sleep 
was also the second most prevalent form of treatment for TTH with 56% (9/16) of 
participants sleeping to relieve headache. No people used relaxation as a form of 
treatment and only 12.5% (2/16) people used massage.  
 
No person experiencing headache reported receiving assessment or treatment from a 
physiotherapist. One person experiencing CGH attended chiropractic for their 
headache and another used pressure on the head. One person used massage while 4/5 
took medication. No-one undertook neck exercises. Medication (79%, n=15/19) and 
sleep (74%, n= 14/19) were also the most common treatments used by people who 
experienced OH to relieve the symptoms. 
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CHAPTER SIX 
Discussion of findings 
6.1 Summary of results 
The aims of this study were to determine the prevalence, characteristics, management 
and impact of headache in people with schizophrenia and schizoaffective disorder. 
One hundred and forty eight eligible patients from the Fremantle Hospital, Mental 
Health Services with a diagnosis of schizophrenia or schizoaffective disorder were 
invited to an interview to complete a questionnaire about headache. Forty-eight people 
declined to participate, leaving a sample of 100 ranging from 19 years to 60 years of 
age. Fifty-five people were recruited from the outpatient depot clinic and forty-five 
from the inpatient wards.  
 
Sixty six of the participants were male and the mean age of all participants was 38.8 
years. The BMI of participants ranged between underweight (16.8) and morbidly obese 
(55.5) with a mean BMI of 29.5. Participants had been diagnosed with either 
schizophrenia or schizoaffective disorder for between 5 months and 50 years with the 
mean length of illness being 14.6 years. All participants were on antipsychotic 
medication, 53 were taking other mental health medication and 39 were taking 
medication for other physical medical conditions. Sixty six people were taking some 
medication that had headache as a common side effect. The most common comorbid 
physical illness was diabetes with 15/100 people reporting the condition. Forty-one 
percent (24/58) of headache sufferers also experienced neck pain or stiffness. 
 
The twelve month prevalence of headache in this population was 57% with 81% of 
these people only experiencing one type of headache. People had been experiencing 
headache from between 5 months and 50 years with a median time of 20 years. Some 
participants were as young as 6 years old when they started experiencing headache. 
Only 7 of the 57 people who experienced headache reported having them on a daily 
basis. Headaches lasted from 10 seconds through to continuous with the median time 
being 3 hours. The average reported intensity of pain associated with headache was 
5.8/10.  
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Gender, age, inpatient/outpatient status, length of mental illness, BMI, medication type 
or diabetes did not impact on presence of headache. There was no correlation between 
chronicity of illness and intensity of pain associated with headache. 
 
Twelve month prevalence of CGH was 4.9%, MH was 17.8%, TTH was 15.8% and 
OH was 18.8%. Age was shown to impact on CGH within the headache only 
population in a non-linear fashion. Within the headache only population people taking 
medication with headache as a side effect were up to 7 times more likely to develop 
MH. People who are inpatients have up to 4.8 times more likelihood of developing OH 
and those taking medication with headache as a common or very common side effect 
are nearly 0.25 less likely to develop an OH. 
 
The frequency of headache impacted on quality of life with more frequent headaches 
impacting moderately on social function, bodily pain and role physical. There was no 
correlation between headache type and QOL suggesting frequency of headache is a 
bigger factor in impact on QOL than type of headache. 
Participants reported utilising a wide variety of strategies to manage their headache, 
often in combinations. The most common strategies reported were medication, sleep 
and massage. No participants reported seeking advice or treatment from a 
physiotherapist to help manage their headache. This includes participants who 
experience CGH, though one of these participants was receiving spinal manipulation 
from a chiropractor. 
 
6.2 Participants and recruitment 
The 100 people recruited represented a good cross section of the Australian population 
of people diagnosed with schizophrenia and schizoaffective disorder with 
demographic and clinical characteristics comparable to those of the participants in the 
Australian Government survey ‘People living with psychotic illness 2010’ (Morgan et 
al., 2011). This finding supports that the recruitment process of using consecutive 
sampling in two clusters, one in the inpatient setting and the other in the outpatient 
depot clinic, was appropriate and captured a true representation of people with these 
illnesses.  
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Non-participation is a common occurrence in research involving people with 
schizophrenia and schizo-affective disorder (Haapea et al., 2007). Haapea et al. (2007) 
report participation rates varying between 53% and 85% which suggests that the 67% 
response rate in this study is appropriate for this demographic. Schafer et al. (2011) 
determined that the more unwell the person with schizophrenia the less likely they are 
to engage in research, however, this was not the case in this study. The participation 
rate was higher in the inpatient setting (71%) where people are deemed more acutely 
unwell than the in the outpatient setting (65%) (Schäfer et al., 2011). Within both 
populations the most common reasons for non-participation were internally driven 
reasons such as lack of interest, not wanting to sign a consent form or being too tired. 
Within the outpatient population there were other more pragmatic reasons for non-
participation that could have affected the response rate, such as being in a hurry to 
attend another appointment, having children waiting for them or feeling unwell after 
just completing a difficult medical appointment with their psychiatrist. These 
externally driven reasons for non-participation may have influenced the different 
response rate between inpatient and outpatient settings or this anomaly may simply 
exist because in the inpatient setting there was more opportunity for the interviewer to 
spend time with the potential participant to better inform them about the research. 
Being better informed might have made people more inclined to engage in the research 
resulting in an improved participation rate in this population.  
 
A Finish study by Haapea et al. (2007) determined that men were less likely to engage 
in psychiatric research, a finding not supported by this study. Within the inpatient 
setting 80% of men meeting the selection criteria who were approached agreed to 
participate in the study while only 53% of women agreed to participate. In the 
outpatient setting participation rate was more equitable with 63% for males and 67% 
for females approached agreeing to participate. If it is considered that people with 
schizophrenia who are more severely ill are less likely to participate in questionnaires 
(Schäfer et al., 2011) then it would be expected that there would be a higher refusal 
rate amongst inpatients. This gender discrepancy in participation rate in the inpatient 
setting could indicate that that women inpatients were more unwell than the men. 
There is no way to measure this possibility. 
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A fear of compromising privacy or concerns that information might be made available 
to a third party were reasons identified by Schafer et al. (2011) for non-participation 
of people within this population (Schäfer et al., 2011). Prior to starting this project 
these concerns were also considered as potential problems and possible barriers for 
participation. However, these fears were possibly over stated as in the outpatient 
population the main reasons given for non-participation were lack of interest/not 
wanting to participate (12/30) or simply for no reason (4/30). Only 3/30 (10%) refusals 
in the outpatient setting was because that person did not want to sign a consent form. 
In the inpatient setting the main reason given for non-participation was also lack of 
interest/not wanting to participate (12/18) but 4/18 people in the inpatient setting 
(22.2%) refused because they did not want to sign a consent form. Fears around 
privacy may have influenced these potential participants because initially they had 
given verbal consent to participate but once the researcher asked them to sign the 
consent form they refused, citing that they did not want to sign a written consent form 
and withdrew from the study. Participants were not pressured to say why they would 
not sign the consent form so it cannot be known what their reasons were for refusal. 
Privacy could have been an issue for them but it is also possible that people who were 
voluntary patients may have feared that they were being tricked into signing something 
to make them involuntary patients. There is also the possibility that they may have had 
paranoid tendencies or as described by Schafer et al. (2011) been concerned that 
information might be passed onto a third party. There is no easy solution to the problem 
of people refusing to sign consent forms as this is an essential component of ethical 
research, though greater time might need to be dedicated to allaying fears of invasion 
of privacy when recruiting people with mental health problems. 
 
6.2.1 Demographics of the sample population 
The prevalence of psychotic illness in Australia has been determined to be 60% in 
males and 40% in females (Morgan et al., 2011). In their systematic review of 
incidence, prevalence and mortality of schizophrenia, McGrath et al. (2008) also 
determined a prevalence of 60% males (McGrath et al., 2008). The male (66%) and 
female (34%) participation rates in this study are comparable with both studies 
indicating a good gender representation of people with schizophrenia in the sample 
population. 
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In contrast, however, a review of the literature on schizoaffective disorder by Abrams 
et al. (2008) identified that schizoaffective disorder is more common amongst women 
with a prevalence of around 66%. Based on this, the higher male prevalence in the 
sample population suggests that it might not be a good representation of people with 
schizoaffective disorder. It could be surmised that more participants had a diagnosis 
of schizophrenia than schizoaffective disorder. While a diagnosis of schizophrenia or 
schizoaffective disorder was an inclusion criterion the diagnosis of each participant 
was not recorded so it was not possible to explore the male/female prevalence in each 
individual disorder.  
 
This concept of a higher representation of people with schizophrenia than 
schizoaffective disorder within the sample cohort is also supported by the findings of 
Perala et al. (2007). In their study of 8,082 people in Finland they found a lifetime 
prevalence of schizophrenia to be 0.87%, more than double the 0.32% for 
schizoaffective disorder (Perälä et al., 2007). Although their study was limited to 
people over 30 years of age Perala et al. (2007) identified that their prevalence findings 
agreed with other studies that had also determined prevalence of schizoaffective 
disorder to be around half of that for schizophrenia (Perala et al., 2007). Knowing that 
the prevalence of schizophrenia is higher than that for schizoaffective disorder and 
considering that there were more males than females in the sample population it is 
reasonable to assume that more people had the diagnosis of schizophrenia. 
 
The mean age of people surveyed in the Australian Government survey ‘People living 
with psychotic illness 2010’ was 39 years with ages ranging from 18 year to 64 years. 
These figures are comparative to this headache study where participants’ ages ranged 
from 19 year to 60 years with a mean age of 39 years. Symptoms of schizophrenia and 
schizoaffective disorder usually appear in young adults with onset of the majority of 
cases before 25 years of age (Abrams et al., 2008; McGrath et al., 2008; Morgan et al., 
2012). In our sample 62% of participants developed their illness before age 25 
consistent with the literature further supporting that the study recruited a good 
representative sample of people with psychotic illness.  
 
Obesity is a characteristic commonly observed in people with psychotic illness, partly 
as an unwanted side effect of psychotropic medication and partly due to lifestyle 
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factors associated with negative symptoms such as sedentary lifestyle (McGrath et al., 
2008; Vancampfort et al., 2011). Within the general population 34% of people are 
considered overweight with a further 21% obese (Morgan et al 2011). Within this 
sample population 31% of people were identified as overweight with a further 43% 
considered obese, a finding more consistent with the psychotic population in the 
Morgan et al. (2011) study where 28% of people had BMI in the overweight range and 
45% in the obese range. Both the Morgan et al. (2011) study and this headache study 
reveal a worrying trend for people with psychotic illness with about three quarters of 
people being overweight or obese as opposed to 55% in the general population. These 
results support the perception of poor management of physical health among this 
demographic. 
 
One consequence of increased BMI is diabetes yet despite almost 75% of the sample 
population being overweight or obese only 15% (15/100) of participants were 
identified as having diabetes. Presence of diabetes was determined either by self-
reporting and/or if diabetic medications were listed in the medication chart. In the 2010 
Australian study population of people with psychotic illness both self-reporting and a 
more accurate fasting blood triglyceride level was used to identify if a person had 
diabetes (Morgan et al, 2011). A slightly higher incidence of 20.5% of people having 
diabetes could be attributed to the different methods used to determine presence of 
diabetes. It is possible that some people in the Australian national study may have been 
unaware that they had diabetes and would not have reported it until they received 
results of the blood tests measuring fasting blood triglyceride level taken during the 
study. If fasting triglyceride levels had also been tested in this headache study sample 
population a higher prevalence of diabetes may have been found. This is, however, 
only supposition. The sample population still reported a higher prevalence of diabetes 
than the 6.2% found in the general population (Morgan et al, 2011).   
 
6.3 Prevalence of headache 
The prevalence of headache in people with schizophrenia or schizoaffective disorder 
within the previous 12 months was calculated as 57%. As explained previously there 
has been little research into the prevalence of headache within the schizophrenic 
population and none in the schizoaffective disorder population (Lake, 3rd et al., 2006; 
Lake et al., 2005). In 1999 Kuritzky et al. asked 108 outpatients with a diagnosis of 
 124 
‘chronic’ schizophrenia (diagnosis for more than 2 years) whether they had ever 
experienced headache and determined a lifetime prevalence of 48%. A control group 
of 100 people without schizophrenia returned a headache prevalence of 41%. These 
findings are a little inconsistent with the findings of our headache survey. This may be 
due to the narrower age range employed by Kuritzky et al. (28-60 years) although this 
is unlikely as our study did not find any correlation to age and presence of headache.  
 
It is possible that the discrepancy in prevalence could be due to the phrasing of the 
question regarding presence of headache. In the Kuritzky et al. (1999) study 
participants were asked if they were ‘subject to headache’ and if the person responded 
‘no’, no further questioning was undertaken. It is possible that people who experienced 
infrequent headaches may not have thought being ‘subject to headache’ applied to 
them associating this term to people with more regular headaches. In the current study 
many people initially stated that they did not get headaches but subsequently answered 
‘yes’ to having a headache in the last 12 months. In order to determine accurate 
prevalence the wording of the question is important (Stovner et al., 2014). Stovner et 
al. (2014) have created guidelines for headache research which include guidance about 
framing this initial question. If all future research follows these guidelines it will be 
easier to compare prevalence between populations. 
 
A recent study by Guveli et al., (Guveli et al., 2014) in Turkey found a prevalence of 
38.6% headache amongst people with schizophrenia, however their control group also 
had a low prevalence of headache (37.1%.) compared to the general population. It 
appears that this study did not look at 12 month prevalence rather considered 
participants who declared a headache at the time of interview or in the past. 
Discrepancies in prevalence have also been attributed to cultural differences in 
participants and methodological differences across studies (Junior et al., 2009; Linde 
et al., 2011; Radtke & Neuhauser, 2009). Junior et al. (2009) attributed the high 
prevalence of headache in Brazil (65.4%) to cultural differences but cultural 
background was not explored in this survey so how much of an impact culture had on 
prevalence of headache in this population is not known. It is possible that cultural 
factors may have also contributed to the low prevalence of headache in both the 
schizophrenic population and the control group in the Guvelli study (Guveli et al., 
2014).  
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When compared to the general population a 57% one year prevalence of headache is 
slightly higher than 46% determined by the WHO Global Burden of Headache (Jensen 
& Stovner, 2008; Stovner et al., 2007). The willingness or not of people with 
schizophrenia or schizoaffective disorder to participate in research studies may have 
impacted on this figure. It has been observed that people in this demographic may be 
more willing to participate in research if they believe there is a relevance to their own 
lives (Schäfer et al., 2011). It is therefore possible that some people who don’t 
experience headache could not see any relevance of this research to themselves 
personally and therefore declined to participate thus increasing the final prevalence 
rate of headache. This may well have been the case for those participants who declined 
because they were ‘not interested’. It cannot be known if this trend is also the same for 
all headache research but it is reasonable to interpret that the prevalence of headache 
in this population is higher than in the general public. 
 
6.4 Clinical characteristics and headache 
This section will examine and compare the clinical characteristics of people with 
schizophrenia and schizoaffective disorder who experience headache to those who do 
not experience headache and to the general population. 
 
6.4.1 Gender and headache  
The gender distribution in this study was 2:1 males to females. Headache prevalence 
within genders population was the same for both males and females. This finding is 
incongruent with those of the general population where the prevalence of headache is 
higher in women than men. A review by Stovner et al. (2007) determined that both 
globally and within each of the continents of Africa, Asia, Australia, Europe, North 
America and South America the prevalence of headache in the general population is 
greater in women than men. There is no data on prevalence of headache by gender for 
people with schizophrenia and schizoaffective disorder to compare against so it is 
unknown if the findings of this headache study are truly representative of that 
population. More research is required to determine if it is a true reflection or an 
aberration.  
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6.4.2 Age and Headache 
This study identified that age did not have a significant impact on the presence of 
headache. Junior et al. (2009) and Stovner et al. (2006) have identified that the 
prevalence of headache diminishes when a person is over 60 years of age but as there 
were no participants over 60 in this study it was not possible to determine if this is the 
case amongst people with schizophrenia or schizoaffective disorder. Further studies 
would need to be undertaken to explore if there were any changes in headache 
prevalence in the older adult population with schizophrenia or schizoaffective 
disorder. It may be worth noting that life expectancy of people with schizophrenia is 
20% less than the normal population (Paton, Esop, Young, & Taylor, 2004) impacting 
on the number of people with the disorder over 60 available for surveying.  
 
6.4.3 Age of onset of headache 
The majority of people in this study had been experiencing headache prior to their 
psychiatric diagnosis. Fifty one percent (29/57) of headache sufferers developed 
headache before or at age 20 years. This finding is consistent with the argument made 
by Lake et al. (2005) and Watson et al (1981) that most headaches are not a result of 
psychosis rather are a comorbid physical illness which should be treated as such. 
However, it doesn’t rule out the possibility of headache as a trigger or early indicator 
of mental illness, an issue that will be explored later in the discussion. 
 
6.4.4 Chronicity of illness and headache 
Kuritzky et al. (1999) and others have suggested that people with schizophrenia and 
schizoaffective disorder have a diminished response to pain or a reduced sensitivity 
which is more pronounced in the chronic phase of the illness (Bonnot et al., 2009; 
Engels et al., 2014; Guieu et al., 1994; Potvin & Marchand, 2008). Therefore, it might 
be expected that more chronic participants, that is those with a less recent diagnosis of 
mental illness, would report headache less frequently than those with a shorter history 
of schizophrenia or schizoaffective disorder, particularly as we found age not to be a 
factor. This was not the case. Our data showed that length of illness did not impact on 
presence of headache. not the case. Our data showed that length of illness did not 
impact on presence of headache. A recent systematic review by Stubbs et al. (2014) 
also determined no significant difference in the prevalence of clinical pain, including 
headache, between people with schizophrenia and a control group of people of similar 
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age and gender without a diagnosis of schizophrenia (Stubbs et al., 2014). The lack of 
evidence to support that headache pain responses diminish with chronicity could 
indicate that in order to elicit pain and for people in the chronic phase of their mental 
illness to report the presence of headache the symptoms and/or impairments driving 
the headache must be more severe. Unfortunately this is a very complex concept and 
not one that can be easily tested. Stubbs et al.,. (2014) also suggest that more research 
is required to determine if this phenomenon is due to an under-reporting of pain or if 
people with schizophrenia have a higher pain threshold and therefore the impairments 
driving the pain experience are more severe. 
 
6.4.5 Medication and headache 
All participants were taking anti-psychotic medication, many were taking other mental 
health medication and a large number were also on medication for comorbid physical 
health conditions. As already mentioned 66/99 people were taking some form of 
medication that listed headache as a common or very common side effect and 59 of 
these 66 people were taking antipsychotic medication where headache was a 
recognised side effect. Taking medications which list headache as a common or very 
common side effect did not have an impact on the presence of headache suggesting 
that the presence of headache should not automatically be attributed to the side effects 
of medication. The argument that headache in this population is related to medication 
is not founded and many people could be missing out on appropriate assessment and 
treatment of their headache if this false assumption is made. This is slightly different 
for some specific headache groups and will be discussed more in later sections. 
 
6.4.6 Inpatient/outpatient status, BMI, diabetes and headache 
Inpatient/outpatient status does not relate to chronicity of illness, rather reflects the 
current acuity of illness or relapse. Inpatients represent those people who have an 
exacerbation of positive or negative symptoms possibly due to stress, relapse or non-
compliance of medication. It could be considered feasible that the extra stresses 
associated with an exacerbation could potentially be a trigger for headache. However, 
inpatient/outpatient status was not found to have an impact on presence of headache. 
There is nothing to support the concept that stresses associated with exacerbations 
and/or the inpatient environment impact on prevalence of headache. This will be 
discussed further when specific headache types are considered.  
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Jensen and Stovner (2008) have suggested a link between obesity and headache. With 
the mean BMI of this population being only slightly below obese (29.4, SD=6.62) it 
could be expected that a large number of this population would experience headache 
and may be one reason why the prevalence rate in our sample is higher than the general 
population. However, we did not find an association between BMI and headache, for 
both headache in general and for each of the different headache types. Diabetes was 
identified as the most prevalent comorbidity, although it should be noted that only 10% 
of people who experienced headache also had a diagnosis of diabetes. In 2003, Warren 
et al. identified headache as a symptom of hyperglycaemia but no relationship was 
found between diabetes and headache (Warren et al., 2003).  
 
6.4.7 Summary of clinical characteristics and headache 
It is evident that no clinical characteristics included in this study have a significant 
impact on the presence of headache, however it is of interest to note that unlike the 
general population there was not a higher prevalence of headache in females. There is 
a lack of evidence to support that either medication or the stresses associated with 
hospitalisation have an impact on the presence of general headache within this 
population. 
 
6.5 Prevalence of specific headache types 
This section will examine and compare prevalence and characteristics of CGH, MH, 
TTH and OH of people with schizophrenia and schizoaffective disorder to the general 
population. Within this study group, prevalence of CGH was 4.9%, MH was 17.8%, 
TTH was 15.8% and OH was 18.8%. Within the headache only population of this study 
group prevalence of CGH was 8.6%, MH was 31%, TTH was 27.6% and OH was 
32.8%. 
 
Eleven people (19% of headache sufferers) reported more than 1 headache type but 
only 1 person completed two questionnaires. This is consistent with findings from 
Torelli et al. (2010) who reported that 80% of headache sufferers in the general 
population experienced only 1 type of headache. The reason only 1 person completed 
two questionnaires is that once one questionnaire was completed the other 10 people 
considered it too onerous a task to complete a second questionnaire. Everyone who 
reported more than one headache type was asked to complete the first questionnaire 
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on their most troublesome headache. There is no data to determine what the 
classification was of the second headache.   
 
6.5.1 Prevalence of specific headache types in schizophrenia 
The only study to date that has attempted to classify headache amongst people with 
schizophrenia was that of Kuritzky et al. (1999). That study classified all headaches 
into only two types MH and TTH. MH was classified against the ICHD (1988 version) 
but all headaches that were not MH were classed into either chronic TTH or episodic 
TTH with what appears to be no reference to the ICHD. Classification for MH was 
based on responses to questions on location, intensity, precipitating events before 
during and after the headache but it is not known if an algorithm was used to guide 
classification and there was no reference to the validity or reliability of their 
classification process. There was no consideration of either CGH or any other 
headache type.  
 
The 19.4% prevalence of MH in the Kuritzky et al. (1999) study is comparable to the 
17.8% of our study. Given the very diverse method of classification for TTH in both 
studies it is not surprising that there was a big difference in the prevalence of TTH. 
Kuritzky et al. (1999) had prevalence for TTH of 28.7%, significantly higher than our 
15.8% determined by using the ICHD guidelines. Variations in the classification 
process clearly contributed to this discrepancy, however, both are still quite low 
compared to the general population prevalence of 42%.  
 
6.5.2 Prevalence of specific headache types in the general population 
The data on prevalence of various headache types by the WHO Lifting the Burden and 
other studies highlights some similarities and some diversity when compared to the 
prevalence of the same headaches types in this study (Chaibi & Russell, 2012; Diener 
et al., 2007; Dong et al., 2012; Fernández-de-las-Peñas et al., 2006; Knackstedt et al., 
2010; Noseda & Burstein, 2013; Stovner et al., 2007; van der Feltz-Cornelis, Biemans, 
& Timmer, 2012). The 5% prevalence of CGH in our study was comparable to that the 
4.6% determined by Knackstedt et al. (2010) in the general population. Painful 
dysfunction of somatic structures in the cervical spine drives the experience of CGH 
and can be triggered by sustained awkward neck postures, neck movement or pressure 
over the occiput (Bogduk and Govind, 2009). The musculoskeletal dysfunctions 
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associated with CGH have been linked to poor posture, muscle dysfunction, restricted 
range of movement, age and previous trauma but no links to schizophrenia or 
schizoaffective disorder have been reported in the literature (Huber, Lisinski & 
Polowcyk, 2013; Jull et al., 2007; Zito et al, 2006; Fernández-de-las-Penos et al., 
2006). 
 
Prevalence of MH (17.8%) within the sample population is higher than the 11% for 
the general population found by Stovner et al. (2007) but closer to the WHO figure of 
14.7% (Steiner et al. 2013) and 16% of Noseda and Burstein (2013). It would be 
expected that prevalence of MH is similar in both populations as MH is considered to 
be an inherited condition (Robbins, Grosberg & Lipton, 2013) with pain attributed to 
altered excitability in the brain in response to common environmental triggers such as 
fatigue, lack of sleep, certain foods, smoke, hunger, menstrual cycle and even light 
activating the trigemino-vascular system (Noseda & Burstein, 2013; Landy, Lobo & 
Rice, 2004). We are unaware of any data linking this brain dysfunction and that 
associated with schizophrenia and schizoaffective disorder, and the equal prevalence 
rates for MH between the general population and the schizophrenic population might 
support this lack of relationship. However, as is outlined below the data on gender 
distribution and age of onset suggests that this relationship might be one worthy of 
further investigation. 
 
The mechanisms behind TTH are less clear but it is accepted that physical and 
emotional stress, lack of sleep and fatigue are common triggers (Cathcart et al., 2010; 
Fumal & Schoenen, 2008; Li et al., 2012). These triggers are associated with lifestyle 
factors in both the general population and people with schizophrenia and 
schizoaffective disorder. It is therefore surprising to find the prevalence of TTH was 
significantly lower at 15.8% in the sample population compared to the WHO of twelve 
month prevalence of 42% for the general population (WHO, 2012). However, knowing 
that there are disparities around classification of TTH, with it often being classified as 
an absence of MH or CGH, if the prevalence of TTH and OH in this study were 
combined the overall prevalence of 34.6% is closer to the WHO prevalence for TTH.  
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6.6 Clinical characteristics and specific headache types 
The following pages will examine and compare the clinical characteristics of specific 
headache types experienced by people with schizophrenia and schizoaffective disorder 
to the general population. 
 
6.6.1 Clinical characteristics and CGH  
The prevalence of CGH among the general population and people with schizophrenia 
and schizoaffective disorder is the same. Although poor posture resulting from 
cerebellar changes associated with schizophrenia was previously considered a possible 
mechanism to precipitate CGH the finding of similar prevalence between the sample 
population and the general population seems to confirm that increased postural 
anomalies do not equate to an increased prevalence of CGH (Ho et al., 2004; Picard et 
al., 2008; Varambally et al., 2012). There is always the possibility that poor posture 
may contribute to CGH but be mitigated by the decreased pain sensitivity experienced 
by people with schizophrenia. This concept requires further investigation (Bonnot et 
al., 2009). 
 
CGH is a headache usually experienced later in life. Five people with schizophrenia 
and schizoaffective disorder had headaches classified as CGH with a mean age of onset 
of headache at 37 years of age. This is consistent with the general population mean age 
of onset of 33 years found in the literature (Antonaci & Sjaastad, 2011; Hall et al., 
2008). Our data also demonstrated a relationship between age and CGH which was not 
linear. Though we are not aware if this relationship has been explored in the CGH 
population, there is clear evidence of a non-linear relationship between age and neck 
pain in the general population (Skillgate, Magnusson, Lundberg & Hallqvist, 2012). 
These findings of similar prevalence and association with age support the notion that 
the sample population has characteristics of CGH consistent with the general 
population and the mechanisms driving the condition are the same.  
 
No other clinical characteristics, gender, medications, inpatient/outpatient status, 
length of illness and BMI impacted on the presence of CGH. The fact that we found 
no relationship between markers of the length and severity of mental illness and CGH 
strengthens the idea that CGH exists as a discrete health problem in this population 
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and should not be dismissed as simply part of the clinical condition of schizophrenia. 
Consideration should be given to appropriate management of CGH in this population. 
 
6.6.2 Clinical characteristics and MH 
The higher prevalence of MH found in males with schizophrenia and schizoaffective 
disorder compared to the general population is notable because amongst the general 
population female gender is usually a strong predictor of MH (Stovner, 2006). Buse et 
al. (2013) report the prevalence of MH as determined by the American Migraine 
Prevalence and Prevention (AMPP) study to be 17% in females compared to 5.6% in 
males (Buse et al., 2013).This is a marked difference to the results in this sample 
population where of the total population 13% of men (13/100) experienced MH and 
only 5% of women (5/100). It must be remembered that there was a 2:1 ratio of males 
to females in the sample population and this will have had some impact on the 
prevalence by gender, however, the prevalence within each gender was similar with 
19.7% (13/66) of the men and 14.7% (5/34) of the women experiencing MH and so 
unlike the general population gender did not have a statistically significant impact on 
MH.  
 
The most common age of onset of MH is between 10 and 30 years of age (Jensen & 
Stovner, 2008) with a median age of about 24 years (Asuni et al., 2010). The study 
undertaken by Asuni et al. (2010) also explored age of onset of MH without aura in a 
population of people attending a headache centre and determined the mean age of onset 
of headache of that population to be 16 years (Asuni et al., 2010). The authors attribute 
this younger age of onset in headache clinic population to the presumption that people 
attending the headache clinic would have more severe symptoms of headache which 
could include earlier onset. A mean age of onset of MH without aura of 17.7 years in 
our study population is more consistent with that of people attending a headache clinic 
(Asuni et al., 2010) than that of the general clinical population (Jensen & Stovner, 
2008). This similarity might suggest that MH headaches experienced by people with 
schizophrenia and schizoaffective disorder are more severe than those experienced by 
the general population and more comparable to people attending headache clinics. 
 
In 2008, Stewart et al. undertook a population based study that did not differentiate 
between MH without aura and MH with aura (Stewart, Wood, Reed, Roy, & Lipton, 
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2008). They surveyed 163,186 people aged over 12 years and looked at age of onset 
within each gender. They determined that 1.2% of men with MH had an age of onset 
younger than 10 years and 5.4% before age of 20 years (Stewart et al., 2008) much 
lower than the 17% and 50% in the sample population. Similarly with females, in the 
sample population 20% of women had an age of onset before 10 years and 60% before 
age of 20 compared to 2.3% and 17.3% in the general population (Stewart et al, 2008). 
The high prevalence of childhood MH amongst people with schizophrenia and 
schizoaffective disorder is worth further investigation in larger samples. If the same 
prevalence is found further studies would need to be undertaken to explore the 
relationship between early onset MH and psychotic illness. Is early onset MH another 
possible predictor of developing schizophrenia or schizoaffective disorder? Is there a 
possible mechanistic link between the two conditions? 
 
The similarity with age of onset of MH is the only characteristic that appears to be 
shared between people with schizophrenia and schizoaffective disorder and people 
attending a headache clinic. The length of time that headache lasts is significantly 
longer in the headache clinic population and the frequency of headaches is also 
significantly higher (Asuni et al. 2010). Within the sample population 83% (10/12) of 
people experiencing MH without aura reported a headache lasting less than 24 hours 
many more than the 28% in the headache clinic population suggesting the headache 
symptoms may be less severe in people with schizophrenia and schizoaffective 
disorder than in people attending a headache clinic. Similarly only 43% (6/14) of 
people in the sample population experienced MH without aura more than twice a 
month compared to 75% of people in the headache clinic population. In an example of 
non-uniformity between studies while Asuni et al. (2010) looked at frequency of 
headache in terms of more or less than 2/month, Buse et al. (2013) looked at frequency 
in terms of more or less than once/month. When compared to the general population 
the frequency of MH was similar in the sample population. Buse et al. (2013) 
determined that 65.5% of females and 74.4% of males in the general population 
experienced MH more than once a month and within the sample population 72.2% 
(13/18) people experienced MH more than once a month. So while the age of onset of 
migraine is comparable to people attending a headache clinic, characteristics related 
to length of headache appear less severe and frequency is more aligned to the findings 
in the general population.  
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It could also be hypothesised that people taking the mood stabiliser sodium valproate 
or the antidepressant drug amitriptyline, two medications recognised by the WHO as 
effective prophylactic medication for MH, are inadvertently receiving prophylactic 
treatment and contributing to the decreased frequency and duration. However, our data 
suggest against this as none of the MH patients were taking amitriptyline and only one 
migraineur was taking sodium valproate and they reported experiencing headache, 
twice a month suggesting the sodium valproate was not an effective prophylactic 
treatment for their MH.  
Another possible explanation for the differences in length or frequency of headache 
between the headache clinic population and the sample population could be linked to 
diminished pain responses in the people with schizophrenia as previously identified by 
many authors (Bonnot et al., 2009; Engels et al., 2014; Guieu et al., 1994; Levesque et 
al., 2012; Potvin & Marchand, 2008). Diminished pain responses have been linked 
with chronicity (length of time experienced the psychotic illness) so it might be that as 
children, before the symptoms of schizophrenia or schizoaffective disorder develop, 
the pain response is more akin to the general population but with increasing age, as 
pain responses diminish, the clinical characteristics of MH may become less noticeable 
with a reduction in frequency and duration. It is not possible to evaluate this theory 
from this study as there was no exploration of how MH had changed in the individual 
over time. Perhaps this phenomenon of shorter duration and lower frequency of 
headache is related to the responses to pain described by Levesque et al. (2012) where 
people with schizophrenia have a reduced response to prolonged pain or to the findings 
of Engels et al. (2014) where people with schizophrenia or schizoaffective disorder 
have diminished responses to medical pain? More investigation is required and the 
question still remains at to whether MH is an example of the impairments driving the 
headache needing to be more severe than the general population in order to provoke a 
response?  
 
No clinical characteristics significantly impacted on the presence of MH within the 
total sample population. However, within the headache only population, medication 
with headache as a common or very common side effect did have a statistically 
significant impact on the presence of MH. If a person was experiencing headache and 
taking medication with headache as a side effect then it was 6 times more likely that 
the headache they were experiencing was MH. As already discussed most people 
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started experiencing MH at an age prior to being diagnosed with schizophrenia or 
schizoaffective disorder and therefore before they started taking this medication so 
more research is needed to determine if the nature of MH changed after starting on 
medication. Ideally a medical review of medications should be conducted to determine 
which of their medications are contributing to the problem or if it is a combination of 
medications.   
 
Obesity has been linked to MH so it might be reasonable to assume that with such a 
high number of overweight and obese people that BMI would have an impact on MH 
(Verrotti, Di Fonzo, Penta, Agostinelli, & Parisi, 2014). In this population of people 
experiencing MH the average BMI was 29.7 (SD=8.0) and it was determined that 
contrary to literature BMI did not have an impact on MH. 
 
6.6.3 Clinical characteristics and TTH 
The lower prevalence of TTH in this population (15.8%) compared to the general 
population (42%) could be explained by the classification algorithm used. In this study 
TTH was classified against a set of characteristics identified in the ICHD classification 
unlike many other studies where TTH is assigned because characteristics of the 
headache do not fit MH or CGH (Fumal & Schoenen, 2008; Kuritzky et al., 1999). 
This could have resulted in lower than expected prevalence of TTH. As already noted 
if all headaches that were not MH and CGH were included in the classification of TTH 
then prevalence would have been recorded as 34.6%. 
 
The finding by Ashina et al, (2014) that there is 50% reduction in TTH if taking 
antidepressant medication could be another explanation for the low prevalence in this 
population. About one quarter (26/100) of participants were taking antidepressant 
medication and of these only 5 people were experiencing TTH meaning that the 
majority of participants taking antidepressants were not experiencing TTH. Further 
investigation needs to be undertaken to evaluate if there is a causative relationship of 
medication leading to the discrepancy in prevalence of TTH between the general 
population and people with schizophrenia and schizoaffective disorder.  
 
With the main triggers for TTH being emotional and physical stress, fatigue and lack 
of sleep it could be anticipated that inpatients, people with exacerbations of their 
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illness, in a known stressful environment would have a higher prevalence of TTH 
(Cathcart et al., 2010; Fumal and Schoenen, 2008; Li et al., 2012). This is not the case 
with inpatient/outpatient status not impacting on TTH. Indeed no one variable had a 
statistically significant impact on TTH in the total cohort. Within the headache only 
population being an inpatient, while statistically significant, meant a person was 
actually 0.28 times less likely to experience TTH.   
 
Once again the association between pain responses and presence of headache need to 
be explored. It is hypothesised that TTH is the result of pain elicited by prolonged 
overloading on pericranial muscles combined with sensitisation of nociceptors in the 
spinal trigeminal neurones and abnormal pain processing in the CNS (Cathcart et al., 
2010; Fumal & Schoenen, 2008; Li et al., 2012; Jensen, 2003). Engels et al. (2014) 
noted that the prevalence and intensity of responses to nociception from clinical pain 
experienced in daily life was diminished in people with schizophrenia. They 
hypothesised that this lower prevalence and intensity of medical related pain could be 
attributed to abnormal processing of motivational-affective aspects of pain due to 
dysfunction in the frontal lobe, in other words the person may feel pain but not exhibit 
pain behaviour. Levesque et al. (2012) identified that people with schizophrenia have 
a reduced response specifically to prolonged pain. It is possible that in the case of TTH 
the person with schizophrenia and schizoaffective disorder may still experience 
prolonged overloading on pericranial muscles in response to stressors provoking 
sensitisation of nociceptors in the spinal trigeminal neurones but somehow the 
abnormal pain processing in the CNS evident in people with TTH is altered resulting 
in lack of translation of nociception to headache which in turn translates to a lower 
prevalence. If this is the case then further investigation is needed to determine if the 
impairments driving TTH are more severe than the general population in order to 
provoke a response from the person with schizophrenia or schizoaffective disorder.  
 
6.6.4 Clinical characteristics and OH 
The classification of OH was assigned if presenting characteristics were not consistent 
with those of MH, TTH or CGH as identified against the algorithm. This resulted in 
quite a high prevalence of this headache type. There are no studies against which to 
make a comparison of prevalence as OH is not any one specific headache type based 
on specific characteristics, rather all headaches that are not CGH, MH or TTH.  
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More people experienced OH on the day of interview than MH or TTH with 36.8% 
(7/19) of people reporting OH compared to 1/18 (5.5%) for MH and 2/16 (12.5%) for 
TTH. In the case of CGH 3/5 (60%) of people were complaining of headache at 
interview. The small number of people experiencing CGH makes it difficult to 
compare with the other headache types. This phenomenon of many people 
experiencing OH on the day of interview was not evident when looking back over the 
previous 4 weeks where almost 2/3 of people experiencing MH, TTH and OH had 
experienced a headache. Once again CGH was slightly higher (80%) but again small 
numbers make comparison more difficult. This high prevalence of OH on the day of 
interview may be linked to inpatient status and will be explored further in the following 
paragraphs. 
 
Both inpatient/outpatient status and the taking of medication with headache as a side 
effect impacted significantly on the presence of OH with an inpatient being over 5 
times more likely to experience OH. As previously stated the number of people 
experiencing an OH on the day of interview was 7/19. Five of these people (5/7, 
71.4%) were inpatients. Similarly, thirteen people or 68.4% of people experiencing 
OH reported having had headache in the previous 4 weeks with ten (10/13, 76.9%) of 
these people being inpatients. Data was not collected on admission dates to the 
inpatient setting so it is unknown how long participants had been in hospital prior to 
interview and more importantly if OH has been experienced only since admission or 
if people were experiencing them prior to admission. The following discussion will 
explore some factors that may contribute to presence of OH within the inpatient 
setting. 
 
When a person is an inpatient it is quite possible that they are trialling new prescribed 
medication and if this medication has a common or very common side effect of 
headache it is also quite reasonable to assume that the headache can be attributed to 
this medication. However, we found this not to be the case because a person is 4.5 
times more likely to experience MH if they are taking medication where headache is 
not a common or very common side effect. Medication with headache as a side effect 
is clearly not the cause of headache. 
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If medication is not the cause of headache in this population then there must be other 
reasons why a person is experiencing OH while an inpatient in hospital. Some possible 
causes could include a reduced caffeine intake (Torelli et al., 2009), effects of either 
nicotine increase and passive smoking (Aamodt, 2006), lack of exercise (Varkey, 
Hagen, Zwart, & Linde, 2008), reduced fluid intake (Spigt et al., 2005), cannabis 
withdrawal (Hesse & Thylstrup, 2013), sleep disturbances (Lateef et al., 2011), side 
effects of electroconvulsive therapy (ECT) (Drew, King, & Callahan, 2005) and other 
possible unknown factors.  
 
Excessive intake of caffeine has negative effects on a person’s health both physical 
and mental, especially people with bipolar affective disorders (Rizkallah et al., 2011). 
People with schizophrenia are known to have an elevated level of caffeine 
consumption, in some instances up to 7 times higher than that of the general population 
(Thompson, Pennay, Zimmermann, Cox, & Lubman, 2014). Within the psychiatric 
hospital setting tea and instant coffee are available to patients only during morning and 
afternoon tea and at meal times. This limited access may contribute to a reduction in 
the intake of caffeine compared to when at home. Many people with schizophrenia and 
schizoaffective disorder also drink quite a lot of carbonated soft drink (Roick et al., 
2007; Amani, 2007). According to the Mayo Clinic most of these drinks contain 
caffeine. These drinks are not available on the wards and although obtainable in the 
hospital must be purchased from areas outside the wards. Any person on restricted 
leave cannot access these areas of the hospital, any people who are experiencing 
significant negative symptoms may not be motivated to access them and people 
without any cash are not in a position to purchase them. So on admission to hospital it 
is possible that many people will experience a reduction in their tea or coffee intake 
and/or a sharp reduction in the amount of soft drink they consume meaning that their 
caffeine intake may be diminished possibly resulting in symptoms of headache as 
identified by Torelli et al. (2009). More research should be conducted to determine if 
caffeine reduction is a cause for OH in this population and if it is, education can be 
provided around the harm of too much caffeine and counselling provided to assist with 
reduction strategies. 
 
People with psychotic mental illness have a high prevalence of cigarette smoking with 
2/3’s of people on average smoking 21 cigarettes a day (Morgan et al., 2012). At the 
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time of this study smoking was banned in hospitals in Western Australia with the 
exception of psychiatric hospitals and units. Until smoking bans were implemented 
there was a high rate of smoking in the units including both patients and staff (Wye et 
al., 2010). People being admitted to an inpatient setting may well have increased their 
nicotine intake because it was an accepted pastime to help alleviate boredom. Smoking 
was only permitted in outdoor areas but because these were not large areas it would 
have been difficult for non-smokers to avoid passive smoking. Headache is frequently 
a side effect of an increase in nicotine and of passive smoking and may contribute to 
the high rate of OH in inpatients (Aamodt, 2006). It would be good to reassess both 
the prevalence of nicotine use and rate of OH now that smoking is banned in the 
inpatient settings to determine if this is a factor associated with headache. 
Physiotherapists have long been involved in facilitating smoking cessation 
programmes and would be a very useful resource in any mental health setting. 
 
It has already been identified that people with schizophrenia and schizoaffective 
disorder have reduced physical activity (Morgan et al., 2012; Vancampfort et al., 
2012). Although not a given, some people may have been admitted to hospital for 
exacerbation of negative symptoms of schizophrenia or schizoaffective disorder or be 
experiencing comorbid depression. Side effects in both instances could be a reduction 
in physical activity. Further investigation should be undertaken to determine if this is 
indeed the case and if reduction of physical activity does contribute to the prevalence 
of OH in this population in this setting. Physiotherapists are experts in the 
implementation of exercise programmes especially where comorbidities exist and are 
a valuable asset to any mental health facility (Australian Physiotherapy Association, 
2011; Vancampfort et al., 2012). 
 
Reduced fluid intake is a trigger for headache (Spigt et al., 2005). One third (5/15) of 
inpatients experiencing OH reported drinking water to relieve their headache 
suggesting that they were becoming dehydrated and their headache was related to this. 
Further investigations would need to be undertaken to determine why people in the 
inpatient setting might become dehydrated as water is readily available. It is possble 
that people with an increase in negative symptoms are drinking less if they are lacking 
motivation to get up and get themselves a drink. Other factors that could have an 
influence a reduced fluid intake and dehydration are if prior to admission the person 
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was used to consuming soft drinks which are no longer freely accessible or the person 
is commenced on medication with dehydration as a side effect. More research needs 
to be undertaken to determine the reason behind headaches from dehydration in the 
inpatient setting.  
 
The use of cannibis and illicit drugs is high in people with psychotic illness in 
Australia. According to Morgan et al. (2010) 63% of males and 42% of females with 
psychotic illness record a lifetime history of illicit drug abuse much higher than the 
12% for males and 6% for females in the general population. Street drugs are known 
to increase the risk of experiencing psychosis in people with schizophrenia and 
schizoaffective disorder (Castle & Buckley, 2011) which in turn can lead to 
hospitalisation. People being admitted to the inpatient facilities due to increases use of 
cannibis could well be experiencing headache as a withdrawal symptom. In this study 
only 3 people reported using cannabis to relieve their headache but none of these 
people were inpatients suggesting that cannibis withdrawal within the inpatient setting 
may not have been a factor contributing to pesence of OH.  
 
Within general medical and general surgical wards the night-time lighting has been 
identified as a problem contributing to patients not getting adequate sleep (Bernhofer 
et al., 2014). It is unknown whether this is a similar problem in this mental health 
setting, however if it is then lack of sleep could contribute to the high prevalence of 
OH amongst inpatients (Lateef et al., 2010). Quality of sleep was not evaluated in this 
study, however, it would be useful to find out how many inpatients experience 
headache because of sleep distrubances. If it was discovered to be the case then further 
investigation could be undertaken to determine the cause for lack of sleep and steps 
could then be taken to make the inpatient environment more condusive to sleep. 
 
ECT is a modality used mainly for the treatment of depression but is also used for the 
management of other psychiatric conditions that do not reposnd to psychotropic 
medication (Drew et al., 2005; Tharyan & Adams, 2005; Read & Bentall, 2010). It is 
not known how many people in this study, if any, were undergoing ECT and therefore 
we were not able to determine if ECT was a factor associated with OH in this 
population.  
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6.6.5 Summary of clinical characteristics and specific headache type 
Age of onset of CGH is consistent with literature from the general population and no 
other clinical characteristics were identified that impacted on the prevalence of this 
headache type. It can be assumed that clinical characteristics of CGH are the same as 
in the general population and should be treated as such. This includes referral to 
physiotherapy.  
 
The high prevalence of MH amongst males and the high prevalence of early age of 
onset of MH are worth exploring further. Within the sample population no variables, 
including gender, impacted on presence of MH. It is worth noting that if a person 
experiencing headache is taking medication with headache as a common or very 
common side effect then MH should be considered a possibility with a need for further 
investigation and/or referral to a neurologist.  
 
It is interesting to note that no clinical characteristics were linked to TTH suggesting 
that when TTH is present it is not related to the mental illness and should be treated 
appropriately following guidelines for TTH management. More research is required to 
determine if the low prevalence of TTH is related to diminished pain responses. 
 
Inpatient status had a significant impact on presence of OH but medication with 
headache as a common or very common side effect, while significant was not the cause 
with people on these medications less likely to experience OH. Further investigation 
to determine the underlying causes for these headaches is recommended. 
 
These findings reinforce the concept that headaches in this population are driven by 
the same mechanisms as in the general population and are not simply a side effect of 
schizophrenia or schizoaffective disorder. Importantly headaches are not usually 
related to medication. This highlights the importance of thoroughly assessing people 
with schizophrenia when they complain of headache. It is important to determine the 
precise headache type in order to initiate appropriate management strategies.   
 
6.7 Impact of headache on quality of life 
The literature identifies a poor quality of life for people with schizophrenia and 
schizoaffective disorder (Cuyún Carter et al., 2011; Vancampfort et al., 2012). People 
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who experience headache and have a comorbid mental health issue are also known to 
have a reduced quality of life (Smitherman & Baskin, 2008; Wang & Juang, 2002). Is 
it possible to assume that people with schizophrenia and schizoaffective disorder who 
also experience headache may have an even further reduced QOL. 
 
This project did not set out to evaluate the QOL of all participants rather to explore 
how headache impacts on the QOL of people of this demographic. As a result no 
comparisons can be made between QOL of those who experienced headache and those 
who did not experience headache. Recall questionnaires about QOL were used so 
participants were only invited to complete the QOL section if they identified that they 
had experienced a headache in the preceding four weeks, in line with the SF-36 
recommendations (Ware & Sherbourne, 1992). Thirty six people completed this 
section meaning that 63% of the people experiencing headache in the previous 12 
months (36/57) and over 1/3 of all participants had experienced a headache in the last 
month.  
 
It has already been detailed that only three sections of the SF-36 were explored in this 
study. These were Bodily Pain (BP), Social Functioning (SF) and Role Physical (RP). 
It is known that people with schizophrenia and schizoaffective disorder have decreased 
social functioning (Cuyún Carter et al., 2011; Morgan et al., 2012; Ritsner et al., 2014) 
as do people with headache. It was hypothesised that headache could further decrease 
the social functioning of the individual with scihzophrenia or schizoaffective disorder. 
Studies exploring the impact of headache on QOL have also identified bodily pain and 
role physical as other key areas of functioning that are reduced (Leiper et al., 2006; 
Solomon et al., 1993; Stovner et al., 2007; Stovner et al., 2006) which is why these 
were included in this study. It is acknowledged that using the whole SF-36 
questionnaire would provide much richer information about quality of life but there 
were concerns about the length of the tool used in this study and so the decision was 
made to include only these three measures as a way of capturing a snapshot of the 
impact of headache on the person with schizophrenia or schizoaffective disorder. 
 
While the SF-36 is recognised as a validated and reliable measure of QOL of people 
with physical illness there are doubts about the validity of it as tool in patients with 
schizophrenia (Papaioannou et al., 2011). However, in most studies looking at QOL 
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of people with schizophrenia or schizoaffective disorder researchers are exploring the 
impact of emotional distress, the side effects of medication or negative symptoms of 
the mental illness on QOL rather than associated physical illnesses (Ritsner et al., 
2014). In the instance where the impact of a physical health issue on QOL is being 
explored the SF-36 is the most appropriate tool. However, unfortunately because most 
QOL studies undertaken with this demographic do not use the SF-36 it is difficult to 
make comparisons with other QOL studies. 
 
Before reviewing the findings of the impact of headache on QOL it is worth bearing 
in mind that in the general population women have a higher prevalence of headache 
than men (Stovner et al., 2007) and the American Migraine Prevalence and Prevention 
has determined that women also have increased symtpoms and increased disability 
associated with headache (Wells et al., 2014). Within the headache population of 
people with schizophrenia and schizoaffective disorder there was not an increased 
prevalence of headache amongst women and this under representation of women might 
mean that overall headache will be shown to have less of an impact on QOL than 
expected. Impact on QOL was not analysed by gender.  
Our analysis did suggest that headache has a moderate impact on RP with less inpact 
on BP and SF. More frequent headaches were associated with greater impact on QOL. 
Many respondent identified that within the previous four weeks the presence of 
headache had impacted on their normal ability to work or perform regular daily 
activities. This finding is consistent with studies undertaken in the general population 
indicating that headache inpacts on role physical (Leiper et al., 2006; Solomon et al., 
1993; Stovner et al., 2007; Stovner et al., 2006).  
 
While direct comparison against SF 36-data for this population is not possible it is 
known that two thirds of people with psychotic illness have severe dysfunction in their 
ability to socialise and one third had severe impairment in their ability to look after 
themselves (Morgan et al., 2011). About one fifth of people with psychotic illness do 
not do their own shopping and cooking. It could be argued that people with 
schizophrenia and schizoaffective disrorder already have significant reduction in 
quality of social functioning (Cuyún Carter et al., 2011; Morgan et al., 2012; Ritsner 
et al., 2014) and the presence of headache may not have as much of an impact on an 
already dimished quality of life.  
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Unlike the general population the presence of headache had less impact on bodily pain. 
This is not an unexpected finding considering people with schizophrenia have reduced 
responses to pain with lower intensity of pain associated with medical causes and a 
diminished response to prolonged pain (Bonnet et al., 2009; Potvin & Marchand, 2008; 
Engels et al., 2014; Levesque et al., 2012).  
 
The presence of either CGH or OH was shown to have more impact on BP, SF and RP 
than MH and TTH which differs from literature in the general population which has 
found CGH, TTH and MH to all have similar impacts on BP, SF and RP (van 
Suijlekom et al., 2003). In particular CGH is known to have a significant impact on a 
person’s SF something that has already been identified as a reduced QOL measure in 
people with schizophrenia and schizoaffective disorder. The person within this 
demographic experiencing treatable CGH would be further disadvantaged. It must be 
noted that the small number of people with CGH in this study has possibly impacted 
on the results and studies of larger sample size would need to be conducted to 
determine if this is a trend or an aberration.  
 
6.8 Management of headache 
Once a headache type has been identified, to reduce the negative impact on QOL the 
person needs to receive best practice treatment. Lake et al. (2005, p. 498) state 
‘Psychiatric comorbidity’ is often a negative prognostic indicator for headache 
treatment’ highlighting that behavioural and psychological factors such as non-
attendance at appointments may contribute to the treatment outcome (Lake et al., 
2005). Kuritzky et al. (1999) suggests that poor treatment outcome might be related to 
people not reporting their headache in the first instance for fear of hospitalisation 
(Kuritzky et al., 1999). This claim was not supported by our study with only 7 of the 
57 people (12%) who experienced headache relating it’s presence to hospitalisation. 
Still people not reporting headache, for whatever reason is probably contributing to 
poor outcomes. According to Vinding et al. (2007) about 50% of people in the general 
population experiencing headaches seek medical help. Only one person in this study 
group was taking medication prescribed by their GP and only 1 other was receiving 
treatment from a chiropractor suggesting that much less than 50% of headache 
sufferers (3.5%) have sought medical help to manage their symptoms. Without 
accurate clinical diagnosis there will always be poor treatment outcomes and even if 
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diagnosis is correct if the right pathway for management of the headache is not 
followed subsequent suboptimal intervention or treatment will result in poor outcomes. 
This section explores the management of headaches experienced by people in this 
study in relation to best practice. 
 
Within a population of people attending a headache clinic Vinding et al. (2007) 
identified that 56% were accessing physiotherapy and 36% were accessing 
chiropractic for some management of their headache. These numbers were 
significantly reduced in the general population with 9% accessing physiotherapy and 
5% accessing chiropractic (Vinding et al., 2007). However, in comparison the numbers 
in this sample population were very poor with only 1 person (1.8%) accessing 
chiropractic and none accessing physiotherapy despite physiotherapy being available 
at the hospital. There are limitations to the physiotherapy service at this mental health 
facility but regardless of that the fact that no one with headache was accessing the 
service suggests it is either undervalued by staff and consumers, mental health workers 
are not aware of the services offered by physiotherapists or mental health workers and 
patients are not informed about the benefits of receiving appropriate physiotherapy. 
This suggests that more education around the role of physiotherapy and promotion of 
the benefits of physiotherapeutic services in this area is required. 
 
Forty one percent (24/58) of people reported associated neck pain while experiencing 
headache. This is lower than the 70% found in people with intermittent headache 
reported by Hall et al. (2007) or the 69% of patients with MH determined by Florencio 
et al. (2014). Not one person identified accessing physiotherapy for assessment of their 
neck pain. 
 
6.8.1 Management of CGH 
Physiotherapists are particularly interested in CGH with manual therapy in 
conjunction with exercise well recognised in the management of CGH (Bogduk & 
Govind, 2009; Jull et al., 2002). No participant in the study accessed physiotherapy for 
treatment of their CGH although one person did report that correcting their posture 
helped relieve their CGH.   
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One person was receiving cervical manipulation from a chiropractor which might 
sound like good management of their CGH, however, it has been identified that manual 
therapy/manipulation without exercise prescription is a sub-standard treatment for 
CGH (Bogduk & Govind, 2009; Fumal & Schoenen, 2008; Jull et al., 2002). 
Physiotherapy using a combination of manual therapy, exercise and education is 
recognised as the most effective form of non-invasive management of this headache 
type and should be the treatment of choice. There is limited physiotherapy available to 
people in this population and it must be made more available and accessible if they are 
to receive optimum treatment. 
 
6.8.2 Management of MH 
Best practice treatment for MH consists of both acute and prophylactic measures 
(Kelley & Tepper, 2012a; Zielman et al., 2012). The WHO (2012) recommend 
symptomatic measures be implemented and trialled unsuccessfully three times before 
specific measures are implemented. People with schizophrenia and schizoaffective 
disorder experiencing migraine were mostly treating their symptoms with ‘over the 
counter’ medication and sleep with no one taking specific measures. 
 
In accordance with the findings of Kelley and Tepper (2012a) the most common 
medication being used by the sample population was simple analgesics, however, very 
few people were reporting rapid relief. One person took no medication opting to sleep 
to relieve the headache and symptoms. The majority (12/18) took paracetamol 
(Panadol) and slept including the people who reported their headache lasting 12, 48 
and 72 hours. These people were obviously not receiving optimum treatment because 
if paracetamol was to be effective it should provide at least 2 hours of relief (Derry & 
Moore, 2013). Only one person was taking analgesic medication prescribed by their 
GP and their headache still lasted for 48 hours suggesting that they too were not 
receiving the best treatment for their MH. Those people with poorly managed MH 
would benefit from a specialist neurologist review and might possibly be considered 
for specific measures such as triptans and ergotamine to reduce the negative impact 
that MH is having on their lives. Symptomatic relief described by the WHO includes 
all symptoms, not just pain, yet while three people reported vomiting occasionally and 
a further 6 people were occasionally nauseous none took any antiemetic medication. 
Once again best practice treatment was not being utilised. 
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Prophylactic measures are usually recommended when people experience migraine 
two or more times a month. In this survey 11/18 people (61.1%) reported experiencing 
MH at least once each month and 7/18 (39%) of these at least once/fortnight. None of 
these people were on prophylactic treatment for their migraine. Referral to a 
neurologist who can prescribe appropriate prophylactic measures for these people may 
mean they experience less disruption to their lives. Other preventative measures 
include CBT and relaxation and once again no-one reported accessing services that 
provided these. 
 
With best practice treatment for MH being both acute (symptomatic and/or specific) 
and prophylactic measures (Kelley & Tepper, 2012a; Zielman et al., 2012) it is quite 
unsatisfactory that so few people with schizophrenia and schizoaffective disorder are 
receiving adequate symptomatic, specific or prophylactic treatment for their migraine. 
  
6.8.3 Management of TTH 
Medication and sleep are also the most common treatments adopted by people with 
schizophrenia and schizoaffective disorder who experience TTH. The use of 
pharmacology for TTH is complex and many variables impact on which medication is 
the most appropriate for each person (Fumal & Schoenen, 2008). It is not possible to 
consider all those variables in this study to determine if participants are taking the best 
medication for their TTH.  
 
There is evidence to support the use of relaxation for TTH and to a lesser extent 
massage (Fumal & Schoenen, 2008). It is disturbing to note that no people used 
relaxation as a form of treatment for headache and only two people with TTH accessed 
massage, although it is unknown if this was from a professional massage therapist. 
This would suggest that no health professional has explored the headache and given 
appropriate advice on management.  
 
Physiotherapy and exercise have been shown to reduce the frequency and intensity of 
TTH (Ashina & Bendsten, 2013) and education on ergonomics and posture to reduce 
the load on myofascial tissues associated with TTH might also be effective 
(Fernández-de-las-Peñas et al., 2006). No person experiencing TTH reported, 
accessing a physiotherapist for treatment, receiving an exercise prescription or 
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undertaking an ergonomics or postural review, suggesting that people are receiving 
sub-optimal measures to address their headache issues.  
 
6.8.4 Summary of management of headache 
The majority of people with schizophrenia and schizoaffective disorder who 
experience MH, TTH or CGH are not receiving appropriate nor adequate treatment to 
manage this potentially disabling condition. The suggestion earlier that many people 
with schizophrenia and schizoaffective disorder report a headache and are 
recommended to take paracetamol unfortunately appears to be the case.  
 
It has already been identified that a negative prognostic indicator for treatment of 
headache is a comorbid psychiatric condition (Lake, 3rd et al., 2006). There could be 
a couple of explanations for this as identified by Birgenheir et al. (2013) who suggests 
that people with severe psychotic illness may be undertreated for pain conditions 
because  
 They are considered difficult to treat and not accepted into mainstream health 
systems 
 Pain management (including headache) is considered less important to 
psychiatric management and overlooked or discounted 
 Mental Health workers may see the pain (including headache) as a symptom 
of a person’s psychotic mental illness rather than a separate condition and not 
refer them to appropriate services 
 Mental Health workers may either not understand and/or underestimate the 
impact of headache on QOL and fail to act on information 
 Mental Health workers may have an understanding of the impact of headache 
but not know about how headache can be managed and so fail to act on 
information from the patient 
 The person themselves does not report presence of pain for their own reasons 
which may include perceptions of all of the above, fear of being hospitalised 
etc. 
 It is difficult to access services for various reasons including waiting lists, 
transport issues, fear of unfamiliar places, fear of stigma etc. 
 Financial constraints 
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6.9 Summary of Discussion 
This was a cross sectional cohort study that consecutively recruited 100 participants 
with schizophrenia or schizoaffective disorder from the Fremantle Hospital Mental 
Health Services. This cohort represented a good cross section of people with psychotic 
illness in Australia. Demographic data collected in the study sample was comparable 
to that collected in the Australian Government’s survey ‘People living with psychotic 
illness 2010’.  
 
Twelve month prevalence of headache is slightly higher than the general population. 
Previous surveys have identified that people with schizophrenia will mainly only 
engage in surveys if they can see the relevance to them. It is possible that many people 
who don’t experience headache chose not to engage in the study resulting in a slightly 
higher prevalence. The prevalence is also higher than a previous study conducted in 
1999, but the recruitment criteria were different in both studies suggesting differences 
might have been related to demographic differences.  
 
None of the clinical characteristics assessed (inpatient/outpatient status, length of 
illness, or medications) impacted on the presence of headache suggesting that 
headache might not be related directly to the mental illness. Regardless of the headache 
type, 41% of people experiencing headache also reported associated neck pain. There 
was no evidence of anybody either seeking or being referred to physiotherapy to assess 
and manage this pain. Headache frequency was found to be negatively correlated with 
quality of life, while there was no relationship with intensity or duration.   
 
CGH had the same prevalence and clinical characteristics in this population as in the 
general population with age being the only significant factor to impact on the presence 
of CGH. It was disappointing to note that while CGH can be successfully managed 
with physiotherapeutic intervention no one in this study reported receiving 
physiotherapist treatment.  
MH also had a prevalence rate comparable to the general population. The most 
noticeable differences in clinical characteristics of people experiencing MH were the 
disparate prevalence in females/males compared to the general population. There were 
also a much higher percentage of people with early age of onset of MH. While 
medication with headache as a side effect had some impact on the presence of MH 
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most participants had started getting MH well before they started taking this 
medication. Unfortunately for the majority of people with MH the management of the 
condition did not follow best practice guidelines and no one was under the care of a 
neurologist, nor was anyone on prophylactic regimes despite meeting the criteria. 
 
Stress is a recognised trigger for TTH and it could be presumed that people with 
schizophrenia and schizoaffective disorder are subject to considerable stress especially 
as inpatients, though our data found no relationship between TTH and 
inpatient/outpatient status. It would be expected that there would be some 
discrepancies in prevalence of this headache type within the literature as many 
previous studies have not used the ICHD to identify TTH, rather classify TTH when 
the characteristics do not fit MH or CGH. The low prevalence of TTH may be 
associated with diminished pain responses to prolonged pain. Regardless of the 
prevalence there was no associations found between clinical characteristics and 
presence of TTH. It is obvious that people experiencing TTH were not accessing 
adequate treatment for the condition. 
 
Inpatients are more likely to experience OH but those taking medications that do not 
list headache as a side effect are also more likely to have OH. This can only make one 
wonder what the mechanism is that is driving OH in the inpatient population. More 
research will need to be undertaken to determine this. Some possibilities could be 
around reduced caffeine intake, increased smoking, withdrawal from illicit drugs, 
dehydration, sleep disturbances, reduced physical activity or ECT. Adequate 
management of this type of headache can only be achieved once the mechanism 
driving the headache is known.    
 
The data available from our survey suggest that the mechanisms behind most 
headaches experienced by people with schizophrenia and schizoaffective disorder are 
the same as for the general population, however, overall the management of headache 
in this population is very poor. Very few people were identified as receiving adequate 
treatment for their particular headache type. Models to address this problem could 
include education in the form of training sessions, educational pamphlets and posters; 
employment of mainstream health professionals into mental health services; 
implementation of mainstream health clinics that people with schizophrenia and 
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schizoaffective disorder can access and screening tools for mental health workers. 
More research will need to be undertaken to determine if any of these measures are 
useful and/or cost effective. 
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CHAPTER SEVEN 
Possible solutions to issues impacting on management of 
headache as identified in the discussion 
7.1 Introduction 
The discussion highlighted some potential perceptions, prejudices and 
misunderstanding of both health workers and patients around mental health issues and 
headache issues. This sections aims to address and provide possible solutions to these 
problems. The hope is that these measures will result in better management of 
headache and improved quality of life for people with schizophrenia and 
schizoaffective disorder who experience headaches. 
  
7.2 Perceptions and prejudices  
Flawed perceptions and prejudices are not restricted to people in the general health 
workforce but also apply to mental health workers. It has been identified that many 
people who work in the mental health field perceive their role is to only address the 
mental health needs of their clients. Many are not cognisant of the importance of 
addressing the physical health needs of their clients in their overall holistic 
management or are uncertain about their role in the monitoring of physical health 
(Happell et al., 2012; Fagiolini, 2008). Regardless of the reasons, it is obvious that 
many people with severe mental illness are not linked to appropriate medical services 
for their physical health needs (Griswold et al., 2010). Griswold et al., (2010) 
recommend improved access for care coordination resulting in better health outcomes.  
 
Within the physical health workforce many health professionals, including 
physiotherapists, do not believe that they are adequately prepared to work with and 
support patients who have a comorbid mental health issue (Arvaniti, 2009). In this 
instance staff will draw on their previous experiences, understandings and beliefs 
about mental illness and unfortunately many people have negative perceptions of 
people with psychotic illness, possibly partly due to the way people are portrayed in 
the media (MacNeela, Scott, Treacy, Hyde, & O'Mahony, 2012). Education about 
mental health issues helps improve attitudes towards people with mental illness. 
Inclusion of more education into undergraduate medical, nursing and allied health 
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courses could help address negative perceptions and prejudices towards people with 
psychotic illness (Probst & Peuskens, 2010). Better perceptions and reduced 
prejudices would result in more positive and welcoming environments within the 
wider health care community thus enabling people with severe mental health issues 
better access to services that provide specialist care for their physical needs (Kuhnigk 
et al., 2009).  
 
One solution to the problem of access to physical healthcare for people with 
schizophrenia or schizoaffective disorder is to promote the role that physiotherapy can 
play in improving the wellbeing of people who access the mental health services. 
Physiotherapists are key health workers in the management of people experiencing 
chronic pain and musculoskeletal conditions including CGH, TTH and neck pain 
(Australian Physiotherapy Association, 2011, 2012) and in the management of chronic 
illnessess such as diabetes (Australian Physiotherapy Association, 2008, 2009, 2011). 
Physiotherapists cannot treat the primary causes behind MH, however, they can 
recognise these headache and provide treatment to secondary symptoms such as 
associated neck pain, soft tissue pain and tension as well as address postural and 
ergonomic anomalies. Physiotherapists are well equipped to refer people to 
appropriate services for management of the headache condition. Physiotherapy 
interventions as part of a multidisciplinary team approach are known to assist with 
management of factors that possibly impact on OH such as excessive nicotine intake, 
reduced physical activity levels and associated sleep disturbances.  
 
As an outcome of this research a brochure has been developed to promote the role of 
physiotherapy in maintaining good physical and mental health and wellbeing for 
people accessing mental health services (APPENDIX Three). This brochure includes 
information about how physiotherapy can be beneficial in the management of 
musculoskeletal conditions as well as in chronic disease. Further research needs to be 
undertaken to evaluate the impact to patients and the cost effectiveness of employing 
physiotherapists into mental health services.  
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7.3 Pain management (including headache) is less important than 
psychiatric management  
There is a belief amongst some mental health workers that psychiatric management is 
the only aspect of the health management for the person with psychotic illness in which 
they should be involved (Happell et al., 2012). During an acute psychotic episode 
management of the psychotic illness would certainly take precedence over physical 
illness, especially if the physical health condition is not life-threatening.  
 
There is no argument that psychotic illness has a serious impact on quality of life and 
mental wellbeing, however chronic pain, including headache, also has significant 
impacts on quality of life, overall wellbeing and as has been demonstrated the 
combined impact of mental illness and headache does further reduced quality of life, 
especially role physical (Cuyún Carter et al., 2011; Leiper et al., 2006; Smitherman & 
Baskin, 2008; Wang & Juang, 2002). What many mental health workers fail to 
recognise is the impact physical health issues, including pain, can have on the overall 
well-being of the person and the close relationship between physical and mental 
wellbeing (Happell et al., 2012). A person experiencing pain from frequent, poorly 
managed headaches is at risk of compromise of their mental health and wellbeing. The 
brochure developed to highlight the role of physiotherapy also focuses on the impact 
of pain on a person’s mental health and the role physiotherapy plays in the 
management of pain. This brochure can be found in Appendix 3. 
 
This study has provided evidence that prevalence of headache in this population is 
similar to that of the general population. A non-stabilised, acute psychotic episode 
(patients in locked wards) was an exclusion criterion so no comment can be made 
about prevalence, characteristics or impact of headache during a very acute phase of 
illness, however, headache experienced at other times is not normally a side effect of 
psychotic illness. Headache does have an impact on quality of life and functioning, 
especially if headache is frequent. Education of mental health workers about the 
impact of headache is essential if clients of that service are to receive appropriate and 
timely treatment. A brochure addressing some basic information about headache, 
questions to ask and some simple management strategies can be found in Appendix 4. 
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Further studies will need to be undertaken to evaluate the effectiveness of providing 
this information to mental health staff. 
  
7.4 Pain (including headache) as a symptom of a person’s psychotic 
mental illness  
Our data suggests that headache is not simply a side effect of schizophrenia and 
schizoaffective disorder and is not normally associated with antipsychotic or any 
mental health medication. Literature indicates that response to pain is diminished in 
this population and it is still unknown if the characteristics driving headache in this 
demographic are in fact more severe in order to illicit a response and prompt behaviour 
to seek assistance for the pain (Bonnot et al., 2009). 
 
CGH is triggered by noxious input from structures innervated by the upper cervical 
nerve roots being referred along the sensory distribution of the trigeminal nerve via 
the ‘cervico-trigeminal relay’. Migraine is a headache activated by the 
trigeminovascular system and physical and/or psychological stress can increase 
muscle tension in the head area resulting in perception of pain and TTH. Education of 
mental health workers about the pathophysiology of headache may help them develop 
a better understanding of the condition. The brochure in Appendix 4 could assist a little 
with this but a series of professional development training sessions could be developed 
for case managers.  
 
7.5 No understanding of the impact of headache on QOL  
Education of mental health workers about the impact of headache is essential if clients 
of that service are to receive appropriate and timely treatment. Frequency of headache 
was identified as the most significant factor impacting on QOL. It is important that 
mental health workers are aware of this and carefully monitor the frequency of 
headache experienced by their clients. The brochure in Appendix 4 contains this 
information. 
 
7.6 No understanding about how headache can be managed  
Education about management of different headache types may assist mental health 
workers to be better equipped to help their clients who experience headache. If a 
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service employed physiotherapists they could provide this education on a regular basis 
to remind staff of the impact of headache and assist with case management for the 
client.  
 
Lake et al. (2006 & 2005) advocate that the development of a screening tool for 
managing people presenting in psychiatric clinics with comorbid headaches would be 
a step towards improving management and treatment outcomes for this group of 
people. The questions included in the brochure (Appendix 4) should assist case 
managers with this process. A screening tool would be of little use without knowing 
what to do with the information so the brochure provides information for a referral 
pathway to appropriate services. This should assist mental health workers to provide 
better advice to their clients.  
 
7.7 Non self-reporting of the presence of pain. 
It has been suggested that many people with schizophrenia and schizoaffective 
disorder do not report pain or headache to their mental health worker. There are 
different reasons why this might be the case, such as fear of hospitalisation, not 
wanting to bother anyone, believing that nothing can be done to help anyway etc. 
 
It is important to emphasise a few things to people with schizophrenia and 
schizoaffective disorder. 
1. People with schizophrenia and schizoaffective disorder experience 
headaches the same as the general population 
2. Headache is not connected to mental illness 
3. Reporting headache will not result in you being admitted to hospital 
4. Effective treatment does exist for headache  
5. To access the best treatment you need to be assessed by an appropriate 
health professional. 
 
The brochure developed in Appendix 4 was done so with the intent of being useful for 
both health care practitioners and patients. It is hoped that by making this available 
throughout the service that patients themselves might identify a pathway for 
management of headache. Further studies will need to be undertaken to evaluate the 
effectiveness of providing this information to patients.   
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7.8 Difficulty accessing services 
There are many reasons, some valid and some not, why a person with a psychotic 
illness will not access mainstream health services. There are a few solutions to this 
problem. 
1. Employ staff who can provide appropriate management. Physiotherapists 
working in the mental health field have skills to lead the promotion of physical 
health amongst users of mental health services (Stubbs et al., 2014). A 
systematic review by Vancampfort et al. (2012) found that targeted 
physiotherapeutic interventions not only improved physical health but also 
improved psychiatric symptoms in many patients. Employing physiotherapists 
could be cost effective when considering the overall wellbeing of patients 
accessing mental health services. 
2. Broker in expert services and conduct regular clinics that are easy for patients 
to access.  
3. Ensure case manager or support workers assist people with schizophrenia and 
schizoaffective disorder as required to negotiate appointment times and 
accompany clients to appointment that are in mainstream health services. 
4. Provide ‘Care Navigators’ as described by Griswold et al. (Griswold, Homish, 
Pastore, & Leonard, 2010). Trained care navigators help patients with severe 
psychiatric conditions to access health services by assisting with 
communication and education and guiding the individual through the complex 
healthcare system. 
 
The 2001 study ‘Duty to Care’ highlights not only the poor physical health of people 
with mental health but also their poor access to services (Coghlan et al., 2001). Linking 
patients to primary care has been shown to produce better outcomes (Griswold et al., 
2010; Griswold et al., 2008).  
 
7.9 Financial constraints 
Eighty percent of people with schizophrenia and schizoaffective disorder receive their 
income through Government pensions and are not in a financial position to access 
private physiotherapy (Morgan et al., 2011). Physiotherapists are included in all 
outpatient departments in Australian General Hospitals but it is obvious that none of 
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the people with CGH in this study have accessed these services. Employing 
appropriate staff or brokering in staff for regular clinics could be suitable ways to 
address these problems.  
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CHAPTER EIGHT 
Limitations, considerations, recommendations and conclusion 
8.1 Limitations and considerations for future research 
The sample size calculation used for this study was based on a prevalence rate for any 
headache, however a larger sample size would have provided richer data for exploring 
issues related to individual headache types. This is particularly the case for CGH. A 
larger sample size would mean that trends observed amongst MH, CGH and TTH 
could be more reliable. 
 
It could be argued that this study is restricted because the participants were recruited 
from one health facility in Perth. When demographic data collected from the sample 
population was compared to that of an Australian wide survey of people with 
schizophrenia and schizoaffective disorder it was demonstrated that the sample was a 
good representation of people with schizophrenia and schizoaffective disorder in 
Australia. In 2011, 216,266 people lived in the catchment area for the facility in the 
southern regions of the greater city of Perth in Western Australia representing 12.5 % 
of the total population for Perth at that time.  
 
Collecting data about length of patient illness from files, as required by Fremantle 
Hospital and Health Service ethics committee, proved to be very difficult. Lack of this 
information would impact on the ability to determine chronicity of illness. Many 
patients with long term psychotic illnesses have multiple files with the ones containing 
original admission and diagnosis data being up to thirty years old and many files 
needed to be requested from archives. Many participants had come to Alma Street 
Mental Health Services from other countries, interstate or other health facilities in 
Perth and their original files were no longer available. Fortunately most patients 
volunteered the information about how long they had been unwell with a mental illness 
without being asked. It is assumed therefore that this is a question that they are 
regularly asked in medical type interviews and they are comfortable answering. 
 
Recruiting all outpatients from the depot clinic may have impacted on the data 
collected if all were involuntary patients on an enforced Community Treatment Order 
(CTO) due to non-compliance of medication or aggression. However, since many 
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people voluntarily opted for a depot injection as it made it easier for them to manage 
their medication there was in fact a cross-section of outpatients. It is not known if the 
cross-section of outpatients would have been different if case managers had enough 
time to engage and recruit other participants who did not attend the depot clinic.  
 
Getting access to an accurate list of ALL medications was challenging as people with 
schizophrenia and schizoaffective disorder are often prescribed medication from their 
psychiatrist as well as their GP and in some instances other medical people. Not all 
participants could remember what they were taking and medications not prescribed in 
the hospital were not often recorded in case notes. All avenues were explored to try 
and ensure accurate data was obtained.  
 
Prior to data collection it was recognised that some participants may be overwhelmed 
and/or suspicious if presented with too much written information to read prior to 
undertaking the questionnaire. Human Research Ethic Committee (HREC) 
requirements include providing a plain language statement as well as a consent form 
to be read and signed. During data collection the majority of participants did not want 
to read the information sheet or the consent form but specifically asked for an oral 
version. It is not known whether this is because of poor literacy, difficulty to 
concentrate or an aversion to reading lengthy documents. Morgan et al. (2011) 
identified that in Australia 1 in 5 people with a psychotic illness have trouble reading 
and writing. In future this is something that needs to be considered when researching 
this demographic.  
 
It became evident quite quickly that due to the length of the questionnaire, maintaining 
attention of the participant was sometimes a challenge, in keeping with the Schafer et 
al. (2011) observation that people with schizophrenia have an aversion to questionnaire 
surveys. Two considerations for future research are to 
 Conduct trails of shorter versions of the questionnaire to determine if 
classification can still be accurately determined with less information and 
without compromising validity and reliability. 
 Continue to use researchers who have experience working with this population 
to ensure they have strategies to maintain engagement of the participant.  
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Gathering data on more than 1 headache when a person experienced multiple headache 
types was difficult. Only one person completed a second questionnaire despite 11 
people identifying that they experienced more than one headache type. The 
questionnaire is lengthy and people lost concentration and focus after completing only 
one. As a result some valuable data was not collected. There is no immediate solution 
to this problem but a shorter questionnaire may prove useful. Throughout this study, 
in order to gather the most appropriate data, people were asked to report about their 
most problematic and troublesome headache first. 
 
Many participants had difficulty rating the intensity of the associated symptoms that 
accompany headache of nausea, vomiting, photophobia, phonophobia, light-
headedness, dizziness, blurred vision, eye swelling, loss of appetite and confused 
thinking. When working with this population again it might be worth considering if 
knowledge of intensity is crucial to classification of headache or if knowledge of 
presence of the symptoms is more important as this was a point where many people 
began to lose impetus to continue with the questionnaire. Pilot studies would need to 
be undertaken to determine the appropriateness of a tool that explores frequency of 
symptoms but not intensity of symptoms.  
 
Collecting data on quality of life of all participants might have given richer information 
about the impact of headache. As indicated the SF-36 is not used much to evaluate 
QOL in psychiatric research so making comparisons between this study and the norms 
for this population was difficult. Gathering SF-36 information from all participants, 
regardless of presence of headache would have provided a reasonable comparison to 
determine the impact of headache on QOL and will be considered in future research.  
 
Rich information was obtained from the client interviews but more rich information 
would have been obtained if case managers were also interviewed or surveyed. 
Determining how many case managers knew if their client’s experienced headache 
would have provided valuable information about how headache is considered amongst 
mental health workers and directed educational support. It would also have given some 
insight into the holistic management of the patient. In the instance where case 
managers were aware of the presence of headache further information about what they 
perceived was the impact of that headache and what were they doing to assist the 
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person would have directed what to target in management strategies developed to 
address the problems. This is something that is being considered for future studies. 
 
This research has highlighted the prevalence of headache in this population. 
Physiotherapists are seen as experts in treating CGH and have a role to play in the 
management of TTH and therefore should be considered in the health workforce of 
mental health services. There is some research beginning to emerge from Europe 
exploring the physical and mental health benefits to people with schizophrenia 
receiving physiotherapeutic intervention for physical conditions (Vancampfort et al, 
2012; Stubbs et al, 2014). More research needs to be undertaken to explore the cost 
effectiveness of employing physiotherapists in mental health settings to provide expert 
input on prevention and/or management of physical health issues and the impact this 
has on metal wellbeing.  
 
8.2 Recommendations for clinical practice 
There is a need for more education for patients and mental health workers in the 
psychiatric setting about headache and an understanding that headache is not simply 
related to psychotic illness such as schizophrenia or schizoaffective disorder. 
Education should highlight that the person with schizophrenia or schizoaffective 
disorder does not have to tolerate the pain and discomfort associated with headache 
and that appropriate treatment is available. To this end pamphlets with information 
about headache and its management will be provided in the outpatient waiting rooms 
and ward areas at Alma Street (Appendix 4). A future research project could survey 
people with schizophrenia and schizoaffective disorder to determine if there is any 
changes in the management and effect on QOL secondary to headache with this 
information being available. 
 
Information and education about headaches, impacts and management of headaches 
should be provided to psychiatrist, case managers and mental health workers. At the 
Alma Street centre this will take the form of a lecture with handouts for future 
reference. Once again a future research project could evaluate if there are any changes 
in the management and quality of life of their clients with schizophrenia and 
schizoaffective disorder who experience headache.  
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Perhaps one of the most important recommendations for clinical practice is to alert 
physiotherapists that the prevalence and characteristics of CGH in people with 
schizophrenia and schizoaffective disorder is the same as for the general population 
and they should be taking an active interest in this group of people as they are currently 
missing out on best practice treatment.  
Another important recommendation for clinical practice is to highlight to neurologists 
and headache specialists that the prevalence and characteristics of CGH in people with 
schizophrenia and schizoaffective disorder is the same as for the general population. 
It is also important to highlight that the prevalence of MH is similar but with different 
clinical characteristics around gender and age of onset and they should be taking an 
active interest in this group of people as they are currently missing out on best practice 
treatment. More research should be conducted to determine the reason that inpatients 
are more likely to experience OH so that appropriate measures can be taken to address 
this issue. 
 
Finally there is a need to advertise the role that physiotherapy can play in the 
management of other physical health issues and the advantages to employing 
physiotherapists in this setting. A pamphlet has been developed for distribution 
providing information about the role and benefits of physiotherapy for the overall 
wellbeing of the person with schizophrenia or schizoaffective disorder (Appendix 3).  
 
8.3 Conclusion 
This study has shown that the prevalence rate of headache amongst people with 
schizophrenia and schizoaffective disorder is similar to that of the general population. 
Medication, acuity or chronicity of schizophrenia and schizoaffective disorder do not 
play significant roles in the presence of headache. The prevalence of CGH and MH 
are within the same parameters as the general population. The mechanisms driving 
these headaches appear not to be related to psychosis or mental illness. There are some 
differences in gender distribution and age of onset of MH which should be explored 
further. More investigation is required to have a better understanding of why inpatients 
are more likely to experience OH. 
 
The frequency of headache has been shown to have the most impact on QOL and it 
was evident that very few people are receiving appropriate treatment for their 
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headaches. Physiotherapy was not included in the management of headache of any 
people including those with CGH. It is recommended that better education is provided 
for both patients and mental health workers about headache and its management as 
well as the role of physiotherapy in managing the physical health and mental wellbeing 
of people accessing mental health services.  
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APPENDIX ONE 
Questionnaire 
 
Code Number ________________ 
 
Location of interview 
 Depot Clinic    
 Inpatient     
 Outpatient     
 
Length of illness  ___________________________________________ 
 
BMI  Height_________________________________________ 
  Weight ________________________________________ 
  Calculated______________________________________ 
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Headache Questionnaire  
Thank you for participating in this headache study. Please answer the following 
questions about you and your headache to the best of your ability. It is important that 
you try to answer All the questions. 
1. What is your age?  _____________years 
2. What is your gender? 
 Male   
 Female  
3. Have you had a headache in the last 12 months?  Yes  No  
 
4. Please list all your current medication.  
______________________________________________________________ 
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
5. Please list any conditions you are receiving treatment for (eg diabetes, high 
cholesterol, asthma, arthritis). 
_________________________________________________________________ 
_________________________________________________________________
_________________________________________________________________ 
_________________________________________________________________ 
If you haven’t experienced a headache in the last 12 months please go straight to 
the end of the questionnaire. 
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6. Are you suffering from the headache today?  Yes  No  
7. Have you experienced a headache in the last month? Yes  No  
8. Some people can experience more than one type of headache. Different types of 
headache can  
 Feel different (have different pain) 
 Have different triggers 
 Be in different parts of the head 
 Have a different effect on day to day functioning 
Do you suffer from more than one type of headache? Yes  No  
If YES, how many different types of headache do you have? _________ 
If you suffer from more than one headache type, please complete a separate 
form for each headache type. 
Headache No ____________ 
9. About how long have you been getting headache?  ____years ____months 
10. About how often do you have headache?   
Almost every day        
 Three or four per week   
 One or two per week     
One per fortnight    
One per month    
 Other       how often _______ 
 
11.  On average how long does your headache last ______hours ______ days  
12. Do your headaches last about the same length of time? Yes  No  
13. Does your headache go away completely between episodes?  
Yes  No  
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14. Please shade in the chart the area where you usually feel your headache or any 
other pain. If applicable, please mark as number 1, where you first feel pain when 
a headache starts and mark as number 2 where pain spreads to, and so forth. 
 
 
 
 
 
15. Does your headache usually start:  in the head   
       in the neck   
16.  My headache is:     always on one side   
      can be on either side     
on both sides    
      on both sides but one side is always 
       worse      
17. I have neck pain or stiffness with my headache  Yes  No  
18.  I feel my headache as (tick as many boxes as applies to your headache) 
      Aching    
      Throbbing   
      Pulsating    
      Stabbing   
      Shooting    
      Band-like   
      Tightness    
      Sharp     
19.  Please mark on the line below, how bad your headache is when you get it. 
 
Worst headache imaginable 
 
R L R L 
R L 
No headache 
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20. Please tick () which if any of the following symptoms accompany your 
headaches and rate their intensity  
 
Accompanying 
symptoms 
How often Intensity 
Never Occasionally Often Mild Moderate Severe 
Nausea       
Vomiting        
Light sensitivity       
Noise sensitivity       
Lightheaded/dizzy       
Unsteadiness       
Blurred vision       
Eye swelling       
Loss of appetite       
Confused thinking       
Shoulder or arm pain 
on the same side as the 
headache 
      
Other._____________ 
 
 
 
      
 
 
21.  Do you feel any of the following sensations for a period of minutes to an hour 
before the onset of your headache? 
         Yes   No 
things such as blind spots, flashing or zigzag lights    
 feeling of pin/needle or numbness       
feeling of weakness         
feeling of difficulty speaking        
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22.  Please tick (√) any of the following which can either give you a headache or 
make it worse (tick as many boxes as applies to your headache)  
Certain foods (e.g. chocolate, cheeses)      
Alcohol (e.g. red wine, beer, spirits)       
Awkward head or neck postures or neck movement     
Sustained neck postures (e.g. reading)      
Pressure over the neck or base of skull on the headache side   
Medication           
Routine physical activity or walking stairs      
Lifestyle factors (e.g. excessive sleep, fasting or dieting, fatigue)   
Exercises/sports          
Environmental factors (e.g. strong odours, smoke, weather changes)  
Stress or anxiety         
Other.  Pleases describe_______________________    
I do not know what brings on my headache      
23. I would like to know what you think started your headaches 
 I do not know          
 I think I know what caused my headache      
 Please describe_____________________________ 
24.  Please tick (√) any of the following which can relieve your headache 
Medication          
Heat/ice applications      
Physical activity         
Neck exercise or change of position    
Alcohol          
Relaxation       
Massage          
Sleeping/rest       
Unknown        
Cannabis or other street drugs     
Other         
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Please describe 
_______________________________________________________ 
25.  Do other members of your family suffer from similar headaches? 
  Yes    No    Unsure  
26. When you have a headache do you notice or do other people comment on 
changes in your thinking, feeling or actions? Yes   No  
If Yes, what changes are noticed? 
______________________________________________________________ 
______________________________________________________________ 
27. Do your think recurrent headaches are ever related to you being admitted to 
hospital?       Yes   No  
28. During the past four weeks, have you had any of the following problems with your 
work or  other regular daily activities as a result of your headache?  
 
          Yes  No 
Cut down on the amount of time you spent on work or other activities   
Accomplished less than you would like       
Were limited in the kind of work or other activities     
Had difficulty performing the work or other activities     
(for example, it took extra effort) 
 
29. How much headache pain have you had during the past four weeks? (Circle one)
    
None        1 
 Very mild       2 
 Mild        3 
 Moderate       4 
 Severe        5 
 Very severe        6 
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30. During the past four weeks, how much did headache interfere with your normal 
  work (including both work outside the home and housework)? 
  Not at all        
  A little bit        
  Moderately        
  Quite a bit        
  Extremely        
31. During the past four weeks to what extent has your headache interfered with your 
normal social activities with family, friends, neighbours, or groups?  
  Not at all        
  Slightly        
  Moderately        
  Quite a bit        
  Extremely        
 
32.  During the past four weeks how many days has your headache keep you from 
doing your usual activities? 
  Number of days _______________ 
  None    
 
 
 
Thank you very much for your assistance in this research into headaches. I really 
appreciate your taking the time to answer these questions. If you would like to be 
contacted about the classification of your headache please let Jo know and she will 
arrange for this.  
A poster in the waiting room will be displayed when we have analysed all the results. 
I hope you enjoy your DÔME voucher. 
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APPENDIX TWO 
Algorithm for headache classification  
       Yes 
    
No 
           
        Yes 
   No 
        
       Yes 
   No 
Which classification best does the patient best suit? 
CGH Defining factors Migraine Defining 
factors 
TTH Defining factors Other Defining 
factors 
Less episodic 
 
Chronic/continuous 
 
*Unilateral without side shift 
 
Starts in neck 
 
Neck stiffness/injury 
 
Headache precipitated by 1 or more of 
*Neck movement 
*sustained awkward head position 
*pressure over upper cervical or 
occipital region on symptomatic side 
 
Ipsilateral neck, shoulder or arm pain 
 
Varying duration of moderate – severe 
pain 
Ache/ sharp/ non-throbbing, non-
lancinating pain or fluctuating 
continuous pain 
 
May have associated nausea, 
photophobia or phonophobia, 
dizziness, ipsilateral blurred vision, 
difficulties swallowing , 
ipsilateral eye oedema, 
 
Aggravated by sport/exercise, stress 
 
Relief with hotpacks, neck exercises, 
change of position, massage, relaxation 
Lasting 4-72 hours 
 
Episodic  
 
Time locked 
 
Fronto-temporal  location 
 
Starts in head 
 
2 of the following 
*Unilateral 
*Pulsating/throbbing/shar
p/stabbing 
*Moderate to severe 
*Aggravated by routine 
exercise, food, 
environment, stress, 
 
At least one of the 
following 
*Nausea/Vomiting 
photophobia or 
phonophobia 
 
May have associated fully 
reversible aura including 
visual –flickering lights, 
spots, lines or loss of 
vision 
Sensory-pins and needles, 
numbness 
 
Relief with medication, 
rest 
lasting 30 min – 7 days 
 
Less episodic   
 
Chronic/continuous 
 
Starts in head 
 
At least 2 of the following 
*Bilateral  
*Pressing/tightening 
pain/bandlike 
*Mild to moderate pain 
*Not aggravated by exercise 
 
Least pain 
 
Both of the following 
*no nausea/vomiting 
*no more than one of 
photophobia or phonophobia 
Unless chronic then mild 
nausea may be associated 
 
Not made worse by normal 
physical activity 
Aggravated by stress 
 
Relief with physical activity, 
relaxation, massage, rest 
alcohol 
Motor weakness 
 
Triggered by 
medication 
 
Inconsistent 
characteristics of 
other three 
headache types 
 
Aggravated by 
food, alcohol, 
lifestyle, 
environment, stress 
 
Eased by alcohol, 
street drugs 
Does this person have mild to moderate, 
pressing/tightening pain which is always bilateral and 
no neck symptoms? 
 
Cervicogenic headache 
 
Tension Type Headache 
Is the headache unilateral and side locked, precipitated 
by neck movement and/or sustained awkward neck 
position and pain starts in neck? 
 
 
 
 
Does this person have unilateral, moderate to severe, 
pulsating/throbbing, time locked pain which 
prohibits activity with associated aura? 
 
Migraine Headache with aura 
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APPENDIX THREE  
Pamphlet about Role of Physiotherapy 
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APPENDIX FOUR 
Pamphlet about Headache 
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APPENDIX FIVE 
 
INFORMATION SHEET 
Exploring headache amongst users of Alma Street Services 
Jo Connaughton from the School of Physiotherapy at the University of Notre Dame 
invites you to be a part of her doctoral research project investigating headaches in 
people accessing Alma Street Services. Jo worked as the Senior Physiotherapist at 
Alma Street between 2002 and 2007. Approval for this project has been granted by the 
Research Committee of the College of Health Sciences under the authority of the 
Human Research Ethics Committee of the University of Notre Dame Australia and the 
South Metropolitan Area Health Services Human Research Ethics Committee.   
Nature and Purpose of the Study 
The aim of the project is to find out how many people who access Alma Street 
experience headaches and how often, what type of headaches, how the headaches 
impact on each person and what, if any treatment, each person is receiving for the 
headaches. Your case manager has identified you are over 18 and might be willing to 
be part of this study. You do not need to experience headaches to be part of this study.   
What the Study Will Involve 
If you decide to participate in this study a researcher will guide you through 30 
questions from a questionnaire. This should take about 15 minutes to complete.  
Benefits 
The results of the project will help provide guidelines for identification of headaches 
and the management of headache for clients of Alma Street and other mental health 
services.  
Confidentiality 
All questionnaires will be de-identified and then data will be kept at the University in a 
password protected computer.   This information will only be available to the 
researcher for the express purpose of performing the study.  All of the collected 
information will be destroyed after 5 years.  If publications arise from this research, 
the identity of participants will not be revealed in any of the published material. 
Voluntary Participation and Withdrawal from Study 
Your participation in this study is entirely voluntary and you may withdraw at any time 
from the project.   
 
If you should have any complaints or concerns about the way in which the study is being 
conducted, you may contact the Chair of the South Metropolitan Area Health Service Human 
Research Ethics Committee on 9431 2929 or the Executive Officer of The University of Notre 
Dame Australia, phone (08) 9433 0964. 
If you have any questions about this study please contact Associate Professor Joanne 
Connaughton on 9433 0186. 
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CONSENT FORM 
TO BE USED IN CONJUNCTION WITH THE INFORMATION SHEET 
Exploring headache amongst users of Alma Street Services  
 
Participant’s Name:.............................................. Date of Birth……………….. 
 
1. I agree entirely voluntarily to take part in this study exploring headache amongst 
users of Alma Street Services. I am over 18 years of age. 
2. I have read and understood the information sheet about this project and my questions 
have been answered to my satisfaction.    
3. I understand that I am entirely free to withdraw from the study at any time without 
prejudice or affect on access to treatment at Alma Street.  
4.  I understand that all information gathered by the researcher will be treated as strictly 
confidential. 
5.  I understand that the protocol adopted by the University Of Notre Dame Australia 
Human Research Ethics Committee for the protection of privacy will be adhered to 
and relevant sections of the Privacy Act are available at http://www.nhmrc.gov.au/  
 6.  I understand that I will not be referred to by name in any report concerning this 
study.  In turn, I cannot restrict in any way the use of the results that arise from this 
study. 
 
Signature by patient     Signature by researcher 
 
Signed.............................................. Signed:........................................................ 
 
Date:.....................................................Date:........................................................ 
If participants have any complaint regarding the manner in which a research project is conducted, 
it should be directed to the Executive Officer of the Human Research Ethics Committee, Research 
Office, The University of Notre Dame Australia, PO Box 1225 Fremantle WA 6959, Phone (08) 
9433 0943.  
 180 
REFERENCES 
Aamodt, A.H.,Stovner, L.J., Hagen, K., Brathen, G. & Zwart, J. (2006). Headache 
prevalence related to smoking and alcohol use. The Head-HUNT Study. 
European Journal of Neurology, 13(11), 1233-1238.  
Abrams, D.J., Rojas, D.C., & Arciniegas, D.B. (2008). Is schizoaffective disorder a 
distinct categorical diagnosis? A critical review of the literature. 
Neuropsychiatric Disease And Treatment, 4(6), 1089-1109.  
Amani, R. (2007). Is dietary pattern of schizophrenia patients different from healthy 
subjects? BMC Psychiatry. 7(15) doi:10.1186/1471-244X-7-15 
Amiri, M., Jull, G., Bullock-Saxton, J., Darnell, R., & Lander, C. (2007). Cervical 
musculoskeletal impairment in frequent intermittent headache. Part 2: subjects 
with concurrent headache types. Cephalalgia: An International Journal Of 
Headache, 27(8), 891-898.  
Anthony, M. (2000). Cervicogenic headache: prevalence and response to local steroid 
therapy. Clinical And Experimental Rheumatology, 18(2 Suppl 19), S59-S64.  
Antonaci, F., & Sjaastad, O. (2011). Cervicogenic headache: a real headache. Current 
Neurology And Neuroscience Reports, 11(2), 149-155.  
Arnedo, J., Svrakic, D.M., del Val, C., Romero-Zaliz, R., Hernandez-Cuervo, H., 
Molecular Genetics of Schizophrenia Consortium, Fanous, A.H., Pato, M., 
Pato, C., de Erausquin, G., Cloninger, R., & Zwir, I. (2014). Uncovering the 
hidden risk architecture of the schizophrenias: confirmation in three 
independent genome-wide association studies The American Journal of 
Psychiatry Retrieved April 9, 2014, from http://ajp.psychiatryonline.org  
Arvaniti, F., Samakouri, M., Kalamara, E., Bochtsou, V., Bikos, C., Livaditis, M. . 
(2009). Health service staff's attitudes towards patients with mental illness. 
Social Psychiatry And Psychiatric Epidemiology, 44(8), 658 -665.  
Ascher-Svanum, H., Peng, X., Faries, D., Montgomery, W., & Haddad, P.M. (2009). 
Treatment patterns and clinical characteristics prior to initiating depot typical 
antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry, 9, 46-
46. 
Ashina, S., & Bendsten, L. (2013). Pathophysiology and Genetics of Tension-type 
Headache. In M. Robbins, B. Grosberg & R. Lipton (Eds.), Headache. 
Hoboken: Wiley. 
 181 
Ashina, S., Bendtsen, L., Lyngberg, A. C., Lipton, R. B., Hajiyeva, N., & Jensen, R. 
(2014). Prevalence of neck pain in migraine and tension-type headache: A 
population study. Cephalalgia: An International Journal Of Headache.  
Ashkenazi, A., Blumenfeld, A., Napchan, U., Narouze, S., Grosberg, B., Nett, R., 
DePalma, T., Rosenthal, B., Tepper, S. & Lipton, R. B. (2010). Peripheral 
nerve blocks and trigger point injections in headache management - a 
systematic review and suggestions for future research. Headache, 50(6), 943-
952.  
Asuni, C., Manchia, M., Deidda, A., Stochino, M. E., Cherchi, A., & Del Zompo, M. 
(2010). Mixture analysis of age at onset in migraine without aura: evidence for 
three subgroups. Headache: The Journal of Head & Face Pain, 50(8), 1313-
1319.  
Atik, L., Konuk, N., Akay, O., Ozturk, D., & Erdogan, A. (2007). Pain perception in 
patients with bipolar disorder and schizophrenia. Acta Neuropsychiatrica, 
19(5), 284-290.  
Australian Institute of Health and Welfare, A. (2010). When musculoskeletal 
conditions and mental disorders occur together.  Canberra:  Retrieved from 
http://www.aihw.gov.au/publication-detail/?id=6442468392. 
Australian Physiotherapy Association. (2008). Primary Health Care and 
Physiotherapy: Position Statement.  
Australian Physiotherapy Association. (2009). Chronic Disease and Physiotherapy: 
Position Statement.  
Australian Physiotherapy Association. (2011). Mental Health and Physiotherapy: 
Position Statement.  
Australian Physiotherapy Association. (2012). Pain Management: Position Statement.  
Beinert, K., & Taube, W. (2013). The Effect of Balance Training on Cervical 
Sensorimotor Function and Neck Pain. Journal of Motor Behavior, 45(3), 271-
278.  
Bera, S. C., Khandelwal, S. K., Sood, M., & Goyal, V. (2014). A comparative study 
of psychiatric comorbidity, quality of life and disability in patients with 
migraine and tension type headache. Neurology India, 62(5), 516-520.  
Bernhofer, E., Higgins, P., Daly, B., Burant, C., & Hornick, T. (2013) Hospital lighting 
and its association with sleep, mood and pain in medical inpatients. Journal of 
Advanced Nursing, 70(5), 1164-01173. 
 182 
Bezov, D., Ashina, S., Jensen, R., & Bendtsen, L. (2011). Pain perception studies in 
tension-type headache. Headache, 51(2), 262-271.  
Birgenheir, D. G., Ilgen, M. A., Bohnert, A. S. B., Abraham, K. M., Bowersox, N. W., 
Austin, K., & Kilbourne, A. M. (2013). Pain conditions among veterans with 
schizophrenia or bipolar disorder. General Hospital Psychiatry, 35(5), 480-
484.  
Bogduk, N.(1993) The Anatomy and Physiology of Nociception. In J Crosbie & J 
McConnell (eds), Physiotherapy: Foundations for practice. Key issues in 
musculoskeletal physiotherapy.(pp. 48 – 88). Oxford: Butterworth-Heinemann 
Ltd. 
Bogduk, N., & Govind, J. (2009). Cervicogenic headache: an assessment of the 
evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurology, 
8(10), 959-968.  
Bonnot, O., Anderson, G., M.,, Cohen, D., Willer, J. C., & Tordjman, S. (2009). Are 
patients with schizophrenia insensitive to pain? A reconsideration of the 
question. The Clinical Journal Of Pain, 25(3), 244-252.  
Borhani Haghighi, A., Aflaki, E., & Ketabchi, L. (2008). The prevalence and 
characteristics of different types of headache in patients with Behçet's disease, 
a case-control study. Headache, 48(3), 424-429.  
Buse, D., Loder, E., Gorman, J., Stewart, W., Reed, M., Fanning, K., Serrano, D. & 
Lipton, R. (2013). Sex differences in the prevalence, symptoms, and associated 
features of migraine, probable migraine and other severe headaches: results of 
the American Migraine Prevalence and Prevention (AMPP) Study. Headache: 
The Journal of Head and Face Pain. 53(8), 1278-1299. 
Calhoun, A. H., Ford, S., Millen, C., Finkel, A., Truong, Y. & Nie, Y. (2010). The 
prevalence of neck pain in migraine. Headache, 50,1273-1277. 
Carragee, E. J. (2007). The pyrite standard: the Midas touch in the diagnosis of axial 
pain syndromes. The spine journal, 7(1), 27-31.  
Carter, N. J. (2012). Extended-release intramuscular paliperidone palmitate: a review 
of its use in the treatment of schizophrenia. Drugs, 72(8), 1137-1160.  
Castle, D., & Buckley, P. (2011). Schizoprenia  (2nd ed.) Augusta: Oxford University 
Press  
 183 
Cathcart, S., Winefield, A. H., Lushington, K., & Rolan, P. (2010). Stress and tension-
type headache mechanisms. Cephalalgia: An International Journal Of 
Headache, 30(10), 1250-1267.  
Chaibi, A., & Russell, M. B. (2012). Manual therapies for cervicogenic headache: a 
systematic review. The Journal Of Headache And Pain, 13(5), 351-359.  
Coghlan, R., Lawrence, D., Holman, C., & Jablensky, A. (2001). Duty to Care: 
Physical Illness in People with Mental Illness. Perth: The University of 
Western Australia   
Connaughton, J., Patman, S., & Pardoe, C. (2013). Are there associations among 
physical activity, fatigue, sleep quality and pain in people with mental illness? 
A pilot study. Journal of Psychiatric and Mental Health Nursing.  
Cosentino, G., Brighina, F., Talamanca, S., Paladino, P., Vigneri, S., Baschi, R., 
Indovino, S., Macorca, S., Alfonsi, E & Fierro, B. (2014). Reduced threshold 
for inhibitory homeostatic responses in migraine motor cortex? A tDCS/TMS 
study. Headache, 54(4), 663-674.  
Cuyún Carter, G. B., Milton, D. R., Ascher-Svanum, H., & Faries, D. E. (2011). 
Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-
year prospective observational study. BMC Psychiatry, 11, 143-143.  
Department of Health and Aging, D. (2009). National Mental Health Policy 2008. 
Canberra: Austalian Government Publishing Service. 
Derry, C. J., Derry, S., & Moore, R. A. (2014). Sumatriptan (all routes of 
administration) for acute migraine attacks in adults - overview of Cochrane 
reviews. The Cochrane Database Of Systematic Reviews, 5, CD009108.  
Derry, S., & Moore, R. A. (2013). Paracetamol (acetaminophen) with or without an 
antiemetic for acute migraine headaches in adults. Cochrane database of 
systematic reviews, 4, CD008040.  
Diener, H. C., Kaminski, M., Stappert, G., Stolke, D., & Schoch, B. (2007). Lower 
cervical disc prolapse may cause cervicogenic headache: prospective study in 
patients undergoing surgery. Cephalalgia: An International Journal Of 
Headache, 27(9), 1050-1054.  
Dong, Z., Di, H., Dai, W., Liang, J., Pan, M., Zhang, M., Zhou, Z., Li, Z., Liu, R. & 
Yu, S. (2012). Application of ICHD-II criteria in a headache clinic of China. 
Plos One, 7(12), e50898-e50898. doi: 10.1371/journal.pone.0050898 
 184 
Drew, B. J., King, M. L., & Callahan, L. (2005). Cryotherapy for treatment of ECT-
induced headache. Journal of Psychosocial Nursing & Mental Health Services, 
43(4), 32.  
Dworkin, R. H. (1994). Pain insensitivity in schizophrenia: a neglected phenomenon 
and some implications. Schizophrenia Bulletin, 20(2), 235-248.  
Engels, G., Francke, A. L., van Meijel, B., Douma, J. G., de Kam, H., Wesselink, W., 
Houtjes, W. &. Scherder, E. J. A. (2014). Clinical pain in schizophrenia: a 
systematic review. The Journal Of Pain: Official Journal Of The American 
Pain Society, 15(5), 457-467.  
Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009). Clozapine versus typical 
neuroleptic medication for schizophrenia. Cochrane database of systematic 
reviews(1), CD000059.  
Evers, S. (2008). Comparison of cervicogenic headache with migraine. Cephalalgia: 
An International Journal Of Headache, 28 Suppl 1, 16-17.  
Fagiolini, A. (2008). Overcoming hurdles to achieving good physical health in patients 
treated with atypical antipsychotics. European Neuropsychopharmacology: 
The Journal Of The European College Of Neuropsychopharmacology, 18 
Suppl 2, S102-S107.  
Fernández-de-las-Peñas, C., Alonso-Blanco, C., San-Roman, J., & Miangolarra-Page, 
J. C. (2006). Methodological quality of randomized controlled trials of spinal 
manipulation and mobilization in tension-type headache, migraine, and 
cervicogenic headache. The Journal Of Orthopaedic And Sports Physical 
Therapy, 36(3), 160-169.  
Fishbain, D. A. (1982). Pain insensitivity in psychosis. Annals Of Emergency 
Medicine, 11(11), 630-632.  
Fleming, R., Forsythe, S., & Cook, C. (2007). Influential variables associated with 
outcomes in patients with cervicogenic headache. The Journal Of Manual & 
Manipulative Therapy, 15(3), 155-164.  
Florencio, L. L., Chaves, T. C., Carvalho, G. F., Gonçalves, M. C., Casimiro, E. C. B., 
Dach, F., . . . Bevilaqua-Grossi, D. (2014). Neck Pain Disability Is Related to 
the Frequency of Migraine Attacks: A Cross-Sectional Study. Headache.  
Frese, A., & Evers, S. (2008). Biological markers of cervicogenic headache. 
Cephalalgia: An International Journal Of Headache, 28 Suppl 1, 21-23.  
 185 
Frese, A., Schilgen, M., Edvinsson, L., Frandsen, E., & Evers, S. (2005). Calcitonin 
gene-related peptide in cervicogenic headache. Cephalalgia: An International 
Journal Of Headache, 25(9), 700-703.  
Fumal, A., & Schoenen, J. (2008). Tension-type headache: current research and 
clinical management. Lancet Neurology, 7(1), 70-83.  
Galea, M. (2002). Neuroanatomy of the nociceptive system. In J Strong (Ed) Pain: A 
textbook for therapists. (pp.13-42). Edinburgh: Chruchill Livingstone. 
Galletly, C. A., Foley, D. L., Waterreus, A., Watts, G. F., Castle, D. J., McGrath, J. J., 
Mickinnon, A., & Morgan, V. A. (2012). Cardiometabolic risk factors in 
people with psychotic disorders: The second Australian national survey of 
psychosis. The Australian And New Zealand Journal Of Psychiatry, 46(8), 
753-761.  
Galletly, C. L., & Murray, L. E. (2009). Managing weight in persons living with severe 
mental illness in community settings: a review of strategies used in community 
interventions. Issues In Mental Health Nursing, 30(11), 660-668.  
Gorczynski, P., & Faulkner, G. (2010). Exercise therapy for schizophrenia. 
Schizophrenia Bulletin, 36(4), 665-666.  
Griswold, K. S., Homish, G. G., Pastore, P. A., & Leonard, K. E. (2010). A randomized 
trial: are care navigators effective in connecting patients to primary care after 
psychiatric crisis? Community Mental Health Journal, 46(4), 398-402.  
Griswold, K. S., Zayas, L. E., Pastore, P. A., Smith, S. J., Wagner, C. M., & Servoss, 
T. J. (2008). Primary care after psychiatric crisis: a qualitative analysis. Annals 
Of Family Medicine, 6(1), 38-43.  
Guieu, R., Samuélian, J. C., & Coulouvrat, H. (1994). Objective evaluation of pain 
perception in patients with schizophrenia. The British Journal Of Psychiatry: 
The Journal Of Mental Science, 164(2), 253-255.  
Gureje, O., Von Korff, M., Kola, L., Demyttenaere, K., He, Y., Posada-Villa, J., et al. 
. (2008). The relation between multiple pains and mental disorders: Results 
from the world mental health surveys. Pain, 135(1-2), 82-91.  
Guveli, H., Bahceci, B., Kirbas, S., Hocaoglu, C., Kandemir, G., Alibasoglu, H., Celik, 
F, H., et al. (2014) The evaluation of headache in patients with schizophrenia: 
A case-control study. The Journal of Psychiatry and Neurological Science, 27, 
204-210. 
 186 
Haapea, M. Miettunen, J., Veijola, J., Lauronen, E., Tanskanen, P. & Isohanni, M.. 
(2007). Non-participation may bias the results of a psychiatric survey. Social 
Psychiatry & Psychiatric Epidemiology, 42(5), 403-409.  
Hagen, K., Zwart, J. A., Vatten, L., Stovner, L. J., & Bovim, G. (2000). Head-HUNT: 
validity and reliability of a headache questionnaire in a large population-based 
study in Norway. Cephalalgia: An International Journal Of Headache, 20(4), 
244-251.  
Hall, T., Briffa, K., & Hopper, D. (2008). Clinical evaluation of cervicogenic 
headache: a clinical perspective. The Journal Of Manual & Manipulative 
Therapy, 16(2), 73-80.  
Hall, T., Chan, H. T., Christensen, L., Odenthal, B., Wells, C., & Robinson, K. (2007). 
Efficacy of a C1-C2 self-sustained natural apophyseal glide (SNAG) in the 
management of cervicogenic headache. The Journal Of Orthopaedic And 
Sports Physical Therapy, 37(3), 100-107.  
Happell, B., Scott, D., & Platania-Phung, C. (2012). Perceptions of Barriers to Physical 
Health Care for People with Serious Mental Illness: A Review of the 
International Literature. Issues In Mental Health Nursing, 33(11), 752-761.  
Health Workforce Australia, A. (2013). Health Workforce Australia 2013, Mental 
Health Workforce  Planning Data Inventory. Canberra: Australian 
Government Publishing 
Hesse, M., & Thylstrup, B. (2013). Time-course of the DSM-5 cannabis withdrawal 
symptoms in poly-substance abusers. BMC Psychiatry, 13(1), 200-221.  
Ho, B.-C., Mola, C., & Andreasen, N. C. (2004). Cerebellar dysfunction in neuroleptic 
naive schizophrenia patients: clinical, cognitive, and neuroanatomic correlates 
of cerebellar neurologic signs. Biological Psychiatry, 55(12), 1146-1153.  
Hooley, J. M., & Delgado, M. L. (2001). Pain insensitivity in the relatives of 
schizophrenia patients. Schizophrenia Research, 47(2-3), 265-273.  
Howes, O. D. (2012). What new evidence tells us about dopamine's role in 
schizophrenia. In A. S. David & S. Kapur (Eds.), Schizophrenia: The Final 
Frontier - A Festschrift for Robin M. Murray (pp. 365-372). East Sussex: 
Psychology Press.  
Huber, J., Lisinski, P., & Poloxcyk, A. (2013). Reinvestigation of the dysfunction in 
neck and shouldre girdle muscles as the reason of cervicogenic headache 
among office workers. Disability and Rehabilitation, 35(10), 793-802. 
 187 
Hussain, A., Stiles, M. A., & Oshinsky, M. L. (2010). Pain remapping in migraine: a 
novel characteristic following trigeminal nerve injury. Headache: The Journal 
of Head & Face Pain, 50(4), 669-671.  
Jäger, M., Bottlender, R., Strauss, A., & Möller, H. J. (2004). Fifteen-year follow-up 
of ICD-10 schizoaffective disorders compared with schizophrenia and 
affective disorders. Acta Psychiatrica Scandinavica, 109(1), 30-37.  
Jensen, R. (2003). Peripheral and central mechanisms in tension-type headache: an 
update. Cephalalgia (Wiley-Blackwell), 23, 49-52. 
Jensen, R., & Stovner, L. J. (2008). Epidemiology and comorbidity of headache. 
Lancet Neurology, 7(4), 354-361.  
Jeste, D.V., Gladsjo, J. A., Lindamer, L.A. & Lacro J.P. (1996). Medical Comorbidity 
in schizophrenia. Schizophrenia Bulletin, 22(3), 413-430.  
Jull, G., Amiri, M., Bullock-Saxton, J., Darnell, R., & Lander, C. (2007). Cervical 
musculoskeletal impairment in frequent intermittent headache. Part 1: Subjects 
with single headaches. Cephalalgia: An International Journal Of Headache, 
27(7), 793-802.  
Jull, G., Sterling, M., Falla, D., Treleaven, J., & O'Leary, S. (2008). Whiplash, 
Headache, and Neck Pain. Edinburgh: Churchill Livingstone. 
Jull, G., Trott, P., Potter, H., Zito, G., Niere, K., Shirley, D., Emberson, J., Marschner, 
I., & Richardson, C. (2002). A randomized controlled trial of exercise and 
manipulative therapy for cervicogenic headache. Spine, 27(17), 1835-1843.  
Junior, A. S., Krymchantowski, A., Moreira, P., Vasconcelos, L., Gomez, R., & 
Teixeira, A. (2009). Prevalence of headache in the entire population of a small 
city in Brazil. Headache, 49(6), 895-899.  
Karlsgodt, K. H., Ellman, L. M., Sun, D., Mittal, V., & Cannon, T. D. (2011). The 
neurodevelopmental hypothesis of schizophrenia. In David, A. S.; Kapur, S. & 
McGuffin, P. (Ed.), Schizophrenia: The Final Frontier - A Festschrift for 
Robin M. Murray (pp. 1-17). East Sussex: Psychology Press.  
Kelley, N. E., & Tepper, D. E. (2012a). Rescue therapy for acute migraine, part 1: 
triptans, dihydroergotamine, and magnesium. Headache, 52(1), 114-128.  
Kelley, N. E., & Tepper, D. E. (2012b). Rescue therapy for acute migraine, part 3: 
opioids, NSAIDs, steroids, and post-discharge medications. Headache, 52(3), 
467-482.  
 188 
Kirthi, V., Derry, S., & Moore, R. A. (2013). Aspirin with or without an antiemetic for 
acute migraine headaches in adults. The Cochrane Database Of Systematic 
Reviews, 4, CD008041.  
Knackstedt, H., Bansevicius, D., Aaseth, K., Grande, R. B., Lundqvist, C., & Russell, 
M. B. (2010). Cervicogenic headache in the general population: the Akershus 
study of chronic headache. Cephalalgia: An International Journal Of 
Headache, 30(12), 1468-1476.  
Knackstedt, H., Kråkenes, J., Bansevicius, D., & Russell, M. B. (2012). Magnetic 
resonance imaging of craniovertebral structures: clinical significance in 
cervicogenic headaches. The Journal Of Headache And Pain, 13(1), 39-44.  
Kristoffersen, E. S., Lundqvist, C., Aaseth, K., Grande, R. B., & Russell, M. B. (2013). 
Management of secondary chronic headache in the general population: the 
Akershus study of chronic headache. The Journal Of Headache And Pain, 
14(1), 5-5.  
Kuhnigk, O., Hofmann, M., Böthern, A. M., Haufs, C., Bullinger, M., & Harendza, S. 
(2009). Influence of educational programs on attitudes of medical students 
towards psychiatry: Effects of psychiatric experience, gender, and personality 
dimensions. Medical Teacher, 31(7), e303-e310.  
Kuritzky, A., Mazeh, D., & Levi, A. (1999). Headache in schizophrenic patients: a 
controlled study. Cephalalgia: An International Journal Of Headache, 19(8), 
725-727.  
Kuswanto, C. N., Teh, I., Lee, T.-S., & Sim, K. (2012). Diffusion tensor imaging 
findings of white matter changes in first episode schizophrenia: a systematic 
review. Clinical Psychopharmacology And Neuroscience: The Official 
Scientific Journal Of The Korean College Of Neuropsychopharmacology, 
10(1), 13-24.  
Lake, A. E., 3rd, Lipchik, G. L., Penzien, D. B., Rains, J. C., Saper, J. R., & Lipton, 
R. B. (2006). Psychiatric comorbidity with chronic headache: evidence-based 
clinical implications--introduction to the supplement. Headache, 46 Suppl 3, 
S73-S75.  
Lake, A. E., Rains, J. C., Penzien, D. B., & Lipchik, G. L. (2005). Headache and 
Psychiatric Comorbidity: Historical Context, Clinical Implications, and 
Research Relevance. Headache: The Journal of Head & Face Pain, 45(5), 493-
506.  
 189 
Lammers, L., Zehm, B., & Williams, R. (2013). Risperidone long-acting injection in 
Schizophrenia Spectrum Illnesses compared to first generation depot 
antipsychotics in an outpatient setting in Canada. BMC Psychiatry, 13(1), 155-
155.  
Landy, S., Rice, K., & Lobo, B. (2004). Central Sensitisation and Cutaneous Allodynia 
in Migraine: Implications for Treatment. CNS Drugs, 18(6), 337-342.  
Lateef, T., Swanson, S., Cui, L., Nelson, K., Nakamura, E., & Merikangas, K. (2011). 
Headaches and sleep problems among adults in the United States: findings 
from the National Comorbidity Survey-Replication study. Cephalalgia: An 
International Journal Of Headache, 31(6), 648-653.  
Law, S., Derry, C., & Moore, R. A. (2013). Naproxen with or without an antiemetic 
for acute migraine headaches in adults. Cochrane database of systematic 
reviews, 10, CD009455.  
Lawyer, G., Nesvag, R., Varnas, K., Okugawa, G., & Agartz, I. (2009). Grey and 
White Matter Proportional Relationships in the Cerebellar Vermis Altered in 
Schizophrenia Cerebellum, 8, 52-60.  
Leese, M., Schene, A., Koeter, M., Meijer, K., Bindman, J., Mazzi, M., Puschner, B., 
Burti, L., Becker, T., Moreno, M., Celani, D., White, I., & Thonicroft, G. 
(2008). SF-36 scales, and simple sums of scales, were reliable quality-of-life 
summaries for patients with schizophrenia. Journal Of Clinical Epidemiology, 
61(6), 588-596.  
Leiper, D. A., Elliott, A. M., & Hannaford, P. C. (2006). Experiences and perceptions 
of people with headache: a qualitative study. BMC Family Practice, 7, 27-27.  
Lévesque, M., Potvin, S., Marchand, S., Stip, E., Grignon, S., Pierre, L., Lipp, O. & 
Goffaux, P. (2012). Pain Perception in Schizophrenia: Evidence of a Specific 
Pain Response Profile. Pain Medicine, 13(12), 1571-1579. 
Li, X., Zhou, J., Tan, G., Wang, Y., Ran, L., & Chen, L. (2012). Clinical characteristics 
of tension-type headache in the neurological clinic of a university hospital in 
China. Neurological Sciences: Official Journal Of The Italian Neurological 
Society And Of The Italian Society Of Clinical Neurophysiology, 33(2), 283-
287.  
Liebert, A., Rebbeck, T., Elias, S., Hawkins, D., & Adams, R. (2013). Musculoskeletal 
physiotherapists' perceptions of non-responsiveness to treatment for 
cervicogenic headache. Physiotherapy Theory And Practice, 29(8), 616-629.  
 190 
Linde, M., Stovner, L. J., Zwart, J.-A., & Hagen, K. (2011). Time trends in the 
prevalence of headache disorders. The Nord-Trondelag Health Studies (HUNT 
2 and HUNT 3). Cephalalgia: An International Journal Of Headache, 31(5), 
585-596.  
Lowry, F. (2014). Schizophrenia not one but many different diseases. Medscape 
Medical News, 2.  
MacNeela, P., Scott, P. A., Treacy, M., Hyde, A., & O'Mahony, R. (2012). A risk to 
himself: attitudes toward psychiatric patients and choice of psychosocial 
strategies among nurses in medical-surgical units. Research In Nursing & 
Health, 35(2), 200-213.  
Madras, B. K. (2013). History of the Discovery of the Antipsychotic Dopamine D2 
Receptor: A Basis for the Dopamine Hypothesis of Schizophrenia. Journal of 
the History of the Neurosciences, 22(1), 62-78.  
Magnusson, J. E., Riess, C. M., & Becker, W. J. (2012). Modification of the SF-36 for 
a headache population changes patient-reported health status. Headache, 52(6), 
993-1004.  
Malhi, G. S., Green, M., Fagiolini, A., Peselow, E. D., & Kumari, V. (2008). 
Schizoaffective disorder: diagnostic issues and future recommendations. 
Bipolar Disorders, 10(1 Pt 2), 215-230.  
Manhalter, N., Bozsik, G., Palásti, A., Csépány, E., & Ertsey, C. (2012). The validation 
of a new comprehensive headache-specific quality of life questionnaire. 
Cephalalgia: An International Journal Of Headache, 32(9), 668-682.  
Martelletti, P., Birbeck, G. L., Katsarava, Z., Jensen, R. H., Stovner, L. J., & Steiner, 
T. J. (2013). The Global Burden of Disease survey 2010, Lifting The Burden 
and thinking outside-the-box on headache disorders. The Journal Of Headache 
And Pain, 14(1), 13-13.  
Martelletti, P., Mitsikostas, D.-D., Lampl, C., Katsarava, Z., Osipova, V., Paemeleire, 
K., Edvinsson, L.,Siva, A., Valade, D., Steiner, Y., & Jensen, R. H. (2013). 
Framing education on headache disorders into the Global Burden of Disease 
Study 2010. The European Headache Federation stands ready. The Journal Of 
Headache And Pain, 14, 41-41.  
Marvel, C. L., Schwartz, B. L., & Rosse, R. B. (2004). A quantitative measure of 
postural sway deficits in schizophrenia. Schizophrenia Research, 68(2-3), 363-
372.  
 191 
McCarley, R. W., Wible, C. G., Frumin, M., Hirayasu, Y., Levitt, J. J., Fischer, I. A., 
& Shenton, M. E. (1999). MRI anatomy of schizophrenia. Biological 
Psychiatry, 45(9), 1099-1119.  
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008). Schizophrenia: a concise 
overview of incidence, prevalence, and mortality. Epidemiologic Reviews, 30, 
67-76.  
McLennan, W. (1998). ABS. Mental health and well being: Profile of Adults, Australia 
1997. Canberra: Australian Government Publishing Service. 
Mondelli, V., & Pariante, C. M. (2012). Stress and psychosis: Professor Murray's 
contribution (so far) to the vulnerability-stress model. In David, A. S.; Kapur, 
S. & McGuffin, P. (Ed.), Schizophrenia: The Final Frontier - A Festschrift for 
Robin M. Murray (pp. 1-17). East Sussex: Psychology Press. 
Moore, R., Derry, S., Wiffen, P., Straube, S., & Bendtsen, L. (2014). Evidence for 
efficacy of acute treatment of episodic tension-type headache: methodological 
critique of randomised trials for oral treatments. Pain, 155(11), 2220-2228.  
Morgan, V., Waterreus, A., Jablensky, A., Mackinnon, A., McGrath, J. J., Carr, V., 
Bush, R., Castle, D., Cohen, M., Harvey, C., Galletly, C., Stain, H., Neil, A., 
McGorry, P., Hocking, B., Shah, S., & Saw, S. (2012). People living with 
psychotic illness in 2010: The second Australian national survey of psychosis. 
The Australian And New Zealand Journal Of Psychiatry, 46(8), 735-752.  
Morgan, V., Waterreus, A., Jablensky, A., Mackinnon, A., McGrath, J. J., Carr, V., 
Bush, R., Castle, D., Cohen, M., Harvey, C., Galletly, C., Stain, H., Neil, A., 
McGorry, P., Hocking, B., Shah, S., & Saw, S. (2011). People living with 
psychotic illness 2010: Report on the second Australian national survey.  
Canberra: Australian Government Publishing Service. 
Murru, A., Pacchiarotti, I., Nivoli, A. M. A., Grande, I., Colom, F., & Vieta, E. (2011). 
What we know and what we don't know about the treatment of schizoaffective 
disorder. European Neuropsychopharmacology: The Journal Of The European 
College Of Neuropsychopharmacology, 21(9), 680-690.  
Naja, Z. M., El-Rajab, M., Al-Tannir, M. A., Ziade, F. M., & Tawfik, O. M. (2006). 
Occipital nerve blockade for cervicogenic headache: a double-blind 
randomized controlled clinical trial. Pain Practice: The Official Journal Of 
World Institute Of Pain, 6(2), 89-95.  
 192 
Narouze, S. N., Casanova, J., & Mekhail, N. (2007). The Longitudinal Effectiveness 
of Lateral Atlantoaxial Intra-articular Steroid Injection in the Treatment of 
Cervicogenic Headache. Pain Medicine, 8(2), 184-188.  
National Mental Health Policy (2008), Commonwealt of Australia 
Ng, A., & Wang, D. (2015). Cervical facet injections in the management of 
cervicogenic headaches. Current Pain And Headache Reports, 19(5), 484-484.  
Nopoulos, P. C., Ceilley, J. W., Gailis, E. A., & Andreasen, N. C. (1999). An MRI 
study of cerebellar vermis morphology in patients with schizophrenia: 
evidence in support of the cognitive dysmetria concept. Biological Psychiatry, 
46(5), 703-711.  
Noseda, R., & Burstein, R. (2013). Migraine pathophysiology: anatomy of the 
trigeminovascular pathway and associated neurological symptoms, cortical 
spreading depression, sensitization, and modulation of pain. Pain, 154 Suppl 
1, S44-S53.  
Olivares, J. M., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., . . . 
Fernández, J. C. (2009). Long-term outcomes in patients with schizophrenia 
treated with risperidone long-acting injection or oral antipsychotics in Spain: 
results from the electronic Schizophrenia Treatment Adherence Registry (e-
STAR). European Psychiatry: The Journal Of The Association Of European 
Psychiatrists, 24(5), 287-296.  
Papaioannou, D., Brazier, J., & Parry, G. (2011). How valid and responsive are generic 
health status measures, such as EQ-5D and SF-36, in schizophrenia? A 
systematic review. Value In Health: The Journal Of The International Society 
For Pharmacoeconomics And Outcomes Research, 14(6), 907-920.  
Paton, C., Esop, R., Young, C., & Taylor, D. (2004). Obesity, dyslipidaemias and 
smoking in an inpatient population treated with antipsychotic drugs. Acta 
Psychiatrica Scandinavica, 110(4), 299-305. 
Peat, J. K. (2002). Health Science Research: A handbook of quantitative methods. 
London: SAGE. 
Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K., Isometsä, E., Pirkola, S., 
Partenon, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppa, T., Harkanen, T., 
Korskinen, S., & Lönnqvist, J. (2007). Lifetime prevalence of psychotic and 
bipolar I disorders in a general population. Archives Of General Psychiatry, 
64(1), 19-28.  
 193 
Pfaffenrath, V., Fendrich, K., Vennemann, M., Meisinger, C., Ladwig, K. H., Evers, 
S., Straube, A., Hoffman, W., & Berger, K. (2009). Regional variations in the 
prevalence of migraine and tension-type headache applying the new IHS 
criteria: the German DMKG Headache Study. Cephalalgia: An International 
Journal Of Headache, 29(1), 48-57.  
Picard, H., Amado, I., Mouchet-Mages, S., Olié, J.-P., & Krebs, M.-O. (2008). The 
role of the cerebellum in schizophrenia: an update of clinical, cognitive, and 
functional evidences. Schizophrenia Bulletin, 34(1), 155-172.  
Pompili, M., Di Cosimo, D., Innamorati, M., Lester, D., Tatarelli, R., & Martelletti, P. 
(2009). Psychiatric comorbidity in patients with chronic daily headache and 
migraine: a selective overview including personality traits and suicide risk. The 
Journal Of Headache And Pain, 10(4), 283-290.  
Posadzki, P., & Ernst, E. (2011). Spinal Manipulations for Cervicogenic Headaches: 
A Systematic Review of Randomized Clinical Trials. Headache: The Journal 
of Head & Face Pain, 51(7), 1132-1139. 
Potvin, S., & Marchand, S. (2008). Hypoalgesia in schizophrenia is independent of 
antipsychotic drugs: a systematic quantitative review of experimental studies. 
Pain, 138(1), 70-78.  
Probst, M., & Peuskens, J. (2010). Attitudes of Flemish physiotherapy students 
towards mental health and psychiatry. Physiotherapy, 96(1), 44-51.  
Queiroz, L. P., Peres, M. F. P., Piovesan, E. J., Kowacs, F., Ciciarelli, M. C., Souza, J. 
A., & Zukerman, E. (2009). A nationwide population-based study of tension-
type headache in Brazil. Headache, 49(1), 71-78. 
Quintner, J. L., Bove, G. M., & Cohen, M. L. (2014). A critical evaluation of the trigger 
point phenomenon. [Electronic Version ]Rheumatology (pp270-277).  
Rabbie, R., Derry, S., & Moore, R. (2013). Ibuprofen with or without an antiemetic 
for acute migraine headaches in adults. Cochrane database of systematic 
reviews, 4, CD008039.  
Racicki, S., Gerwin, S., Diclaudio, S., Reinmann, S., & Donaldson, M. (2013). 
Conservative physical therapy management for the treatment of cervicogenic 
headache: a systematic review. The Journal Of Manual & Manipulative 
Therapy, 21(2), 113-124.  
Radtke, A., & Neuhauser, H. (2009). Prevalence and burden of headache and migraine 
in Germany. Headache, 49(1), 79-89.  
 194 
Read, J. & Bentall, R. (2010). The effectiveness of electroconvulsive therapy: A 
literature review. Epidemiologia e Psichiatria Sociale, 19. 333-347. 
Reza, A., Sievert, L. L., Rahberg, N., Morrison, L. A., & Brown, D. E. (2012). 
Prevalence and determinants of headaches in Hawaii: The Hilo Women's 
Health Study. Annals Of Human Biology, 39(4), 305-314.  
Richardson, C., Faulkner, G., McDevitt, J., Skrinar, G., Hutchinson, D., & Piette, J. 
(2005). Integrating physical activity into mental health services for persons 
with serious mental illness. Psychiatric Services, 56(3), 324-331.  
Riina, J., Anderson, P. A., Holly, L. T., Flint, K., Davis, K. E., & Riew, K. D. (2009). 
The effect of an anterior cervical operation for cervical radiculopathy or 
myelopathy on associated headaches. The Journal Of Bone And Joint Surgery. 
American Volume, 91(8), 1919-1923. doi: 10.2106/JBJS.H.00500 
Ritsner, M. S., Lisker, A., & Grinshpoon, A. (2014). Predicting 10-year quality-of-life 
outcomes of patients with schizophrenia and schizoaffective disorders. 
Psychiatry And Clinical Neurosciences, 68(4), 308-317.  
Rizkallah, É., Bélanger, M., Stavro, K., Dussault, M., Pampoulova, T., Chiasson, J.-
P., & Potvin, S. (2011). Could the use of energy drinks induce manic or 
depressive relapse among abstinent substance use disorder patients with 
comorbid bipolar spectrum disorder? Bipolar Disorders, 13(5/6), 578-580.  
Roick, C., Fritz-Wieacker, A., Matschinger, H., Heider, D., Schindler, J., Riedel-
Heller, S. & Angermeyer, A. (2007). Health habits of patients with 
schizophrenia. Social Psychiatry and Psychiatric Epidemiology. 42, 268-276 
Rubio, G., Martínez, I., Ponce, G., Jiménez-Arriero, M. A., López-Muñoz, F., & 
Alamo, C. (2006). Long-acting injectable risperidone compared with 
zuclopenthixol in the treatment of schizophrenia with substance abuse 
comorbidity. Canadian Journal Of Psychiatry. Revue Canadienne De 
Psychiatrie, 51(8), 531-539.  
Sawa, A., & Snyder, S. H. (2002). Schizophrenia: diverse approaches to a complex 
disease. Science (New York, N.Y.), 296(5568), 692-695.  
 
 
 
 
 
 195 
Schäfer, I., Burns, T., Fleischhacker, W., Galderisi, S., Rybakowski, J., Libiger, J., 
Rossler, W., Molodynski, A., Edlinger, M., Piegari, G., Hrnciarova, J., Gorna, 
K., Jaeger, M., Fett, A., Hissback, J. & Naber, D. (2011). Attitudes of patients 
with schizophrenia and depression to psychiatric research: a study in seven 
European countries. Social Psychiatry & Psychiatric Epidemiology, 46(2), 
159-165. doi: 10.1007/s00127-010-0181-7 
Sim, K., Su, A., Ungvari, G. S., Fujii, S., Yang, S.-Y., Chong, M.-Y., Si, T., Chung, 
E., Tsang, H-Y., Chan, Y., Shinfuku, N & Tan, C. H. (2004). Depot 
antipsychotic use in schizophrenia: an East Asian perspective. Human 
Psychopharmacology, 19(2), 103-109.  
Singh, M. K., Giles, L. L., & Nasrallah, H. A. (2006). Pain insensitivity in 
schizophrenia: trait or state marker? Journal Of Psychiatric Practice, 12(2), 
90-102.  
Sjaastad, O. (2008). Cervicogenic headache: comparison with migraine without aura; 
Vågå study. Cephalalgia: An International Journal Of Headache, 28 Suppl 1, 
18-20.  
Sjaastad, O., & Bakketeig, L. S. (2008a). Migraine without aura: comparison with 
cervicogenic headache. Vågå study of headache epidemiology. Acta 
Neurologica Scandinavica, 117(6), 377-383.  
Sjaastad, O., & Bakketeig, L. S. (2008b). Prevalence of cervicogenic headache: Vågå 
study of headache epidemiology. Acta Neurologica Scandinavica, 117(3), 173-
180.  
Sjaastad, O., & Bovim, G. (1991). Cervicogenic headache. The differentiation from 
common migraine. An overview. Functional Neurology, 6(2), 93-100.  
Sjaastad, O., Fredriksen, T. A., & Pfaffenrath, V. (1998). Cervicogenic headache: 
diagnostic criteria. The Cervicogenic Headache International Study Group. 
Headache, 38(6), 442-445.  
Skillgate, E., Magnusson, C., Lundberg, M., & Hallqvist, J. (2012). The age- and- 
specific occurrence of bothersome neck pain in the general population – results 
from the Stockholm public health cohort. BMC Musculoskeletal Disorders, 13, 
185. http://www.biomedcentral.com/1471-2474/13/185 
Smitherman, T. A., & Baskin, S. M. (2008). Headache secondary to psychiatric 
disorders. Current Pain And Headache Reports, 12(4), 305-310.  
 196 
Solomon, G. D., Skobieranda, F. G., & Gragg, L. A. (1993). Quality of life and well-
being of headache patients: measurement by the medical outcomes study 
instrument. Headache, 33(7), 351-358.  
Spigt, M. G., Kuijper, E. C., Schayck, C. P., Troost, J., Knipschild, P. G., Linssen, V. 
M., & Knottnerus, J. A. (2005). Increasing the daily water intake for the 
prophylactic treatment of headache: a pilot trial. European Journal of 
Neurology, 12(9), 715-718. 
Stanton, T. R., Fritz, J. M., Hancock, M. J., Latimer, J., Maher, C. G., Wand, B. M., 
& Parent, E. C. (2011). Evaluation of a treatment-based classification 
algorithm for low back pain: a cross-sectional study. Physical Therapy, 91(4), 
496-509.  
Steiner, T. J., Lange, R., & Voelker, M. (2003). Aspirin in episodic tension-type 
headache: placebo-controlled dose-ranging comparison with paracetamol. 
Cephalalgia (Wiley-Blackwell), 23(1), 59-66.  
Steiner, T. J., Stovner, L. J., & Birbeck, G. L. (2013). Migraine: The Seventh Disabler 
Migraine: The Seventh Disabler. Headache: The Journal of Head & Face 
Pain, 53(2), 227-229.  
Stewart, W. F., Wood, C., Reed, M. L., Roy, J., & Lipton, R. B. (2008). Cumulative 
lifetime migraine incidence in women and men. Cephalalgia (Wiley-
Blackwell), 28(11), 1170-1178. 
Stovner, L. J., Al Jumah, M., Birbeck, G. L., Gururaj, G., Jensen, R., Katsarava, Z., . . 
. Steiner, T. J. (2014). The methodology of population surveys of headache 
prevalence, burden and cost: Principles and recommendations from the Global 
Campaign against Headache. The Journal Of Headache And Pain, 15(1), 5-5.  
Stovner, L. J., Hagen, K., Jensen, R., Katsarava, Z., Lipton, R., Scher, A., Steiner, T., 
& Zwart, J. A. (2007). The global burden of headache: a documentation of 
headache prevalence and disability worldwide. Cephalalgia: An International 
Journal Of Headache, 27(3), 193-210.  
Stovner, L. J., Zwart, J. A., Hagen, K., Terwindt, G. M., & Pascual, J. (2006). 
Epidemiology of headache in Europe. European Journal Of Neurology: The 
Official Journal Of The European Federation Of Neurological Societies, 13(4), 
333-345.  
 
 197 
Stubbs, B., Mitchell, A.J., De Hert, M., Correll, C.U., Soundy, A., Stroobants, M. & 
Cancampfort, D. (2014). The prevalence and moderators of clinical pain in 
people with schizophrenia: A systematic review and large scale meta-analysis. 
Schizophrenia Research, 160, 1-8. 
Stubbs, B., Soundy, A., Probst, M., Parker, A., Skjaerven, L. H., Lundvik Gyllensten, 
A., & Vancampfort, D. (2014). Addressing the disparity in physical health 
provision for people with schizophrenia: an important role for physiotherapists. 
Physiotherapy, 100(3), 185-186.  
Tharyan, P., & Adams, CE. (2005). Electroconvulsive therapy for schizophrenia. 
Cochrane Database Systematic Review. 2. CD000076 
The Chartered Society of Physiotherapy, C. (2008). Recovering mind and body: a 
framework for the role of physiotherapy in mental health and wellbeing. The 
Chartered Society of Physiotherapy.  
The Headache Classification Subcommitee of the International Headache Society. 
(2004). The International Classification of Headache Disorders Cephalalgia: 
An International Journal Of Headache (Vol. 24. Supplement 1). 
Thompson, L., Pennay, A., Zimmermann, A., Cox, M., & Lubman, D. I. (2014). 
"Clozapine makes me quite drowsy, so when I wake up in the morning those 
first cups of coffee are really handy": an exploratory qualitative study of 
excessive caffeine consumption among individuals with schizophrenia. BMC 
Psychiatry, 14(1), 1-18.   
Tobin, J. A., & Flitman, S. S. (2009). Occipital nerve blocks: effect of symptomatic 
medication: overuse and headache type on failure rate. Headache, 49(10), 
1479-1485. 
Torelli, P., Abrignani, G., Berzieri, L., Castellini, P., Ferrante, T., Lambru, G., Latte, 
L., Russo, M., Zani, S. & Manzoni, G. C. (2010). Population-based pace study: 
lifetime and past-year prevalence of headache in adults. Neurological 
Sciences: Official Journal Of The Italian Neurological Society And Of The 
Italian Society Of Clinical Neurophysiology, 31 Suppl 1, S145-S147.  
Torelli, P., Evangelista, A., Bini, A., Castellini, P., Lambru, G., & Manzoni, G. C. 
(2009). Fasting headache: a review of the literature and new hypotheses. 
Headache: The Journal of Head & Face Pain, 49(5), 744-752.  
 198 
van der Feltz-Cornelis, C. M., Biemans, H., & Timmer, J. (2012). Hearing voices: does 
it give your patient a headache? A case of auditory hallucinations as acoustic 
aura in migraine. Neuropsychiatric Disease And Treatment, 8, 105-111.  
van Griensven, H. (2005). Pain in Practice: Theory and treatment strategies for 
manual therapists. Edinburgh: Butterworth-Heinemann Elsevier. 
van Suijlekom, H. A., Lamé, I., Stomp-van den Berg, S. G. M., Kessels, A. G. H., & 
Weber, W. E. J. (2003). Quality of life of patients with cervicogenic headache: 
a comparison with control subjects and patients with migraine or tension-type 
headache. Headache, 43(10), 1034-1041.  
Vancampfort, D., Probst, M., De Hert, M., Soundy, A., Stubbs, B., Stroobants, M., & 
De Herdt, A. (2014). Neurobiological effects of physical exercise in 
schizophrenia: a systematic review. Disability And Rehabilitation.  
Vancampfort, D., Probst, M., Helvik Skjaerven, L., Catalán-Matamoros, D., Lundvik-
Gyllensten, A., Gómez-Conesa, A., . . . De Hert, M. (2012). Systematic review 
of the benefits of physical therapy within a multidisciplinary care approach for 
people with schizophrenia. Physical Therapy, 92(1), 11-23.  
Vancampfort, D., Probst, M., Sweers, K., Maurissen, K., Knapen, J., & De Hert, M. 
(2011). Relationships between obesity, functional exercise capacity, physical 
activity participation and physical self-perception in people with 
schizophrenia. Acta Psychiatrica Scandinavica, 123(6), 423-430. 
Varambally, S., Venkatasubramanian, G., & Gangadhar, B. N. (2012). Neurological 
soft signs in schizophrenia - The past, the present and the future. Indian Journal 
Of Psychiatry, 54(1), 73-80.  
Varambally, S., Venkatasubramanian, G., Thirthalli, J., Janakiramaiah, N., & 
Gangadhar, B. N. (2006). Cerebellar and other neurological soft signs in 
antipsychotic-naïve schizophrenia. Acta Psychiatrica Scandinavica, 114(5), 
352-356.  
Varkey, E., Hagen, K., Zwart, J. A., & Linde, M. (2008). Physical activity and 
headache: results from the Nord-Trøndelag Health Study (HUNT). 
Cephalalgia (Wiley-Blackwell), 28(12), 1292-1297. 
Verhagen, A., Damen, L., Berger, M., Lenssinck, M., Passchier, J., & Kroes, B. 
(2010). [Treatment of tension type headache: paracetamol and NSAIDs work: 
a systematic review]. Nederlands Tijdschrift Voor Geneeskunde, 154, A1924-
A1924.  
 199 
Verri, A. P., Proietti Cecchini, A., Galli, C., Granella, F., Sandrini, G., & Nappi, G. 
(1998). Psychiatric comorbidity in chronic daily headache. Cephalalgia: An 
International Journal Of Headache, 18 Suppl 21, 45-49.  
Verrotti, A., Di Fonzo, A., Penta, L., Agostinelli, S., & Parisi, P. (2014). Obesity and 
Headache/Migraine: The Importance of Weight Reduction through Lifestyle 
Modifications. BioMed Research International, 1-7.  
Vincent, M. B. (2010). Cervicogenic headache: the neck is a generator: con. Headache, 
50(4), 706-709.  
Vinding, G. R., Zeeberg, P., Lyngberg, A., Nielsen, R. T., & Jensen, R. (2007). The 
burden of headache in a patient population from a specialized headache centre. 
Cephalalgia: An International Journal Of Headache, 27(3), 263-270.  
Wand, B. M. (2014). Musculoskeletal Physiotherapy, Spinal 2. PHTY321 Course 
Reader. Fremantle: The University of Notre Dame Australia. 
Wang, S.-J., & Juang, K.-D. (2002). Psychiatric comorbidity of chronic daily 
headache: impact, treatment, outcome, and future studies. Current Pain And 
Headache Reports, 6(6), 505-510.  
Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health 
survey (SF-36). I. Conceptual framework and item selection. Medical Care, 
30(6), 473-483.  
Warren, R. E. (2003). The symptoms of hyperglycaemia in people with insulin-treated 
diabetes: classification using principal components analysis. 
Diabetes/metabolism research and reviews, 19(5), 408-414.  
Watson, D. H. & Drummond, P. D. (2012). Head Pain Referral During Examination 
of the Neck in Migraine and Tension-Type Headache. Headache: The Journal 
of Head & Face Pain, 52(8), 1226-1235. 
Watson, G. D., Chandarana, P. C., & Merskey, H. (1981). Relationships between pain 
and schizophrenia. The British Journal Of Psychiatry: The Journal Of Mental 
Science, 138, 33-36.  
Wells, R. E., Burch, R., Paulsen, R. H., Wayne, P. M., Houle, T. T., & Loder, E. 
(2014). Meditation for migraines: a pilot randomized controlled trial. 
Headache, 54(9), 1484-1495.  
 
 
 200 
Wiendels, N. J., Knuistingh Neven, A., Rosendaal, F. R., Spinhoven, P., Zitman, F. 
G., Assendelft, W. J. J., & Ferrari, M. D. (2006). Chronic frequent headache in 
the general population: prevalence and associated factors. Cephalalgia: An 
International Journal Of Headache, 26(12), 1434-1442.  
Wojakiewicz, A., Januel, D., Braha, S., Prkachin, K., Danziger, N., & Bouhassira, D. 
(2013). Alteration of pain recognition in schizophrenia. European Journal Of 
Pain (London, England), 17(9), 1385-1392.  
World Health Organisation, W. (2012). Lifting The Burden: the Global Campaign to 
reduce the burden of headache.  Retrieved from 
www.who.int/mental_health/neurology/headache/en. 
Wye, P., Bowman, J., Wiggers, J., Baker, A., Knight, J., Carr, V., Terry, M., & Clancy, 
R. (2010). Total smoking bans in psychiatric inpatient services: a survey of 
perceived benefits, barriers and support among staff. BMC Public Health, 10, 
372-382.  
Zhou, L., Hud-Shakoor, Z., Hennessey, C., & Ashkenazi, A. (2010). Upper cervical 
facet joint and spinal rami blocks for the treatment of cervicogenic headache. 
Headache, 50(4), 657-663. 
Zielman, R., Veenstra, P., Zwet, E. v., & Berg, J. v. d. (2012). How general 
practitioners treat migraine patients: evaluation of a headache guideline. 
Cephalalgia: An International Journal Of Headache, 32(12), 908-915.  
Zito, G., Jull, G., & Story, I. (2006). Clinical tests of musculoskeletal dysfunction in 
the diagnosis of cervicogenic headache. Manual Therapy, 11(2), 118-129.  
 
 
